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Zusammenfassung
Ziel der vorliegenden Studie war es zu untersuchen, ob eine entzündliche Stimulierung mesen-
chymaler Stammzellen des Fettgewebes (ASC) durch Medium, welches mit Tumornekrosefaktor
(TNF) supplementierte wurde, in vitro eine osteogene Differenzierung dieser Zellen bewirkt bzw.
unter osteogenen Bedingungen einen Einfluß auf die osteogene Differenzierung dieser Zellen
hat.
Die Motivation für diese Untersuchung resultiert aus der bekannten Rolle von TNF als Pro-
motor der Differenzierung und Aktivierung von Osteoklasten in vitro und in vivo, die in entzünd-
lichen Erkrankungen wie der rheumatoiden Arthritis dazu führt, daß das im Gesunden ausbalan-
cierte System der Osteoblasten-vermittelten Knochenbildung und der Osteoklasten-vermittelten
Knochenresorption in Richtung Knochenresorption verschoben wird. Da TNF die osteogene Dif-
ferenzierung der hämatopoetischen Osteoklastenvorläufer stimuliert, stellte sich die Frage, ob
es auch einen Einfluß auf die osteogene Differenzierung der mesenchymalen Osteoblastenvor-
läufer, zu denen auch ASC zählen, hat.
Zu diesem Zweck untersuchte ich die Proliferation und die osteogene Differenzierung von
ASC unter dem Einfluß von TNF in vitro im Vergleich zu osteogen stimulierten und unstimulier-
ten Zellen. ASC, die sowohl mit TNF als auch osteogen stimuliert wurden, dienten der Untersu-
chung eines Effektes von TNF auf die osteogene Differenzierung unter osteogenen Bedingungen.
TNF bindet zwei Rezeptoren, TNFRSF1A und TNFRSF1B. Beide Rezeptoren wurden von
ASC exprimiert, TNFRSF1B dabei weitaus schwächer als TNFRSF1A. TNF-Behandlung der ASC
veränderte die Expression der Rezeptor-Proteine nicht.
Die TNF-Rezeptoren regulieren drei intrazelluläre Signalwege: Apoptose, den MAP-Kinase-
und den NFκB-Weg. Apoptose wurde in ASC nicht ausgelöst, weder durch TNF noch durch osteo-
gene Stimulation. Der MAP-Kinase-Weg wurde ebenfalls weder durch TNF noch durch osteoge-
ne Stimulation reguliert. Nichtsdestrotrotz waren zwei Mitglieder der MAP-Kinase-Familie, der
Transkriptionsfaktor AP1 und die Kinase p38, konstitutiv bis mindestens Tag sieben der Kultur
aktiviert. Im Gegensatz zum Apoptose- und MAP-Kinase-Weg wurde der NFκB-Weg durch TNF,
aber nicht durch osteogene Stimulanzien, aktiviert, und Ko-Stimulation mit sowohl TNF als
auch osteogenen Stimulanzien bewirkte denselben Effekt wie TNF allein.
TNF erhöhte signifikant die Proliferation der ASC, was auch zutraf für osteogene Stimulation
und Ko-Stimulation mit TNF und osteogenen Stimulanzien.
Der Zellzyklus wurde von TNF in entgegengesetzter Weise reguliert wie durch die osteoge-
nen Stimulanzien. Während TNF den Anteil der ASC in der Synthese-Phase des Zellzyklus’ signi-
fikant reduzierte, wurde dieser durch osteogene Stimulation signifikant erhöht. Ko-Stimulation
der ASC mit sowohl TNF als auch osteogenen Stimulanzien verringerte die Stärke der S-Phasen-
Reduktion durch TNF.
Die metabolische Aktivität der ASC verringerte sich im Verlauf der Kultur unter Stimulation
X
mit TNF zunehmend, während osteogene Stimulation einen starken zwischenzeitlichen Anstieg
bewirkte. Ko-Stimulation bewirkte einen ähnlichen zeitlichen Verlauf der metabolischen Aktivi-
tät wie TNF allein, aber von Anfang an auf niedrigerem Niveau.
Um herauszufinden, ob TNF einen spezifischen osteogenen Effekt hat, habe ich die Expres-
sion und Aktivität einer Reihe osteogener Zeigermoleküle untersucht.
Die Expression des Transkriptionsfaktors ZBTB16 ist ein früher Marker der osteogenen Dif-
ferenzierung. ZBTB16 reguliert Expression und Aktivität des Schlüsseltranskriptionsfaktors der
osteogenen Differenzierung, RUNX2. Die ZBTB16-Expression wurde durch TNF nicht signifikant
beeinflußt, durch osteogene Stimulation und Ko-Stimulation mit TNF und osteogenen Substan-
zen hingegen bis zu 10.000-fach erhöht.
Die Bindung des Transkriptionsfaktors RUNX2 an die regulatorischen Sequenzen seiner Ziel-
gene wurde durch TNF initial erhöht, nachfolgend aber reduziert, hingegen durch osteogene
Stimulation stark erhöht. Ko-Stimulation bewirkte ebenfalls eine initial signifikant verstärkte
Bindung, die allerdings schwächer war als unter ausschließlicher osteogener Stimulation und
nachfolgend stark reduziert wurde.
Neben diesen Transkriptionsfaktoren als frühen Markern der osteogenen Differenzierung
habe ich Expression und Aktivität des Schlüsselenzyms der Kalzifikation der extrazellulären Ma-
trix, der Alkalischen Phosphatase, als einem intermediären Marker untersucht. TNF hatte keinen
signifikanten Effekt auf Expression und Aktivität der Alkalischen Phosphatase, wohingegen die
osteogene Stimulation beide signifikant erhöhte. Die Ko-Stimulation mit TNF und osteogenen
Substanzen erhöhte die Expression und Aktivität der alkalischen Phosphatase in gleichem Maße
wie die osteogene Stimulation allein.
Als einen finalen Indikator der osteogenen Differenzierung analysierte ich den Kalziumge-
halt der extrazellulären Matrix. TNF hatte hierauf keinen Einfluß, während die osteogene Sti-
mulation ihn signifikant erhöhte. In gleichem Maße galt dies für Ko-Stimulation mit TNF und
osteogenen Substanzen.
Demnach induziert TNF nicht die osteogene Differenzierung von ASC als mesenchymalen
Osteoblastenvorläuferzellen in vitro, was im Gegensatz zu der bekannten, die Differenzierung
fördernden Wirkung von TNF auf hämatopoetische Osteoklastenvorläuferzellen in vitro und
in vivo steht. Da TNF unter osteogenen Bedingungen die osteogene Differenzierung von ASC
zusätzlich weder inhibierte noch verstärkte, ist der Effekt der Osteolyse der Röhrenknochen in
chronisch-entzündlichen Erkrankungen, die charakterisiert sind durch erhöhte Konzentrationen
dieses Zytokins, wahrscheinlich hauptsächlich auf den pro-osteoklastogenen Effekt von TNF
zurückzuführen.
Auf den ersten Blick paradoxerweise können dieselben entzündlichen Bedingungen, die die
Reduktion der Mineraldichte in den Röhrenknochen bewirken, an heterotoper Stelle zu einer
Kalzikation führen. Dieser Umstand wurde bislang hauptsächlich für die Kalzifikation der Vas-
kulatur berichtet. Demnach bewirken chronisch-entzündliche Erkrankungen zusammenfassend
ein “Aufweichen” von Hartgewebe und ein “Verhärten” von Weichgewebe.
Die zwei Hauptergebnisse dieser Arbeit verallgemeinernd läßt sich sagen, daß, da TNF in
vitro nicht die osteogene Differenzierungsfähigkeit der ASC reduzierte, aber ihre Proliferation
verstärkte, entzündliche Prozesse in vivo als Promotoren der Stammzellerneuerung angesehen
werden können, ohne einen Einfluß auf deren Differenzierung zu haben, während andere Um-
gebungsfaktoren die Differenzierung dieser vergrößerten Stammzellpopulation in das jeweilige
Gewebe induzieren. Daher erhöht die entzündliche Aktivierung eines infizierten oder beschädig-
ten Gewebes dessen regeneratives Potential initial, benötigt aber zusätzliche Umgebungssignale,
um den Regenerationsprozeß abzuschließen.
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Abstract
The present study aimed at finding out whether an inflammatory treatment of mesenchymal
stem cells (MSC) from the adipose tissue (adipose tissue-derived stem cells, ASC), as was done
by the culture of ASC in tumor necrosis factor- (TNF)-supplemented medium in vitro, will di-
rect these cells into osteogenic differentiation or will affect this differentiation pathway under
osteogenic conditions.
The rationale for the study came from the well-known role of TNF as a promoter of os-
teoclast maturation and activity in vitro and in vivo, which in inflammatory diseases, as e.g.
rheumatoid arthritis, shifts the tightly balanced system of osteoblast-mediated bone formation
and osteoclast-mediated bone resorption towards bone resorption. Hence, if TNF increases os-
teogenic differentiation of hematopoietic osteoclast precursors, it may also have an impact on
differentiation of mesenchymal osteoblast precursors as ASC.
To this end, I analyzed proliferation and osteogenic differentiation of ASC treated with TNF
in vitro in comparison to osteogenically stimulated and unstimulated cells. ASC treated with
both TNF and osteogenic stimulants were analyzed to elucidate the impact of TNF on osteogenic
differentiation under osteogenic conditions.
TNF exerts its cellular effects via two receptors, TNFRSF1A and TNFRSF1B. Both receptors
were found to be expressed on ASC, TNFRSF1B being much weaker expressed than TNFRSF1A,
and TNF treatment did not change the expression levels of both receptor proteins.
The TNF receptors regulate three signal transduction pathways: apoptosis, the MAP kinase
and the NFκB pathway. Apoptosis was not induced in ASC, irrespective of TNF or osteogenic
stimulation. The MAP kinase pathway was also not regulated by TNF or osteogenic stimulation,
although two of its members, the kinase p38 and the transcription factor AP1, were found to be
constitutively activated at least until day seven of culture. Contrastingly, the NFκB pathway was
strongly induced by TNF, but not by osteogenic stimulants, and it was found to be active also
when osteogenic substances were present in addition to TNF.
TNF significantly increased ASC proliferation rates, which was also true for osteogenic stim-
ulation and stimulation with both TNF and osteogenic substances.
Cell cycle data however showed contrasting effects for TNF and osteogenic stimulation.
While TNF significantly decreased the portion of ASC within the synthesis phase of the cell
cycle, osteogenic substances increased this portion. Treatment with both TNF and osteogenic
stimuli yielded a lower decrease of synthesis phase cells as TNF treatment alone.
The temporal course of the metabolic activity of ASC was changed by TNF in direction of
a continuous decrease with increasing duration of cell culture, whereas osteogenic stimulation
induced a strong intermediate peaking. Treatment with both osteogenic stimulants and TNF
yielded a temporal course of metabolic activity resembling that found for TNF alone, but at a
lower level of overall metabolic activity.
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To elucidate whether TNF has any specific effect on osteogenic differentiation of ASC, I
analyzed expression and activity of a variety of osteogenic markers.
As an early hallmark of osteogenic differentiation, expression of the transcription factor
ZBTB16, an upstream regulator of expression and activity of the osteogenic key transcription fac-
tor RUNX2, was analyzed. ZBTB16 expression was neither significantly increased nor decreased
by TNF treatment of ASC, whereas osteogenic stimulation and stimulation with both TNF and
osteogenic stimulants yielded a significant and up to 10,000-fold increase in expression of this
gene.
Binding of the osteogenic key transcription factor RUNX2 to the regulatory sequence of
its target genes was found to be reduced by TNF, but significantly increased in osteogenically
stimulated ASC. Co-stimulation with both TNF and osteogenic stimulants also resulted in a
significant, though less strong increase in DNA-binding activity of this transcription factor.
Besides these osteogenic transcription factors as early markers of osteogenic differentiation,
I analyzed the expression and activity of the key enzyme involved in extracellular matrix cal-
cification, alkaline phosphatase, as an intermediate marker. TNF treatment of ASC had no sig-
nificant impact on expression and activity of this enzyme, whereas osteogenic stimulation and
co-stimulation with TNF and osteogenic stimulants significantly and equally strong increased it.
As a final indicator of osteogenic differentiation, I analyzed the extent of extracellular matrix
calcium content. TNF treatment of ASC had no effect on extracellular matrix calcium content,
whereas osteogenic stimulation and co-stimulation with TNF and osteogenic stimulants signifi-
cantly and equally strong increased it.
Thus, treatment of ASC with TNF did not induce osteogenic differentiation of these stem
cells in vitro. This is in contrast to the well-known differentiation-promoting effect of TNF on
osteoclast precursor cells from the hematopoietic lineage. Since TNF did neither increase nor
reduce the osteogenic differentiation capacity of ASC in an osteogenic environment in vitro, the
effect of osteolysis of the long bone observed in chronic inflammatory diseases characterized by
increased TNF levels presumably is mainly due to the pro-osteoclastogenic effect of this cytokine
in vivo.
Seemingly paradoxically, the same inflammatory stimuli that induce osteolysis of the long
bone can nevertheless induce calcification at ectopic sites, as was reported primarily for the
vasculature via a variety of different pathways. Therefore, chronic inflammatory diseases can be
summarized to cause “softening” of hard tissue and simultaneous “hardening” of soft tissue.
Generalizing the two main findings of this study, i.e. the finding that TNF did not impair ASC
osteogenic differentiation capability in vitro, but increased ASC proliferation rate, inflammatory
processes in vivo appear to act as a driving force for stem cell self-renewal without affecting their
differentiation potential, and environmental factors other than the mediators of inflammation
govern subsequent differentiation of this enlarged stem cell pool into the desired tissue. Thus,
inflammatory activation of infected or damaged tissue increases its regenerative potential as a
starting point, but requires further signals for regeneration to complete.
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Chapter 1
Introduction
1.1 Aim and Motivation
The present study aimed at finding out whether an inflammatory treatment of mesenchymal
stem cells (MSC) from the adipose tissue (adipose tissue-derived stem cells, ASC), as was done
by the culture of ASC in tumor necrosis factor- (TNF)-supplemented medium in vitro, will di-
rect these cells into osteogenic differentiation or will affect this differentiation pathway under
osteogenic conditions.
The rationale for the study came from the well-known role of TNF as a promoter of os-
teoclast maturation and activity in vitro and in vivo, which in inflammatory diseases, as e.g.
rheumatoid arthritis, shifts the tightly balanced system of osteoblast-mediated bone formation
and osteoclast-mediated bone resorption towards bone resorption [Azuma et al., 2000]. Hence,
if TNF increases osteogenic differentiation of hematopoietic osteoclast precursors, it may also
have an impact on differentiation of mesenchymal osteoblast precursors as ASC.
1.2 Adipose Tissue-Derived Stem Cells
1.2.1 Biological Niche of ASC
ASC are isolated from the stromal vascular fraction of subcutaneous adipose tissue obtained in
large quantity and minimally invasive by liposuction. ASC, as MSC, are adult stem cells which
embryonically originate from the mesodermal layer. They are multipotent, i.e. they are able
to differentiate into all types of cells belonging to the connective tissue, as e.g. adipocytes, os-
teoblasts, chondrocytes and myocytes [Zuk et al., 2001]. In vitro, ASC express typical MSC
markers as cluster of differentiation (CD) 29, CD44, CD105 and CD166, and in primary culture
immediately after isolation also STRO-1 antigen [Kalbermatten et al., 2011], a surface protein
whose expression was found to be characteristic for that subpopulation of cells from bone mar-
row aspirates that is able to undergo osteoblastogenesis [Gronthos et al., 1994; Kaneko et al.,
2009].
As other types of MSC that were found to be in close contact to blood vessels within their
appropriate niche in vivo [Crisan et al., 2008; da Silva Meirelles et al., 2008], ASC are also of
perivascular origin, express the pericyte marker CD34 and were found to interact with endothe-
lial cells to stabilize vascular networks in vitro [Traktuev et al., 2008]. Therefore, the charac-
teristic of CD34 expression shifted from being formerly interpreted as an exclusive feature of
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activated hematopoietic precursors towards being nowadays considered as a global marker of
vasculature-associated cells [Furness and McNagny, 2006].
1.2.2 Differentiation Capabilities of ASC
Before I go into detail regarding the differentiation capacities of ASC, I have to define the terms
used in discussions of stem cell differentiation and which were concisely reviewed by Ratajczak
and colleagues [Ratajczak et al., 2008].
Differentiation capacities of cells during development continuously decline from the fertil-
ized egg called zygote to the fully differentiated adult tissue. The zygote is able to differentiate
into both all tissues and organs of the developing organism and into the placental tissue govern-
ing nutrient supply and exchange of metabolic waste products. Therefore, the zygote is said to
be totipotent. Embryonic stem (ES) cells, which are derived from a morula-stage embryo, from
the inner cell mass of a blastocyst-stage embryo or from the epiblast cells of a cylinder-stage
embryo, can also differentiate into all cells the developing organism will be made of, but have
lost the capability to differentiate into placental tissue and therefore are referred to be pluripo-
tent. These pluripotent stem cells can give rise to any of the three embryonic germ layers the
embryo is made of, i.e. the ectodermal, the mesodermal and the endodermal layer. Each of the
germ layers gives rise to a distinct set of tissues and organs, and stem cells that are able to
differentiate into any of these tissues and organs of a distinct germ layer are called multipotent.
Stem cells that are able to differentiate only into one distinct tissue or organ of a distinct germ
layer are said to be monopotent.
After embryogenesis has completed and the entire organism is formed, cells having reached
the end of their lifetime or which were damaged in any way are replaced by adult stem cells
differentiating into the cell type of the affected tissue. In case this replacement process occurs
by stem cells originating from another embryonic germ layer, this process is called transdif-
ferentiation. Adult stem cells reside in specialized environments of the body which are called
“niches” and which have the property to promote self-renewal (proliferation) of the stem cells
and preclude their spontaneous differentiation.
Following these definitions, ASC reside to the perivasculature of adipose tissue as their niche
and are adult multipotent stem cells, since they were shown to differentiate into all mesenchy-
mal tissues which themselves develop from the mesodermal layer during embryogenesis.
Moreover, there are also reports describing pluripotent differentiation capabilities of ASC.
ASC were found to express embryonic stem cell markers as POU5F1 (formerly called OCT4)
and NANOG [Kalbermatten et al., 2011], what suggests even broader differentiation capabili-
ties, and indeed, some early indications of a transdifferentiation capability of mesodermal ASC
into human ectodermal neuron-like cells [Zuk et al., 2002] were confirmed in vitro for rat ASC
which differentiated into Schwann cells and contributed to nerve regeneration mostly indirectly
by secretion of neurotrophic factors, but hardly by direct differentiation into neural cells [Kalber-
matten et al., 2011]. Supportingly, neural pre-differentiation of rat ASC in vitro improved their
differentiation into glia cells in the healing of a spinal cord injury in vivo in comparison to un-
differentiated ASC, but did not augment their neuronal differentiation [Arboleda et al., 2011].
Therefore, ASC are currently thought to participate in neuronal regeneration in vivo mainly by
differentiating into neural stromal cells and by secretion of paracrine factors that recruit other
neuronal precursors from their niches.
Besides their neural differentiation capacities, the potency of ASC to differentiate into ec-
todermal tissues was substantiated by the finding of ASC differentiating into epithelial cells
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[Gimble and Bunnell, 2010]. Thus, in addition to their ability to differentiate into mesoder-
mal smooth muscle, cardiac progenitor, endothelial and hepatic cells, these findings underline
a broad differentiation capacity of ASC, being able to differentiate not only into different mes-
enchymal tissues and thus along the mesodermal lineage, but also to transdifferentiate into the
ectodermal lineage to participate in neural regeneration. During embryogenesis, this process
of epithelial-to-mesenchyme transition is of paramount significance, since neural crest cells in
this way give rise to not only ectodermal tissues as neurons, glia cells, endocrine cells and skin
melanocytes, but also to mesenchymal cell types as chondrocytes, osteoblasts, myofibroblasts
and adipocytes [Douarin et al., 2008].
1.2.3 ASC Isolation
In addition to their broad differentiation capacity, ASC, as compared to bone marrow-derived
MSC, offer the advantage of being isolated by minimally invasive means, in large quantity and
from mostly young and healthy donors.
The liposuction technique that was used for adipose tissue isolation in this study was based
on the subcutaneous application of a sodium chloride solution which is exhausted from the
adipose tissue after mechanical agitation. This tumescence-based technique was reported to
offer the best results for subsequent stem cell isolation with respect to ASC viability, prolifera-
tion rate and osteogenic and chondrogenic differentiation capacity [Oedayrajsingh-Varma et al.,
2006]. ASC isolation from directly resected adipose tissue or by ultrasound-based liposuction
techniques yielded significantly less viable cells.
The anatomical site the adipose tissue was harvested from was reported to influence ASC
yield, the abdominal region yielding significantly more ASC than the hip or thigh region [Ju-
rgens et al., 2008]. However, the differentiation capacity of ASC isolated from these differing
sites did not differ. For human bone marrow-derived MSC, osteogenic and chondrogenic as well
as adipogenic and myogenic differentiation were reported to be even independent of the donor
age [Roura et al., 2006; Fickert et al., 2011], what may also be true for ASC. Therefore, the
reduced regenerative potential of elderly people presumably is due to a reduced total number
of adult stem cells within their respective niches, but not due to an impaired differentiation
capacity of these stem cells. However, the body mass index of the donor individual was re-
ported to negatively correlate with ASC adipogenic differentiation capacity, whereas ASC yield
was reported to positively correlate with this parameter [Isakson et al., 2009]. Hence, a lesser
adipogenic differentiation capacity in vivo is compensated by a higher number of progenitor
cells.
The time between liposuctive surgery and isolation of ASC from the adipose tissue should
not exceed one day, since increasing storage times of the adipose tissue at room temperature for
up to three days was shown to significantly and increasingly reduce ASC yield [Carvalho et al.,
2011]. By comparing these results to those obtained in another study [Matsumoto et al., 2007],
storage of adipose tissue at 4 ◦C is not recommended.
Thus, ASC can be isolated from various adipose tissues with varying yield, but unchanged
differentiation capacity for subsequent in vitro or in vivo approaches. Most importantly, the
isolation technique needs to be sufficiently gentle to avoid ASC death in situ, but rough enough
to allow liberation of the adipose tissue from the patient. Currently, tumescence-based systems
balance these opposed demands the best.
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1.2.4 ASC Culture
ASC have a remarkable long-term genomic stability. Culture of these cells for up to 35 passages
was not accompanied by accumulation of genomic aberrations, whereas other primary cells as
e.g. chorionic villus cells showed 12 % tetraploidy even after eight passages [Grimes et al.,
2009].
Nevertheless, the duration of cell culture, as reflected by the number of passages, affects pro-
liferation and differentiation behaviour. Osteoblast-like cells from bone biopsies yielded highest
proliferation rates in the fourth passage and subsequently decreased their proliferation rate
as well as their osteogenic differentiation capacity [Pradel et al., 2008], which was confirmed
for human bone marrow stromal cells [Rosa and Beloti, 2005]. Therefore, ASC, as other mes-
enchymal stem cells, should be used as early as possible after isolation and adaptation to in
vitro conditions. In this study, they were seeded into experimentation exclusively in the fourth
passage.
Use of differing serum lots in culture of ASC derived from the same patient can change dif-
ferentiation capacities of these cells, but no serum substitute so far has been shown to be as
reliable as serum with respect to differentiation along the adipogenic, osteogenic and chondro-
genic lineage [Lund et al., 2009]. Moreover, not only the particular serum chosen influences ASC
differentiation, even the composition of the basal medium does. Alpha-modified Eagle medium
(MEM) in the same study was reported to induce stronger proliferation as well as adipogenesis
and osteogenesis, but weaker chondrogenesis in ASC than Dulbecco’s MEM. Therefore, some
media formulations appear to promote distinct differentiation pathways, and no single medium
equally well supports all of them. With respect to these inherent limitations, I decided to use
the widely-used DMEM in all experiments.
Additionally, use of cryopreserved cells can alter experimental results in comparison to
non-cryopreserved cells, but also in dependence on the cryopreservation method used. The
osteogenic differentiation capacity of osteoblast-like cells was reported to differ with respect
to the cryproservation method used, the best method being freezing cells in DMEM contain-
ing 10 % DMSO without any serum or serum replacement and culturing cells after thawing in
DMEM supplemented with autologous serum [Reuther et al., 2006]. However, other cell types
may require other freezing conditions. To avoid any impact of cryopreservation on experimental
outcome, use of cryopreserved cells was completely avoided in this study.
1.2.5 Summary on ASC in vitro
Summarizingly, ASC represent an important population of mesenchymal stem cells. They can
be obtained minimally invasive and in large quantity from various adipose tissues, have a dif-
ferentiation capacity clearly exceeding that of the widely used bone marrow-derived MSC, but
do not require higher effort for culture in vitro. Therefore, they are a crucial type of adult stem
cells for fundamental as well as for translational research.
1.3 TNF, its Receptors and Signal Transduction Pathways
1.3.1 TNF
Tumor necrosis factor (TNF, formerly TNFα) was named after its inductive effect on necrosis of
tumors, a condition discovered almost 150 years ago in cancer patients showing spontaneous
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tumor regression after acute bacterial infection [Clark, 2007]. In 1975, the excess production of
the pro-inflammatory cytokine TNF by bacterial endotoxin-activated macrophages was demon-
strated to kill these tumors [Carswell et al., 1975; Helson et al., 1975; Mansell et al., 1975].
However, the molecular identity of TNF was not resolved until 1985 [Pennica et al., 1984; Ag-
garwal et al., 1985].
TNF is produced predominantly by activated macrophages and T lymphocytes as a plasma
membrane-bound pro-protein (“mTNF”) which subsequently undergoes cleavage in its extracel-
lular domain by metalloproteinases to give rise to the shorter soluble form of TNF. Both the
membrane bound and the soluble form of TNF are biologically active. The metalloproteinase
that cleaves TNF was formerly called TNFα converting enzyme (TACE), but is nowadays offi-
cially referred to as ADAM metallopeptidase domain 17 (ADAM17).
TNF is the major cytokine involved in the pathogenesis of chronic inflammatory diseases,
and its neutralization has proven to efficiently ameliorate the prognosis of inflammatory diseases
as rheumatoid arthritis and Crohn’s disease [Clark, 2007].
1.3.2 TNF Receptors and Signaling Pathways
TNF binds two distinct receptors, TNF receptor 1 (tumor necrosis factor receptor superfamily
member 1A, TNFRSF1A) and 2 (tumor necrosis factor receptor superfamily member 1B, TN-
FRSF1B). Upon binding of a homotrimer of TNF molecules, the TNF receptors that initially
were organized as trimers loosely interconnected via their pre-ligand-binding assembly domain
(PLAD) form a stable trimeric complex [MacEwan, 2002]. Binding of TNF to the extracellular
portion of the receptor results in the release of inhibitory factors bound to the intracellular do-
mains of these transmembrane receptors, and these intracellular domains subsequently recruit
a variety of different factors, so-called adaptor proteins, that activate downstream signaling
cascades [Wajant and Scheurich, 2011]. Thus, activated TNF receptors do explicitely not have
catalytic activity and are regulated through the presence or absence of cytoplasmic inhibitory
factors.
The cellular functions first discovered to be regulated by TNFRSF1A were apoptosis, in-
flammatory response and function of the immune system, but later on also proliferation and
differentiation [Chen and Goeddel, 2002]. The major pathways activated upon TNF binding
to TNFRSF1A are the nuclear factor of kappa B light chain (NFκB), mitogen-activated protein
kinase (MAPK) and apoptosis pathway.
TNFRSF1B also directly regulates activation of the NFκB and MAPK pathway, whereas acti-
vation of the apoptosis pathway occurs only indirectly via cross-talk with TNFRSF1A signaling
[Faustman and Davis, 2010].
Although TNFRSF1A cannot directly activate the NFκB pathway, it can do so by crosstalk-
ing with TNFRSF1B [Bradley, 2008]. Vice versa, TNFRSF1B can pass its ligand to TNFRSF1A
for activation of apoptosis [Haridas et al., 1998]. Hence, TNF signaling involves not only cross-
talk between the signaling pathways regulated by one distinct TNF receptor, but involves also
cross-talk between the pathways activated by different TNF receptors. Figure 1.1 on page 6 sum-
marizes these findings and depicts the signal molecules analyzed in ASC to determine activation
of a distinct pathway.
TNFRSF1A is expressed on most cell types, whereas TNFRSF1B is largely confined to cells
of the hematopoietic lineage and to endothelial cells [Santee and Owen-Schaub, 1996], but
was lately reported to be also expressed on diverse neuronal subtypes and mesenchymal stem
cells [Faustman and Davis, 2010]. Despite the activation of other non-TNF receptor-regulated,
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Figure 1.1: TNF receptors and downstream signaling cascades. Binding of TNF to its receptors, designated
here as TNFR1 and TNFR2, regulates activation of three distinct signaling pathways: the apoptosis pathway,
the MAPK and NFκB pathway (see left, middle and right part of this illustration, respectively). I analyzed
NFκB activation by assessing translocalization of the NFκB transcription factor subunit p65 to the nucleus.
MAPK pathway activation was analyzed by assessing nuclear translocalization of the kinases extracellular
signal-regulated kinase 1 and 2 (ERK1/2) and p38 as well as by assessing nuclear translocalization of the
transcription factor activator protein 1 (AP1) subunit cJUN. Activation of the apoptosis pathway was assessed
indirectly by analyzing cytoskeletal organization, nuclear envelope integrity and cellular viability. Illustration
taken and modified from Pathway Central [SABiosciences, 2011].
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but cross-talking intracellular signal transduction pathways, the ratio of the expression of both
receptors on a distinct cell type thus determines the outcome of receptor activation by TNF. For
ASC, expression of TNF receptors was not analyzed so far.
1.4 Osteogenic Differentiation in vitro
1.4.1 Osteogenic Differentiation Markers in vitro
Osteogenic differentiation of ASC was analyzed by quantifying the expression of the osteogenic
transcription factor zinc finger and BTB domain containing 16 (ZBTB16), the DNA-binding ac-
tivity of the runt-related transcription factor 2 (RUNX2), expression and activity of extracellular
matrix-mineralizing alkaline phosphatase (ALPL) and the calcium content of the extracellular
matrix.
The Role of ZBTB16 in Osteogenic Differentiation
The important role of ZBTB16 in osteogenic differentiation is highlighted by the severe skeletal
defects present in patients suffering from monozygous loss-of-function mutations of the ZBTB16
gene [Fischer et al., 2008]. In mice, Zbtb16 regulates limb and axial skeletal patterning by im-
pacting differentiation of limb bud cells through the Hox family of genes as well as proliferation
and apoptosis through the Bmp gene family, in the latter case to give rise to the interdigital
separations [Barna et al., 2000].
ZBTB16, the former promyelocytic leukemia zinc finger (PLZF), is a transcription factor
which was reported to increase transcript and protein activity levels of the osteogenesis key
transcription factor RUNX2 described below and thus indirectly promotes expression of RUNX2-
targeted genes involved in osteoblastic differentiation of human bone marrow-derived MSC
[Ikeda et al., 2005]. When the osteogenic differentiation program is in the course of completing,
expression of ZBTB16 is no longer required and was reported to decline gradually, as was shown
for human CD34 positive bone marrow progenitor cells [Reid et al., 1995].
As an early marker of osteogenic differentiation, I quantified expression of the ZBTB16 gene
in ASC following treatment with TNF and in comparison to osteogenic stimulation.
The Role of RUNX2 in Osteogenic Differentiation
RUNX2 is a transcription factor involved in a large variety of processes in bone development in
vivo, as is seen in patients suffering from the heterogeneous disease cleidocranial dysplasia that
is caused by mutations of the RUNX2 gene [Otto et al., 2002] (see figure 1.2 on page 8).
RUNX2, formerly known as core binding factor-alpha 1 (CBFA1), was shown to upregulate
expression of osteopontin, osteocalcin, alkaline phosphatase and collagen 1 and 10 genes during
osteogenic differentiation in vitro [Komori, 2010]. In rodents, Runx2 levels are upregulated in
the osteoblastic lineage, which is a direct consequence of an increased transcription rate of the
gene [Shui et al., 2003] as well as a decreased proteasomal degradation of the protein product
through Bmp2-induced Runx2 acetylation in turn precluding Runx2 ubiquitinylation [Jeon et al.,
2006]. In differentiation of human osteoblasts however, RUNX2 is permanently and constantly
expressed, RUNX2 activity being regulated exclusively post-transcriptionally through the extent
of phosphorylation [Shui et al., 2003].
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Figure 1.2: The role of RUNX2 mutations in skeletal development. (A) Runx2 knockout in mice inhibits
chondrocyte to bone transition in the process of endochondral ossification: (a) During skeletal development,
mice wild-type for Runx2 show cartilaginous as well as bony parts of the skeleton, as demonstrated by alcian
blue staining and alizarin red staining, respectively. (b) Mice with fully deleted Runx2 show normal cartilage
development, but complete absence of ossification. These mice die shortly after birth. Illustration taken and
modified from [Gilbert and National Center for Biotechnology Information (U.S.), 2000]. (B) In humans,
the most prominent non-lethal skeletal disease associated with mutations of the RUNX2 gene is Cleidocranial
Dysplasia, a disease characterized by delayed closure of the cranial sutures, hypoplastic or aplastic clavicles and
multiple dental abnormalities. The image shows an individual with clavicular hypoplasia resulting in extreme
flexibility of shoulder deflection even to the midline. The disease is inherited in an autosomal dominant fashion,
but epidemiologically shows a high incidence of de novo mutations. Illustration taken from [Roberta et al.,
1993 - 2011].
Therefore, I did not analyze RUNX2 expression, but RUNX2 binding to the consensus pro-
moter sequence of its target genes as the only reliable measure of active RUNX2 in the human
system and as an early marker of osteogenic differentiation of ASC in vitro.
The Role of ALPL in Osteogenic Differentiation
The liver/bone/kidney-specific alkaline phosphatase (ALPL) plays a pivotal role in osteogenesis
in vitro and in vivo. Alpl-deficient mice exhibit impaired skeletal calcification [Anderson et al.,
2004], which is also true for humans where mutations in the ALPL gene were found to be
associated with bone diseases as skeletal hypophosphatasia in infants [Baumgartner-Sigl et al.,
2007] and age-related bone loss in adults [Goseki-Sone et al., 2005] (see figure 1.3 on page 9).
ALPL plays a role in the process of extracellular matrix mineralization, although the mech-
anism is still not completely understood. It was discovered that calcification in osteogenic dif-
ferentiation occurs via the generation of vesicles that bud off from the osteoblast’s cytoplasmic
membrane [Anderson, 1995]. These so-called matrix vesicles contain a high concentration of
calcium and inorganic phosphate ions and make up an appropriate environment for nucleation
of hydroxyapatite crystals. When growing, these crystals destroy the matrix vesicle’s membrane
and grow further using extracellular calcium and phosphate ions, which finally generates the
calcified extracellular matrix of bony tissue.
Alkaline phosphatase is localized to the outer surface of the matrix vesicle membrane and
degrades inorganic pyrophosphate present in the extracellular matrix, which both reduces the
amount of hydroxyapatite formation-inhibiting pyrophosphate and yields free inorganic phos-
phate [Orimo and Shimada, 2008]. This free inorganic phosphate can then be incorporated
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Figure 1.3: The role of ALPL mutations in human skeletal diseases. The most prominent skeletal disease
caused by mutations of the ALPL gene is hypophosphatasia. Hypophosphatasia is characterized by defective
mineralization of bone and teeth in the presence of low activity of serum and bone alkaline phosphatase. (A) Ra-
diographic image showing loss of bone surrounding teeth in childhood hypophosphatasia. (B) Pseudofracture
in a long bone in adult hypophosphatasia. There are two different inheritance patterns for hypophosphatasia
which differ in the age of onset of the disease: Perinatal and infantile hypophosphatasia are inherited in an
autosomal recessive fashion, whereas the late onset types of the disease may also be inherited in an autosomal
dominant way, depending on the effect the ALPL mutation has on the phosphatase’s activity. The incidence
of de novo mutations of ALPL, in contrast to RUNX2, is low. Illustrations taken and modified from [Roberta
et al., 1993 - 2011].
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from the extracellular space into the matrix vesicle by type III sodium-phosphate cotransporters.
In conjunction with several calcium ion-binding phospholipids and proteins as well as annexins
which have the ability to function as calcium ion channels through the matrix vesicle membrane,
the calcium and phosphate ion concentration inside the matrix vesicle is raised to facilitate nu-
cleation of hydroxyapatite crystals [Anderson, 1995].
After completion of the nucleation phase, the ALPL-mediated liberation of inorganic phos-
phate promotes the reaction with free calcium ions to form hydroxyapatite in the extracellular
space [Orimo and Shimada, 2008]. Thus, ALPL activity is required for both the initiation and
the propagation phase of mineralization.
I analyzed the extent of extracellular matrix calcification as a final parameter of osteogenic
differentiation and the expression of the alkaline phosphatase gene and the activity of the gene
product as median markers of osteogenic differentiation of ASC.
Proliferation, Cell Cycle and Metabolic Activity
Proliferation, cell cycle and and metabolic activity are basal parameters of living cells that
were analyzed in addition to the specific markers of osteogenic differentiation in order to more
broadly characterize the changes induced by the differentiation processes.
The increase in cell number, called proliferation, is regulated in a tightly controlled system
of cell cycle phases. The cell cycle defines all replicative stages of a cell. It is composed of a
DNA synthesis (S) phase and a mitosis (M) phase which are separated from each other by gap
(G) phases. Progression of cells through these phases of the cell cycle involves passage through
several quality control checkpoints to avoid erroneous reduplication (see figure 1.4 on page 11).
By summing up the time needed for a cell to pass all of the distinct stages of the cell cycle,
the duration of one cellular replication can be calculated. Since the individual cells of a popu-
lation usually pass the cell cycle not in a synchronized fashion, the percentage of all cells of a
population that is present in a distinct cell cycle stage directly corresponds to the time needed
to pass this stage. Hence, a large percentage of cells in a distinct cell cycle phase reflects slow
passage through this stage.
Proliferation, but also differentiation of cells, involves metabolic pathways that break down
larger molecules into smaller ones to release energy (catabolism), but also biosynthetic (an-
abolic) reactions. Therefore, ASC metabolic activity was analyzed in an assay quantifying the
cellular capacity for NADH and NADPH generation, these reduced redox equivalents being gen-
erated in catabolic reactions as e.g. glycolysis and their generation rate thus reflecting overall
cellular metabolic activity.
1.4.2 Bone Remodeling
The bony structures generated during embryogenesis are subject to lifelong remodeling. In this
manner, the complete skeleton is replaced every ten years [Novack, 2011]. The process of re-
modeling is governed by a tightly balanced system of bone matrix-secreting cells (osteoblasts)
and bone matrix-resorbing cells (osteoclasts) (see figure 1.5 on page 11).
Regulation of Bone Remodeling
Bone remodeling is regulated via the rate of differentiation of osteoclast and osteoblast precur-
sors as well as via the bone-resorbing and bone-forming activity of the corresponding mature
10
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Figure 1.4: Progression and regulation of the cell cycle. (A) Entry into the M phase after DNA replication
(G2 checkpoint), exit from the M phase (metaphase checkpoint) as well as entry into the S phase after mitosis
(G1 checkpoint) are subject to intrinsic cellular quality control: In case DNA synthesis or mitosis did not take
place free of errors, error factors are produced that arrest the cell cycle at the corresponding checkpoints until
the error is repaired and the error signal disappears. If the error cannot be corrected, the cell is subjected
to apoptosis. (B) The factors driving cellular progression through the cell cycle are called cyclins and are
regulated by phosphorylation through cyclin-dependent kinases (CDKs). The constitutively expressed CDKs
are only active when bound to cyclins. The levels of individual cyclins change due to proteasomal degradation
during the cell cycle, what makes the activity of the cyclin-CDK complexes change in a simultaneous manner.
By this means, passage through the distinct cell cycle phases is governed. As is illustrated for human CDK2,
cyclin-binding to CDK2 makes the CDK2 T-loop to move out of the kinase’s active site, which results in
partial activation of the enzyme. Full activation occurs upon phosphorylation through CDK-activating kinase
(CAK) at the CDK T-loop. Illustrations taken from [Alberts et al., 2002].
Figure 1.5: The remodeling of bone. Bone is com-
posed of bone matrix-secreting cells (osteoblasts)
and matrix-eroding cells (osteoclasts). These cells
differentiate from mesenchymal and hematopoi-
etic stem cells, respectively. When osteoblasts be-
come entrapped within the bone matrix, they dif-
ferentiate into osteocytes. These osteocytes are
connected to each other and to the surfacial os-
teoblasts by channels called lacunae. Rupture of
a lacuna ceases communication and induces osteo-
cytes to secrete signals inducing bone regeneration
at the affected site. Resorption of the bone ma-
trix at the affected site usually takes only a few
weeks, whereas matrix formation is much slower
and takes several months to complete, as multiple
layers of new bone are formed by successive waves
of osteoblasts. Illustration taken from [Office of
the Surgeon General (U.S.), 2004].
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cells.
Following the observation that mature monocytes and macrophages are able to differenti-
ate into mature osteoclasts in vitro [Udagawa et al., 1990], receptor activator of nuclear factor
kappa-B ligand (RANKL, officially designated tumor necrosis factor (ligand) superfamily mem-
ber 11 (TNFSF11)), was revealed as the driving force of osteoclastogenesis in bone remodeling
in vivo, Rankl knockout mice being found to develop severe osteopetrosis due to a complete lack
of osteoclasts [Kong et al., 1999].
Impact of TNF on Bone Remodeling
As RANKL, also TNF was found to induce osteoclastogenesis [Boyce et al., 2010]. Both cy-
tokines induce osteoclastogenesis through activation of the canonical NFκB pathway signaling
through the p65(RELA)-NFKB1 heterodimer, whereas RANKL also activates the non-canonical
NFκB pathway which signals through p52(RELB)-NFKB2. As was reported for Rankl knockout
mice, double knockouts for both the canonical and the non-canonical NFκB pathway developed
severe osteopetrosis due to insufficient osteoclast precursor maturation.
The primary source of RANKL driving osteoclastogenesis in vivo is marrow stromal cells
[Kitaura et al., 2004], and TNF was found to increase RANKL secretion by these cells [Romas
et al., 2002]. Importantly, a high TNF concentration of 50 ng/ml was reported to induce osteo-
clastogenesis in vitro even without RANKL-secreting marrow stromal cells. However, this direct
contribution of TNF on osteoclastogenesis in vivo has to be questioned, since in chronic inflam-
matory diseases TNF concentrations were not reported to exceed 50 pg/ml (see page 91 for
further details).
In addition to their role in promoting osteoclastogenesis by RANKL secretion, marrow stro-
mal cells were both in vitro and in vivo reported to secrete a decoy receptor for RANKL, osteo-
protegerin (OPG), which inactivates the pro-osteoclastogenic signal by preventing RANKL from
binding to RANK on osteoclast precursors [Simonet et al., 1997]. Hence, the ratio of OPG to
RANKL determines the outcome on osteoclast maturation rate. TNF and glucocorticoids were
reported to decrease the OPG/RANKL ratio, which promotes osteoclastogenesis, whereas TGFβ
and estrogens increase it [Kearns et al., 2008; Wright et al., 2009]. In line with the increase in
osteoclastogenesis by TNF, NFκB activation in osteoblasts was reported to inhibit osteoblastic
bone matrix-secretion activity in vivo [Novack, 2011], what substantiates the osteolytic proper-
ties of TNF.
The impact of TNF on bone remodeling is summarized in figure 1.6 on page 13.
1.4.3 Induction of Osteogenic Differentiation in vitro
Osteogenic differentiation of ASC in vitro can be induced by molecules of the transforming
growth factor beta (TGFβ) superfamily, as e.g. by bone morphogenetic protein 2 (BMP2), but
also by glucocorticoids as dexamethasone [Lindroos et al., 2011; Kroeze et al., 2011]. Since
BMP2-mediated osteogenic differentiation of ASC is less well described and since there are in-
dications that ASC do not have a functional canonical BMP2 signaling pathway, suggesting that
BMP2 may not influence the osteogenic fate of these cells [Zuk et al., 2011], induction of os-
teogenic differentiation of ASC in this study was done using cell culture medium supplemented
with dexamethasone, ascorbic acid and β-glycerophosphate.
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Figure 1.6: The role of TNF in bone remodeling.
TNF, as other pro-inflammatory stimuli like IL1,
stimulates RANKL expression on the surface of os-
teoblasts. RANKL binds to a receptor on the sur-
face of osteoclast precursors which is called RANK.
This stimulates osteoclast precursors to differenti-
ate into mature osteoclasts, but also increases the
resorptive activity of mature osteoclasts. To fast
shut down stimulation of osteoclastic differentia-
tion, osteoblasts secrete osteoprotegerin (OPG), a
soluble factor binding RANKL and thus prevent-
ing it from activating the RANK receptor. Besides
IL1, also parathyroid hormone (PTH), 1,25 dihy-
droxy D (calcitriol, the active form of vitamin D3)
and prostaglandin E2 (PGE2) stimulate RANKL
expression by osteoblasts, but also expression of
macrophage colony stimulating factor (M-CSF),
which induces differentiation of pre-osteoclast pre-
cursors into pre-osteoclasts. Thus, the osteoclastic
differentiation rate is tightly bound to the number
and activity of osteoblasts to balance bone resorp-
tion and bone formation. Illustration taken from
[Office of the Surgeon General (U.S.), 2004].
The Role of β-Glycerophosphate in Induction of Osteogenic Differentiation
β-Glycerophosphate serves as a source of inorganic phosphate ions after hydrolyzation through
phosphatases as alkaline phosphatase [Chung et al., 1992]. In addition, β-glycerophosphate
induces ALPL activity in both the initiation and the propagation phase of matrix mineraliza-
tion [Orimo and Shimada, 2008]. The phosphate ions liberated from β-glycerophosphate react
with extracellular calcium ions to form minerals of tricalcium orthophosphate to build up the
calcified extracellular matrix of bony tissue. Via this general mechanism, β-glycerophosphate
can promote osteogenic differentiation of a broad range of osteoblastic progenitor cells across
different species.
The β-glycerophosphate concentration used here was 10 mM, which is in accordance with
all publications on osteogenic differentiation of mesenchymal stem cells that were analyzed
[Jaiswal et al., 1997; Wang et al., 2006; Hou et al., 2007; Jaeger et al., 2008; Celebi et al.,
2010; Liu et al., 2010].
The Role of Ascorbic Acid in Induction of Osteogenic Differentiation
Ascorbic acid is a water-soluble organic compound that cannot be synthesized by humans and
is designated as vitamin C. Dietary deficiency in ascorbic acid will result in scurvy, a disease
characterized by weakening of the extracellular matrix [Munday, 2003]. The major component
of the organic extracellular matrix of connective tissue in general and bone in special is collagen,
and ascorbic acid was found to play an important role in the biosynthesis of collagens, as is
illustrated in figure 1.7 on page 14.
From these findings, it results that a portion of all active prolyl hydroxylases catalyzes
the oxidative decarboxylation of α-ketoglutarate without simultaneously hydroxylating colla-
gen proline residues, which vice versa increasingly reduces the portion of active hydroxylases.
Connective tissue made from such insufficiently hydroxylated collagen fibers is very weak, since
13
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Figure 1.7: The role of ascorbic acid in collagen biosynthesis. In collagen biosynthesis, an enzyme called
prolyl hydroxylase catalyzes the transfer of an oxygen atom from molecular oxygen to a collagen proline
residue and thus generates hydroxyproline (A). The remaining oxygen atom is transferred to α-ketoglutarate,
which subsequently decarboxylates into succinate. Activation of molecular oxygen is assisted by an Fe2+ ion in
the hydroxylase’s active center. However, the enzyme can also convert α-ketoglutarate into succinate without
hydroxylating proline, which leaves one oxygen atom in the hydroxylase’s catalytic center and thus inactivates
it. (B) In order to regenerate the prolyl hydroxylase in that case, the oxidized catalytic center is reduced by
ascorbate, which in turn oxidizes ascorbate to dehydroascorbic acid. Illustrations taken from [Berg et al., 2002].
(C) Insufficient hydroxylation of collagen prolines, as a result of dietary ascorbic acid deficiency, reduces the
extent of hydrogen bonding within the collagen helices and makes them lose their native conformation even
below body temperature. Illustration taken from [Lodish et al., 1999].
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hydrogen bonding between collagen fibers is impaired, resulting in increased appearance of skin
and blood vessel lesions as well as bone fragility seen in diseases as scurvy and Ehlers-Danlos
syndrome.
Ascorbic acid regenerates the inactivated hydroxylases by reducing the ferrous ion in their
active center and thereby itself is oxidized [Myllyharju, 2008]. Therefore, it increases overall
activity of prolyl hydroxylases and thus the extent of hydroxylation of collagen proline residues
to yield the normal strength of connective tissue.
Besides its obvious importance in collagen biosynthesis, the role of ascorbic acid in os-
teogenic differentiation on the molecular level is hardly characterized. In a broad gene expres-
sion analysis, treatment of mouse MC3T3-E1 osteoblast precursor cells with 280 µM ascorbic
acid was found to alter the expression of genes involved in the regulation and synthesis of ex-
tracellular matrix, cell-matrix and cell-cell interaction, cell cycle progression, cell growth and
structure, as well as apoptosis [Carinci et al., 2005]. The results of a gene expression anal-
ysis investigating the effect of treatment of the same cell type with both the same ascorbic
acid concentration and 10 mM β-glycerophosphate are in line with what was found for ascor-
bic acid alone: distinct cyclins were down- and anti-proliferative factors were simultaneously
upregulated to promote exit from the cell cycle [Beck et al., 2001]. At the same time, matrix-
remodeling factors were induced.
Since a change in gene expression does not necessarily translate into a change in protein ac-
tivity, a high throughput analysis of the kinome, i.e. the entity of kinases, involved in osteogenic
differentiation of MC3T3-E1 mouse pre-osteoblasts treated with β-glycerophosphate and 280
µM ascorbic acid substantiated the gene expression data mentioned above and revealed that
the process of osteogenic differentiation involves regulation of at least the Mapk and Wnt sig-
naling pathways as well as regulation of the factors Akt, Fak, Pka, Pkc and Vegf [Chaves Neto
et al., 2011].
Ascorbic acid treatment of human bone marrow-derived MSC was reported to induce ef-
fects on the extent of osteogenic differentiation in dependency of its concentration. Medium
containing an ascorbic acid concentration below or equal to 250 µM induced MSC proliferation,
whereas higher concentrations decreased proliferation rates and were beneficial for subsequent
osteogenic as well as adipogenic differentiation [Choi et al., 2008]. Human ASC cultured in
medium containing 250 µM ascorbic acid were also found to increase proliferation rates with-
out inducing osteogenic differentiation [Potdar and D’Souza, 2010]. Moreover, the loss of dif-
ferentiation potency usually occuring with increasing duration of cell culture was prevented,
and multipotency and pluripotency markers as CD34 and POU5F1 (also designated as OCT4),
respectively, continued to be expressed for up to four weeks.
Hence, a low concentration of ascorbic acid was found to keep mesenchymal stem cells in an
undifferentiated and proliferative state in vitro, whereas higher concentrations promoted their
differentiation. In this study, ascorbic acid was used at a comparatively high concentration of
1.5 mM to have an inductive effect on promotion of bone-like matrix collagen synthesis and
osteogenic differentiation.
The ascorbic acid concentration used was 0.25 g/l, which corresponds to 1.42 mM and
lies in the middle of the very broad range of ascorbic acid concentrations used for osteogenic
differentiation of MSC, ranging from as little as 0.000284 mM [Wang et al., 2006; Hou et al.,
2007] over 0.25 mM [Jaiswal et al., 1997] and 0.8 mM [Liu et al., 2010] to as much as 50 mM
[Jaeger et al., 2008] or even 284 mM [Celebi et al., 2010].
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The Role of Dexamethasone in Induction of Osteogenic Differentiation
Dexamethasone belongs to the group of artificial glucocorticoids, i.e. it is a synthetic steroid
hormone inspired by the naturally occuring steroid hormones cortisol and corticosteron that in
vivo are produced by the nephric adrenal gland. After freely diffusing over the cell membrane,
the hydrophobic glucocorticoid binds its receptor, a transcription factor belonging to the family
of nuclear hormone receptors (see figure 1.8 on page 17).
The molecular mechanism of dexamethasone-induced osteogenic differentiation is only par-
tially understood. In primary human osteoblasts derived from trabecular bone explants, dexam-
ethasone was found to increase expression of the osteogenic marker genes RUNX2 and osteocal-
cin (OCN) [Viereck et al., 2002]. In human endometrial stromal and myometrial smooth muscle
cells, dexamethasone significantly increased the expression of the ZBTB16 gene and its pro-
tein product via an AP1-dependent mechanism and also caused nuclear translocalization of the
ZBTB16 transcription factor [Fahnenstich et al., 2003]. Expression ofWwtr1 (earlier designated
as Taz), a co-activator of Runx2, was upregulated by dexamethasone in rat MSC [Hong et al.,
2009]. By binding to diverse SMAD molecules, TAZ controls their nuclear translocalization and
transcriptional activity and is therefore an important regulator in TGFβ-mediated developmen-
tal processes [Varelas et al., 2008]. In bovine vascular pericytes, the dexamethasone-promoted
osteogenesis was reported to be accompanied not only by upregulation of alkaline phosphatase
activity and extracellular matrix calcium content, but also by downregulation of calcification-
inhibitor molecules as osteopontin and matrix Gla protein [Kirton et al., 2006].
Dexamethasone-induced osteogenic differentiation was reported to occur most strongly in
early cell culture passages [Beloti and Rosa, 2005] and in an exposure time-dependent man-
ner. This effect could be confirmed even after implantation of dexamethasone-treated MSC into
immune-deficient mice [Song et al., 2009]. There is evidence that the presence of dexametha-
sone is only required during the initiation of osteogenic differentiation in vitro. Short-term treat-
ment of mouse MC3T3-E1 osteo-progenitor cells with a low concentration of less or equal 0.1
µM dexamethasone promoted osteogenic differentiation induced by 280 µM ascorbic acid and
10 mM β-glycerophosphate in a dose-dependent manner, but acted inhibitory in the long run
[Park, 2010].
As was stated before for ascorbic acid, dexamethasone also has a concentration-dependent
effect on the extent of osteogenic differentiation of MSC. This effect is biphasic, i.e. low dexam-
ethasone concentrations affecting osteogenic differentiation in a way directly opposed to that of
high dexamethasone concentrations.
High concentrations of dexamethasone, lying in the range of those applied clinically for
treatment of chronic inflammatory diseases and ranging from 10−6 to 10−7 M, which is 30
times higher than the concentrations of endogenous steroid hormones, were found to decrease
expression of the co-activator of Runx2, Taz, and lowered activity of alkaline phosphatase in rat
bone marrow-derived MSC, whereas low concentrations, ranging from 10−8 to 10−9 M, had the
opposite effect on alkaline phosphatase [Hong et al., 2009].
Treatment of mouse osteoblasts with a low concentration of the glucocorticoid corticos-
terone upregulated the levels of diverse Wnts, whereas a higher concentration lowered them
[Mak et al., 2009]. These Wnts are important mediators of osteogenic differentiation and auto-
stimulatory keep osteoblasts in a differentiated state, whereas they induce osteogenic differen-
tiation of osteoblast precursors.
In addition to the WNT pathway, glucocorticoids were found to regulate the MAP kinase
pathway in a dose-dependent manner. With increasing concentration of the glucocorticoid, the
16
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Figure 1.8: The role of glucocorticoids in regulation of gene expression. (A) After diffusing over the cell
membrane, the lipophilic glucocorticoid hormone binds its receptor (GR) which, in the absence of hormone, is
inactivated by binding of a heat shock protein (Hsp90) to the receptor’s ligand-binding domain (LBD). After
glucocorticoid-binding, the LBD undergoes a conformational change that inables the heat shock protein to
bind, and the glucocorticoid-GR complex translocalizes from the cytoplasm to the nucleus. In the nucleus,
the DNA-binding domain (DBD) of the complex binds to glucocorticoid response elements in the promoters
of target genes and thus enables the activation domain (AD) to stimulate transcription of target genes.
(B) Transcriptional activation by glucocorticoid receptors occurs by recruitment of histone acetyl transferases
(HATs) that catalyze the acetylation of lysine residues at the N-terminal tails of histones. Since each acetylation
replaces the positive charge of a lysine ammonium group by an uncharged acetyl group, the ionic attraction
between the positive charge of the histone and the negative charge of the de-protonated phosphate groups
of the DNA backbone diminishes, resulting in de-condensing of the DNA to make it more accessible for
transcription factors and the multimeric RNA polymerase transcriptional apparatus. (C) Thus, regulation of
histone acetylation is a means for transcriptional activation (by HATs) or repression (by histone de-acetylases,
HDACs). Illustrations taken and modified from [Cooper and National Center for Biotechnology Information
(U.S.), 2000].
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activity of JUN was decreased, and the reduced JUN activity subsequently reduced proliferation
of MSC [Carcamo-Orive et al., 2010]. Therefore, a high concentration of dexamethasone of
approximately 10−6 M promoted adipogenesis of bone marrow-derived MSC, whereas a ten-
times lower concentration of 10−7 M yielded a much lesser reduction in proliferation and thus
a proper biochemical environment for osteogenesis.
In spinal ligament cells in vitro, dexamethasone dose-dependently reduced proliferation
with increasing concentration, but simultaneously increased alkaline phosphatase activity [Mu-
rata et al., 2004]. The same was true for bone marrow-derived MSC [Walsh et al., 2001]. At
a 10−8 M, the number of alkaline phosphatase-expressing cells and the intensity of expression
were increased, whereas expression of the osteo-progenitor marker antigen STRO-1 was re-
duced. With a dexamethasone concentration increasing over 10−7 to 10−6 M, the proliferation
rate was increasingly reduced, accompanied by an increase in alkaline phosphatase activity.
Even translating a low dose of dexamethasone into the temporal dimension as a short-term
treatment confirmed the biphasic action of this synthetic glucocorticoid: Short-term adminis-
tration of dexamethasone to ascorbic acid- and β-glycerophosphate-treated MC3T3-E1 mouse
osteo-progenitor cells promoted their osteogenic differentiation, whereas long-term treatment
had a rather inhibitoy effect [Park, 2010].
Hence, both high concentrations and long-term treatment with glucocorticoids were found
to inhibit osteogenic differentiation in vitro and to promote a phenotype of bone resorption in
vivo, whereas low concentrations in vitro promoted osteogenic differentiation of diverse precur-
sor cell types.
It has to be added that such a biphasic behavior on osteogenic differentiation was reported
also for other regulators of bone metabolism. Parathyroid hormone (PTH) stimulates bone re-
sorption as well as bone formation, low PTH concentrations resulting in bone formation, and
high concentrations stimulating bone resorption in vivo [Office of the Surgeon General (U.S.),
2004]. The sex hormone estrogen showed a similar dose-dependent effect on bone metabolism
in vivo, low concentrations increasing bone formation, but high concentrations leading to clo-
sure of the articular growth plates in the adult female. Thus, bone metabolism is regulated in a
biphasic fashion by a variety of factors.
The dexamethasone concentration used here was 1 µM, which lies at the upper end of the
concentrations published on osteogenic differentiation of MSC, ranging from 0.01 µM [Celebi
et al., 2010] over 0.1 µM [Jaiswal et al., 1997; Wang et al., 2006; Hou et al., 2007; Liu et al.,
2010] to 1 µM [Walsh et al., 2001; Murata et al., 2004].
1.5 Experimental Outline
To investigate whether TNF has any specific effect on osteogenic differentiation of ASC, I ana-
lyzed expression and activity of a variety of osteogenic markers. As early hallmarks of osteogenic
differentiation, expression of the transcription factor ZBTB16, an upstream regulator of RUNX2
expression and activity, was analyzed just as DNA binding activity of RUNX2. The transcription
factor RUNX2 has a key role in osteogenic differentiation and induces expression of a plethora
of genes involved in this differentiation process. I analyzed activation of this factor to bind to
the regulatory sequence of its target genes. Besides these osteogenic transcription factors and
as later markers of osteogenic differentiation, I analyzed the expression and activity of the key
enzyme involved in extracellular matrix calcification, alkaline phosphatase, and the extent of
extracellular matrix calcium content.
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These analyses were supplemented by the surveillance of more basal cellular parameters as
proliferation, cell cycle and metabolic activity. Analysis of the expression of the TNF receptor
genes and proteins as well as analysis of activation of the signal transduction pathways down-
stream of these receptors, i.e. the NFκB, MAPK and apoptosis pathway, completed this study.
All parameters were investigated for TNF-treated ASC in comparison to osteogenically stim-
ulated and unstimulated ASC. ASC treated with both TNF and osteogenic stimulants were ana-
lyzed to elucidate the impact of TNF under osteogenic conditions.
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Materials
The following pages contain the devices, software and consumables used in this work and are
organized in a tabulated manner.
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Table 2.1: Devices used.
Device Manufacturer
additional information Residence
city country
general laboratory equipment JL-200 analytical balance Chyo
SONOREX DIGITEC ultrasound water bath Carl Roth GmbH + Co. KG Karlsruhe Germany
REAX 2000 test tube shaker Heidolph Instruments GmbH & Co. KG Schwabach Germany
Unimax orbital platform shaker with heating module and incubator hood Heidolph Instruments GmbH & Co. KG Schwabach Germany
BTR5-12V tube roller mixer Ratek Instruments Pty. Ltd. Victoria Australia
5417 R and 5810 R centrifuges Eppendorf AG Hamburg Germany
Easypet Reference and Research pipettes Eppendorf AG Hamburg Germany
Transferpette S -8 and S -12 pipettes BRAND GmbH + Co KG Wertheim Germany
cell culture CB 150 humidified atmosphere incubator for 37 ◦C and 5 % CO2 BINDER GmbH Tuttlingen Germany
NuncFlow Model Safeflow 1.2 laminar airflow cabinet Nunc GmbH & Co. KG Langenselbold Germany
VACUSAFE comfort liquid exhaustion system INTEGRA Biosciences GmbH Fernwald Germany
Cell Counter Model DT cell number counter Schärfe System GmbH Reutlingen Germany
microscopes Axiovert 25 and 40 C inverse bright-field phase contrast microscopes Carl Zeiss MicroImaging GmbH Göttingen Germany
Axio Scope.A1 and Axio Observer.Z1 upright and inverse fluorescence microscopes Carl Zeiss MicroImaging GmbH Göttingen Germany
TCS SP2 inverse confocal fluorescence microscope Leica Microsystems GmbH Wetzlar Germany
AxioCam ICc1 microscope camera at bright-field microscope Carl Zeiss MicroImaging GmbH Göttingen Germany
AxioCam MRc and MRm microscope cameras at upright and inverse fluorescence microscope Carl Zeiss MicroImaging GmbH Göttingen Germany
microplate reader anthos 2010 filter-based optical density microplate reader anthos Mikrosysteme GmbH Krefeld Germany
infinite M200 monochromator-based fluorescence, luminescence and optical density microplate
reader
Tecan Deutschland GmbH Crailsheim Germany
RNA and gene expression Bosch KN83.1 microwave oven Carl Roth GmbH + Co. KG Karlsruhe Germany
Sub-Cell Model 96 Complete System agarose gel electrophoresis unit Bio-Rad Laboratories GmbH München Germany
ChemiDoc MP System gel documentation system Bio-Rad Laboratories GmbH München Germany
NanoDrop ND-1000 spectrophotometer PEQLAB Biotechnologie GmbH Erlangen Germany
NuncFlow AURA PCR passive PCR cabinet Nunc GmbH & Co. KG Langenselbold Germany
MyCycler thermal cycler Bio-Rad Laboratories GmbH München Germany
7500 Real-Time PCR System thermal cycler for real-time PCR Life Technologies GmbH Darmstadt Germany
flow cytometry FACSCalibur flow cytometer BD Biosciences AG Heidelberg Germany
Flow Supply System sheath fluid volume extension system for flow cytometer BD Biosciences AG Heidelberg Germany
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Table 2.2: Software used.
Software Developer
additional information Residence
city country
Windows 7 Professional SP1 operating system Microsoft Deutschland GmbH Unterschleißheim Germany
Mac OS 9.2.2 operating system Apple Inc. Cupertino USA
WinRead 2.36 anthos microplate reader control anthos Mikrosysteme GmbH Krefeld Germany
i-control 1.5 TECAN microplate reader control Tecan Deutschland GmbH Crailsheim Germany
NanoDrop 1000 3.7.1 NanoDrop control Fisher Scientific GmbH Schwerte Germany
Axiovision 40 Rel. 4.8.0.0 bright-field microscope image acquisition Carl Zeiss MicroImaging GmbH Göttingen Germany
Axiovision 40 Rel. 4.8.2.0 fluorescence microscope image acquisition Carl Zeiss MicroImaging GmbH Göttingen Germany
Leica Confocal Software 2.61 confocal fluorescence microscope image acquisition Leica Microsystems GmbH Wetzlar Germany
Volocity Demo 6.0.0 microscope image processing PerkinElmer Life and Analytical Sciences, Inc. Rodgau Germany
Photoshop CS 8.0.1 image processing Adobe Systems Software Ireland Limited Dublin Ireland
Sequence Detection Software 1.4 real-time cycler control and data analysis Life Technologies GmbH Darmstadt Germany
CellQuest Pro 4.0.2 flow cytometer control BD Biosciences AG Heidelberg Germany
FlowJo 7.6.3 flow cytometer data analysis Tree Star, Inc. Ashland USA
SPSS Statistics 19 statistical data analysis IBM Deutschland GmbH Ehningen Germany
SigmaPlot 11 scientific plot generation Systat Software GmbH Erkrath Germany
LibreOffice 3.3.3 open source office package The Document Foundation Wiesbaden Germany
Office Professional Plus 2007 proprietary office package Microsoft Deutschland GmbH Unterschleißheim Germany
TeX Live 2011 TeX distribution TeX Users Group Heidelberg Germany
Ghostscript 9.02 open source postscript package Artifex Software, Inc. San Rafael USA
GSview 4.9 open source postscript viewer Ghostgum Software Pty Ltd. Glen Waverley Australia
TeXnicCenter 1.0 Stable Release Candidate 1 TeX editor The TeXnicCenter Team
JabRef 2.6 open source reference manager The JabRef Team
Endnote X2 proprietary reference manager Thomson Reuters New York USA
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Table 2.3: Consumables used.
Consumable Manufacturer
additional information Residence
city country catalog #
ASC isolation CD34 Progenitor Cell Selection System kit for labeling cells with an CD34 antibody conju-
gated to a magnetic bead
Life Technologies GmbH Darmstadt Germany 113-01D
DynaMag-15 permanent magnet for holding one 15 ml tube with
cell suspension during CD34+ cell isolation
Life Technologies GmbH Darmstadt Germany 123-01D
metal sieve stainless steel with wire gauze, 800 µm pore size,
100 mm diameter x 40 mm height, ISO 3310/1
RETSCH GmbH Haan Germany 60.106.000800
Albumin solution from bovine serum
(BSA)
35 % in DPBS, sterile-filtered, BioXtra, endotoxin
tested, suitable for cell culture
Sigma-Aldrich Chemie GmbH Taufkirchen Germany A7979
Cell Strainer, 100 µm, yellow sterile, nylon mesh BD Biosciences AG Heidelberg Germany 352360
Cell Strainer, 40 µm, blue sterile, nylon mesh BD Biosciences AG Heidelberg Germany 352340
Collagenase NB 4 from Clostridium histolyticum, collagenase class I
and class II and proteolytic activity
SERVA Electrophoresis GmbH Heidelberg Germany 17454
cell counting CASY clean liquid system cleaning solution for CASY cell
counter
Roche Applied Science Mannheim Germany 05651786001
CASY cups disposable sample tube for cell suspension in CASY
cell counting
Roche Applied Science Mannheim Germany 05651794001
CASY ton isotonic saline solution for cell suspension in CASY
cell counting
Roche Applied Science Mannheim Germany 05651808001
cell culture medium DMEM high glucose, GlutaMAX, pyruvate, phenol red, w/o
HEPES
Life Technologies GmbH Darmstadt Germany 31966
Fetal Calf Serum (FCS) from South America, virus and mycoplasma tested,
health class 1a
PAN Biotech GmbH Aidenbach Germany 3302-P281305
Penicillin-Streptomycin (P/S), liquid 10,000 units/ml Life Technologies GmbH Darmstadt Germany 15140-122
osteogenic stimulants L-Ascorbic acid powder, cell culture tested, gamma-irradiated Sigma-Aldrich Chemie GmbH Taufkirchen Germany A4403
ß-Glycerol phosphate disodium salt pentahydrate Sigma-Aldrich Chemie GmbH Taufkirchen Germany 50020
Dexamethasone powder, BioReagent, suitable for cell culture, ≥ 97
%
Sigma-Aldrich Chemie GmbH Taufkirchen Germany D4902
adipogenic stimulants 3-Isobutyl-1-methylxanthin (IBMX) ≥ 99 % (HPLC), powder Sigma-Aldrich Chemie GmbH Taufkirchen Germany I5879
Insulin human, recombinant (expressed in yeast) Sigma-Aldrich Chemie GmbH Taufkirchen Germany I2643
Indomethacin ≥ 99 % (TLC) Sigma-Aldrich Chemie GmbH Taufkirchen Germany I7378
TNF Tumor Necrosis Factor (TNF) human, recombinant (expressed in yeast) Sigma-Aldrich Chemie GmbH Taufkirchen Germany T0157
other cell culture solutions Dulbecco’s PBS (DPBS, 1x) without Ca and Mg, sterile, 500 ml PAA Laboratories GmbH Cölbe Germany H15-002
Trypsin-EDTA 1x, 0.25 %, with phenol red Life Technologies GmbH Darmstadt Germany 25200
cell culture plasticware Cell culture multiwell plate, 6 well sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 657160
Cell culture multiwell plate, 12 well sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 665180
Cell culture multiwell plate, 24 well sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 662160
Cell culture multiwell plate, 48 well sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 677180
Cell culture plate, 96 well sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 655180
Cell culture flask, 25 cm2 sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 690175
Cell culture flask, 75 cm2 sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 658175
Pipette, 2 ml sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 710180
Pipette, 5 ml sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 606180
Pipette, 10 ml sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 607180
Pipette, 25 ml sterile, polystyrene Greiner Bio-One GmbH Frickenhausen Germany 760180
cell culture glassware Fisherbrand Pasteur Pipette 230 mm, glass Fisher Scientific GmbH Schwerte Germany 10786941
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Table 2.3: Consumables used.
Consumable Manufacturer
additional information Residence
city country catalog #
diverse plasticware Pipette tip, 200 µl, yellow sterile, polypropylene SARSTEDT AG & Co. Nümbrecht Germany 70.760.002
Pipette tips, 100 – 1000 µl sterile, polypropylene Greiner Bio-One GmbH Frickenhausen Germany 686290
Tube, 12 ml sterile, polystyrene, conical bottom Greiner Bio-One GmbH Frickenhausen Germany 164161
Tube, 15 ml sterile, polypropylene, conical bottom Greiner Bio-One GmbH Frickenhausen Germany 188271
Tube, 50 ml sterile, polypropylene, conical bottom Greiner Bio-One GmbH Frickenhausen Germany 227261
Standard and Safe-Lock reaction tubes unsterile, polypropylene Eppendorf AG Hamburg Germany 0030.120.xxx
Microplate, 96 well for optical density determination Greiner Bio-One GmbH Frickenhausen Germany 655101
Rotilabo fluid reservoir, 55 ml unsterile, PVC Carl Roth GmbH + Co. KG Karlsruhe Germany E830.2
POLYMER PLUS Latex examination gloves Brimon Hamburg Germany 11034
diverse solutions Aqua ad iniectabilia ultra pure water B. Braun Melsungen AG Melsungen Germany 619-3703452
Triton X-100 non-ionic detergent Sigma-Aldrich Chemie GmbH Taufkirchen Germany 93420
Tween 20 non-ionic detergent Sigma-Aldrich Chemie GmbH Taufkirchen Germany P1379
crystal violet assay Crystal Violet for microscopy (Bact., Bot., Hist., Vit.), indicator
(pH 0.1 - 2.0)
Sigma-Aldrich Chemie GmbH Taufkirchen Germany 61135
Isopropanol molecular biology grade SERVA Electrophoresis GmbH Heidelberg Germany 39559.02
Acetic acid absolute („glacial“) Merck KGaA Darmstadt Germany 100063
ALPL assays Fast Red Violet LB Salt, Technical grade Sigma-Aldrich Chemie GmbH Taufkirchen Germany F3381
Naphthol AS-MX phosphate powder, ≥ 99 % (HPLC) Sigma-Aldrich Chemie GmbH Taufkirchen Germany N4875
2-Amino-2-methyl-1,3-propanediol
(AMPED)
≥ 99 % Sigma-Aldrich Chemie GmbH Taufkirchen Germany A9754
Tris Buffered Saline (TBS) 10x solution Sigma-Aldrich Chemie GmbH Taufkirchen Germany T5912
4-Nitrophenyl phosphate para-nitrophenyl phosphate (pNPP) disodium salt
hexahydrate
AppliChem GmbH Darmstadt Germany A1442
Magnesium chloride (MgCl2) hexahydrate Molecular biology grade AppliChem GmbH Darmstadt Germany A4425
PMSF Benzylsulfonyl fluoride, Phenylmethanesulfonyl
fluoride
AppliChem GmbH Darmstadt Germany A0999
Sodium hydroxide (NaOH) standard
solution
2 M Sigma-Aldrich Chemie GmbH Taufkirchen Germany 3525
ECM mineralisation assay o-Cresolphthalein Complexone indicator (for complexometry) Sigma-Aldrich Chemie GmbH Taufkirchen Germany 64000
2-Amino-2-methyl-1-propanol (AMP) purum, ≥ 97.0 % (GC) Sigma-Aldrich Chemie GmbH Taufkirchen Germany 08580
8-Hydroxyquinoline ACS reagent, 99 % Sigma-Aldrich Chemie GmbH Taufkirchen Germany 252565
Hydrochloric acid (HCl) 36.5 - 38.0 %, BioReagent, for molecular biology Sigma-Aldrich Chemie GmbH Taufkirchen Germany H1758
RUNX2 assay Nuclear Extract Kit isolation of total nuclear protein Active Motif La Hulpe Belgium 40010
TransAM AML-3/Runx2 Transcription Factor ELISA Kit Active Motif La Hulpe Belgium 44496
Cell scraper with thin, flexible 2-position blades SARSTEDT AG & Co. Nümbrecht Germany 831832
OPG-ELISA Nunc-Immuno Plates, 96-well unsterile, polystyrene, MaxiSorp, flat bottom Nunc GmbH & Co. KG Langenselbold Germany 456537
human OPG/TNFRSF11B DuoSet ELISA Development kit R&D Systems GmbH Wiesbaden-Nordenstadt Germany DY805
Wash Buffer for ELISA R&D Systems GmbH Wiesbaden-Nordenstadt Germany WA126
Reagent Diluent for ELISA R&D Systems GmbH Wiesbaden-Nordenstadt Germany DY995
Substrate Solution for ELISA R&D Systems GmbH Wiesbaden-Nordenstadt Germany DY999
Stop Solution for ELISA R&D Systems GmbH Wiesbaden-Nordenstadt Germany DY994
other assays BODIPY 493/503 fluorescent stain for neutral lipids and other
nonpolar lipids
Life Technologies GmbH Darmstadt Germany D-3922
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Table 2.3: Consumables used.
Consumable Manufacturer
additional information Residence
city country catalog #
Sodium chloride (NaCl) solution for molecular biology, 5 M Sigma-Aldrich Chemie GmbH Taufkirchen Germany S5150
CellTiter 96 AQueous One Solution Cell Proliferation (MTS) Assay PROMEGA GmbH Mannheim Germany G3581
660 nm Protein Assay for total soluble protein quantification Fisher Scientific GmbH Schwerte Germany 22662
RNA isolation Safe Seal Tips Professional Line filter tips certified free of RNase, DNase, human
DNA and PCR inhibitors
Biozym Scientific GmbH Hessisch Oldendorf Germany 7700xx
RNase-ExitusPlus RNase decontamination solution AppliChem GmbH Darmstadt Germany A7153
innuPREP RNA Mini Kit total RNA isolation kit Analytik Jena AG Jena Germany 845-KS-2040250
QIAshredder cell-lysate homogenizer QIAGEN GmbH Hilden Germany 79654
Ethanol absolute, gradient grade Merck KGaA Darmstadt Germany 111727
Water for molecular biology DEPC-treated, sterile and autoclaved Carl Roth GmbH + Co. KG Karlsruhe Germany T143.1
RNA electrophoresis Agarose For routine use Sigma-Aldrich Chemie GmbH Taufkirchen Germany A9539
Tris Acetate-EDTA (TAE) buffer DNase- and RNase-free, 10x concentrate Sigma-Aldrich Chemie GmbH Taufkirchen Germany T4038
Ethidium bromide solution BioReagent, for molecular biology, 10 mg/ml in
H2O
Sigma-Aldrich Chemie GmbH Taufkirchen Germany E1510
Gel Loading Solution All-purpose, for native agarose Life Technologies GmbH Darmstadt Germany AM8556
real-time RT PCR QuantiTect Rev. Transcription Kit for cDNA synthesis in real-time two-step RT-PCR QIAGEN GmbH Hilden Germany 205311
Multiply PCR Plates 96 well, polypropylene SARSTEDT AG & Co. Nümbrecht Germany 721.979.202
MicroAmp Optical Adhesive Film optically-clear adhesive film to seal microplates in
(real-time) PCR
Life Technologies GmbH Darmstadt Germany 4311971
Power SYBR Green PCR Master Mix for real-time PCR Life Technologies GmbH Darmstadt Germany 4368708
immunofluorescence Paraformaldehyde (PFA) reagent grade, crystalline Sigma-Aldrich Chemie GmbH Taufkirchen Germany P6148
Ultra pure bovine serum albumin (BSA) for immune fluorescence New England Biolabs GmbH Frankfurt am Main Germany 9998
µ-Slide 8 well ibiTreat, tissue culture treated ibidi GmbH Martinsried Germany 80826
Fluoromount-G fluorescence mounting medium eBioscience Frankfurt am Main Germany 00-4958-02
antibodies anti-human Lamin A/C clone 4C11, mouse monoclonal Ab New England Biolabs GmbH Frankfurt am Main Germany 4777
anti-human NF-κB p65 rabbit polyclonal Ab New England Biolabs GmbH Frankfurt am Main Germany 3987
anti-human Phospho-c-Jun rabbit polyclonal Ab New England Biolabs GmbH Frankfurt am Main Germany 9261
anti-human Phospho-p44/42 MAPK
(Erk1/2)
clone D13.14.4E, rabbit monoclonal Ab New England Biolabs GmbH Frankfurt am Main Germany 4370
anti-human Phospho-p38 MAPK clone 3D7, rabbit monoclonal Ab New England Biolabs GmbH Frankfurt am Main Germany 9215
goat anti-rabbit IgG (H+L) Alexa Fluor 555 F(ab’)2 fragment, 2 mg/ml Life Technologies GmbH Darmstadt Germany A-21430
goat anti-mouse IgG (H+L) Alexa Fluor 647 F(ab’)2 fragment, 2 mg/ml Life Technologies GmbH Darmstadt Germany A-21237
anti-human TNF receptor 1 clone 16803, mouse monoclonal Ab, isotype IgG1,
PE-labeled
R&D Systems GmbH Wiesbaden-Nordenstadt Germany FAB225P
anti-human TNF receptor 2 clone 80M2, mouse monoclonal Ab, isotype IgG1,
FITC-labeled
Biozol Diagnostica Vertrieb GmbH Eching Germany K0040-4
anti-human CD14 clone 61D3, mouse monoclonal Ab, isotype IgG1,
PE-labeled
eBioscience Frankfurt am Main Germany 12-0149
anti-human CD31 clone HC1/6, mouse monoclonal Ab, isotype IgG1,
FITC-labeled
Millipore GmbH Schwalbach/Ts. Germany CBL468F
anti-human CD68 clone Y1/82A, mouse monoclonal Ab, isotype
IgG2a, FITC-labeled
eBioscience Frankfurt am Main Germany 11-0689
anti-human IgG1 mouse isotype control W3/25, PE-labeled Acris Antibodies GmbH Herford Germany SM10R
non-antibody-mediated staining SYTOX Blue nucleic acid stain, 5 mM solution in DMSO Life Technologies GmbH Darmstadt Germany S11348
Alexa Fluor 594 Phalloidin actin cytoskeleton stain Life Technologies GmbH Darmstadt Germany A12381
Propidium iodide dead cell nucleic acid stain, 1.0 mg/ml, solution in
water
Life Technologies GmbH Darmstadt Germany P3566
Calcein, AM live cell stain Biomol GmbH Hamburg Germany ABD-22002
Flow Cytometry Round-Bottom Tube FACS tube w/o cap, unsterile, polystyrene BD Biosciences AG Heidelberg Germany 352008
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Table 2.3: Consumables used.
Consumable Manufacturer
additional information Residence
city country catalog #
BD FACSFlow Sheath Fluid isotonic saline solution for cell suspension in flow
cytometry
BD Biosciences AG Heidelberg Germany 342003
BD FACS Clean Solution sodium hypochlorite and hydroxide containing
solution for cleaning the flow cytometer liquid
system
BD Biosciences AG Heidelberg Germany 340345
BD FACSRinse Solution sodium azide containing salt solution for rinsing
the flow cytometer liquid system after cleaning
BD Biosciences AG Heidelberg Germany 340346
PI/RNase Staining Buffer for staining of cells for flow cytometric cell cycle
analysis
BD Biosciences AG Heidelberg Germany 550825
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Methods
3.1 Isolation and Culture of ASC
ASC were isolated from adipose tissue obtained from healthy patients having undergone liposuction. The
predominant part of the patients was female and aged between 20 and 40 years. The most prominent
site of subcutaneous tissue harvesting was the abdominal and the hip region. Figure 3.1 on page 28
gives an overview on the procedure of ASC isolation from adipose tissue obtained by tumescence-based
liposuction. Detailed isolation protocols are given below.
3.1.1 Isolation of ASC
The stromal vascular fraction was obtained by collagenase digestion of the adipose tissue of the patient’s
processed lipoaspirate. The procedure refers to protocols published before by e.g. Patricia Zuk [Zuk et al.,
2001]:
1. wash adipose tissue 3x with PBS and transfer 30 ml of tissue to a 50 ml tube
2. add 10 ml of a mixture of Collagenase I and II (6 mg/ml or 0.6 Wünsch units/ml in PBS) to adipose
tissue
3. incubate shaking at 100 rpm and 37 ◦C for 60 min
4. transfer tissue via a 100 µm mesh filter to a new 50 ml tube
5. centrifuge for 10 min at 400 g and room temperature
6. carefully discard supernatant and resuspend pellet in 10 ml PBS (10 % FCS)
7. transfer resuspended cells to new 50 ml tube and centrifuge for 10 min at 400 g and room temper-
ature
8. resuspend pellet in 12 ml DMEM (10 % FCS, 1 % penicillin/streptomycin) and transfer to 75 cm2
cell culture flask
9. incubate untouched for 24 h at 37 ◦C, 5 % CO2 in a humidified atmosphere
From this primary culture, ASC were isolated via their characteristic expression of CD34 surface
antigen by applying a magnetic bead-based cell sorting system. The protocol for doing so was established
in our group:
1. add 40 µl CD34 Dynabeads to 7 ml PBS (0.1 % BSA), mount to magnet, discard supernatant,
demount tube from magnet and add 4 ml DMEM (10 % FCS, 1 % penicillin/streptomycin)
2. wash cells 2x with PBS
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Figure 3.1: Isolation of ASC from adipose tissue. ASC were isolated from processed lipoaspirate (PLA),
the non-fluid fraction of tissue obtained following liposuction. The fluid fraction containing liposuction aspi-
rate fluid cells (LAF) was discarded. The PLA was digested by collagenase treatment and thus yielded the
stromal vascular fraction (SVF). From this fraction, ASC were purified as the CD34+ and plastic-adherent
subpopulation. The scale bar corresponds to 120 µm.
3. add 3 ml Dynabead suspension to cells, distribute homogeneously by gently moving flask and
incubate for 5 − 10 min at 37 ◦C, 5 % CO2 in a humidified atmosphere until beads are bound to
cell surface
4. wash cells 2x with PBS, add 1 ml 0.25 % Trypsin and distribute homogeneously by gently moving
flask
5. incubate for 5 − 10 min at 37 ◦C, 5 % CO2 in a humidified atmosphere until cells are detached
6. resuspend cells in 7 ml PBS (10 % FCS) and transfer to 15 ml tube
7. incubate cells for 10 min at 4 ◦C on a tube roller mixer
8. transfer cells via a 40 µm mesh filter to a new 15 ml tube
9. mount tube to magnet, discard supernatant, demount tube from magnet and resuspend cells in 7
ml PBS (0.1 % BSA)
10. incubate cells for 10 min at 4 ◦C on a tube roller mixer
11. mount tube to magnet, discard supernatant, demount tube from magnet and resuspend CD34+
cells in 12 ml DMEM (10 % FCS, 1 % penicillin/streptomycin)
This yields the first ASC passage.
3.1.2 ASC Culture
ASC were cultured until 90 % confluency was reached and then passaged into new flasks at an area
ratio of one to three, i.e. 75 cm2 of 90 % confluent ASC were detached using Trypsin, resuspended in
36 ml DMEM (10 % FCS, 1 % penicillin/streptomycin) and aliquoted into three new 75 cm2 flasks at a
volume of 12 ml cell suspension each. This was done until passage three was reached. Each passage took
three to four days. Passage four was seeding of cells into experimentation. The absence of contaminating
monocytes/macrophages and endothelial cells in this culture of primary cells was confirmed by flow
cytometry proving the absence of CD14/CD68+ and CD31+ cells, respectively.
To ascertain the same degree of gas exchange for all formats of cell culture vessels, the height of the
medium column over the cell layer was kept constant in relation to the cell culture area, taking 100 µl of
medium for each well of a 96-well plate as a reference.
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3.1.3 ASC Counting
Unless otherwise noted, ASC were seeded into experimentation at 20,000 cells/cm2 growth area. De-
termination of the cell number was done using electrical current exclusion and pulse area analysis in a
CASY system. The principle of this method is described in figure 3.2 on page 30.
Cell counting was done according to the manufacturer’s instructions as detailed below:
1. add 100 µl cell suspension to 10 ml CASY ton in CASY cup
2. perform measurement in appropriate program
3. note viable cells per ml and discard CASY cup with cell solution
4. clean 3x and measure 3x using CASY ton:
• if less than 100 counts per ml: device is sufficiently cleaned
• if more than 100 counts per ml: wash again using a new CASY cup with CASYton
3.1.4 ASC Stimulation Media
After seeding, cells were cultured until confluency was reached, which took two to three days. Renewal
of the cell culture medium was done every second day. At confluency, culture with distinct stimulation
media began, termed day zero, and took up to 28 days.
The differentiation media were termed as follows: US indicates medium without differentiation fac-
tors used for the unstimulated ASC control cultures, OS indicates osteogenic differentiation stimulating
medium, AS adipogenic differentiation stimulating medium, and TNF TNF-supplemented medium. These
media contained the following factors at the indicated concentrations:
US OS TNF OS+TNF AS
DMEM, high glucose, ⊕ ⊕ ⊕ ⊕ ⊕
GlutaMAX-I
FCS 10 % 10 % 10 % 10 % 10 %
penicillin/streptomycin 1 % 1 % 1 % 1 % 1 %
ascorbic acid 0.25 g/l 0.25 g/l
dexamethasone 1 µM 1 µM 1 µM
β-glycerophosphate 10 mM 10 mM
TNF 30 IU/ml 30 IU/ml
IBMX 500 µM
indomethacin 200 µM
insulin 10 µM
These concentrations were chosen in accordance with the current literature published for osteogenic and
adipogenic differentiation of mesenchymal stem cells.
The medium for the unstimulated ASC control cultures was supplemented with 10 % FCS, since
serum replacements so far failed to support stem cell differentiation equally well as fetal calf serum did
[Lund et al., 2009]. In addition, 1 % penicillin/streptomycin, corresponding to 100 units per ml and 100
µg per ml, respectively, was added to the medium to suppress a possible microbial contamination of the
primary tissue.
For osteogenic differentiation, this cell culture medium was supplemented with β-glycerophosphate,
ascorbic acid and dexamethasone. The β-glycerophosphate concentration used here was 10 mM, which
is in accordance with all publications invoked [Jaiswal et al., 1997; Wang et al., 2006; Hou et al., 2007;
Jaeger et al., 2008; Celebi et al., 2010; Liu et al., 2010]. The ascorbic acid concentration used was
0.25 g/l, which corresponds to 1.42 mM. This concentration lies in the middle of the very broad range
of ascorbic acid concentrations used for osteogenic differentiation of MSC, ranging from as little as
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Figure 3.2: The principle of cell counting by electrical current exclusion and pulse area analysis. (A) A cell
suspension in an electrolyte is exposed to a low voltage field, and the electrical current flowing through the
suspension is quantified as each cell passes the detector. Due to its intact membrane, a viable cell will act as
an electric insulator and thus reduce the current conduction by the electrolyte (see subfigure on the right).
This reduction in current conduction will be much less if a dead cell passes the detector, since only its intact
nucleus will act as an insulator (see subfigure on the left). Therefore, cell viability and size can be deduced
as a function of the magnitude of the electrical current flow through the electrolyte, which is called electrical
current exclusion. (B) Applying this measurement with a frequency of one million per second, up to several
hundred measurements are made per cell, and the complete process of cell passing through the detector is
monitored. This results in a gaussian signal generated by each cell, this signal first increasing when the cell
is in process of entering the detector, then peaking when it is completely inside, and subsequently decreasing
when the cell is leaving the detector. Thus, the width of each pulse is analyzed, which is therefore called pulse
area analysis. This high frequency analysis gives an accurate signal for each cell and thus for the entire cell
population investigated. Illustrations taken from [Roche Diagnostics, 2010].
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0.000284 mM [Wang et al., 2006; Hou et al., 2007] over 0.25 mM [Jaiswal et al., 1997] and 0.8 mM
[Liu et al., 2010] to as much as 50 mM [Jaeger et al., 2008] or even 284 mM [Celebi et al., 2010].
The dexamethasone concentration used was 1 µM, which lies at the upper end of the concentrations
published, ranging from 0.01 µM [Celebi et al., 2010] over 0.1 µM [Jaiswal et al., 1997; Wang et al.,
2006; Hou et al., 2007; Liu et al., 2010] to 1 µM [Walsh et al., 2001; Murata et al., 2004].
For adipogenic differentiation, mixtures of cell culture medium with dexamethasone, 3-isobutyl-1-
methylxanthin (IBMX), indomethacin and insulin are commonly used. The dexamethasone concentration
used here was 1 µM, which is in accordance with the uppermost portion of the literature published
[Wu et al., 1995; Giri et al., 2006; Celebi et al., 2010; Liu et al., 2010] and close to the 0.5 µM used
in another study [Smith et al., 1988]. Thus, the dexamethasone concentration used was identical for
osteogenic and adipogenic stimulation. The IBMX concentration used here was 500 µM and is identical
to the single concentration published so far [Smith et al., 1988; Wu et al., 1995; Kelly and Gimble, 1998;
Giri et al., 2006; Celebi et al., 2010; Liu et al., 2010]. The indomethacin concentration used was 200 µM,
corresponding to 0.2 mM and lying in the middle of what was published before, these concentrations
ranging from 0.06 mM [Kelly and Gimble, 1998] over 0.1 mM [Lehmann et al., 1997; Liu et al., 2010] to
10 mM [Celebi et al., 2010]. The insulin concentration used was 10 µM and lies at the upper end of the
concentration range published, ranging from 0.172 µM [Wu et al., 1995; Liu et al., 2010] over 0.2 µM
[Lehmann et al., 1997] to 1.7 µM [Giri et al., 2006] and 2 µM [Smith et al., 1988]. Only under serum-
free conditions, an insulin concentration of 1 nM was sufficient to induce adipogenic differentiation
[Sorisky, 1999]. Since the maximum activating effect of insulin on glycerol-3-phosphate dehydrogenase,
an enzyme downstream of the insulin-binding IGF receptors, lies between 1 and 10 µM, I decided to use
the 10 µM concentration.
The TNF concentration used was 30 international units per ml medium, which corresponds to a mass
concentration of 300 pg/ml. In vivo, even lower TNF concentrations around 50 pg/ml are biologically
active and were so far not reported to have been exceeded (see page 91).
3.2 In vitro Assays
3.2.1 Quantification of Cell Number
The basic dye crystal violet, also called hexamethylpararosaniline chloride or gentian violet, is positively
charged under physiologic conditions and thus binds negatively charged cellular macromolecules, most
of which being DNA, via ionic attraction [Noeske, 1966]. This binding occurs in a linear fashion and
therefore is well applicable to indirectly determine cell numbers by quantifying the dye intensity [Gillies
et al., 1986].
On the basis of a protocol published previously [van Kooten et al., 1999], crystal violet staining was
done in 96-well plates according to the following protocol:
1. wash cells 2x with PBS
2. fix cells for 10 min in 100 µl 2-Propanol
3. permeabilize cells by washing 3x with PBS (0.05 % Tween 20)
4. add 50 µl crystal violet (0.1 % in PBS) and incubate shaking for 20 min at room temperature
5. wash 3x with ddH2O
6. dissolve bound crystal violet in 100 µl acetic acid (33 %)
7. transfer 70 µl of solution to an optical plate
8. quantify optical density in microplate reader at 600 nm
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Figure 3.3: The principle of the metabolic activity assay. The tetrazolium compound MTS is reduced into
a differently colored formazan salt by electron transfer from the reduced reduction equivalents NADH or
NADPH via the electron coupling reagent phenazine ethosulfate (PES) to MTS, leaving NADH and NADPH
in their oxidized state NAD+ and NADP+ in the cytoplasm. Illustration taken and modified from [Promega,
2009].
3.2.2 Quantification of Cellular Metabolic Activity
Upon transfer of electrons from NADH or NADPH via a coupling reagent to MTS, the tetrazolium dye
MTS is reduced into a differently colored, soluble formazan salt [Berridge et al., 2005] (see figure 3.3
on page 32). Thus, quantification of the amount of formazan salt generated in a given time indirectly
reflects the amount of reduced reduction equivalents generated in a cell in that time and can therefore
be used to determine the cellular metabolic activity.
Staining was done in 96-well plates according to the manufacturer’s instructions as detailed below:
1. thaw MTS reagent at 37 ◦C in the water bath
2. prepare a master mix containing 100 µl medium plus 20 µl MTS reagent per well
3. exchange supernatant of cultured cells in test plate with 100 µl MTS master mix
4. incubate for 60 min at 37 ◦C, 5 % CO2 in a humidified atmosphere
5. transfer 70 µl supernatant to an optical plate
6. quantify optical density in microplate reader at 490 nm (reference wavelength for background
correction 650 nm)
3.2.3 Quantification of RUNX2 DNA-Binding Activity
DNA-binding activity of the osteogenic key transcription factor RUNX2 was assayed in an ELISA-based
system (see figure 3.4 on page 33).
The assay was done in accordance with the manufacturer’s instructions, required however a substan-
tial deal of improvement regarding the isolation of nuclear proteins. The final protocol used is detailed
below:
• Prepare nuclear envelope:
1. wash cells once in ice-cold PBS containing Phosphatase Inhibitors
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Figure 3.4: The principle of the RUNX2 DNA binding assay. An oligonucleotide with the consensus binding
sequence of RUNX2-regulated genes (5’-AACCACA-3’) is immobilized to the wells of a 96-well test plate. A
nuclear extract is then applied to the wells, and in case it contains activated RUNX2, the transcription factor
will bind its target sequence. Via a primary and secondary antibody in a typical ELISA-based setting, RUNX2
is detected and quantified. Illustration taken from [Active Motif, 2010].
2. scrape cells from the cell culture surface in 6 ml ice-cold PBS containing Phosphatase In-
hibitors
3. transfer cells to pre-chilled tube and centrifuge at 500 g and 4 ◦C for 5 min
4. resuspend cell pellet in 500 µl 1X Hypotonic Buffer at 4 ◦C by pipetting up and down
5. incubate resuspended cells on ice for 30 min
6. add 25 µl Detergent and vortex for 10 s at highest force
7. centrifuge lysed cells at 14,000 g and 4 ◦C for 30 s and discard supernatant (cytoplasmic
fraction)
• Lyse nuclear envelope:
1. freeze pellet (nuclear fraction) for 30 min at −80 ◦C and subsequently thaw it on ice
2. add 50 µl Complete Lysis Buffer, resuspend pellet by pipetting up and down and vortex at
highest force for at least 10 s
3. incubate shaking on ice at 150 rpm for 30 min, vortex at highest force for 30 s and incubate
in the ultrasonic water bath for 30 s
4. centrifuge for 10 min at 14,000 g and 4 ◦C, transfer supernatant (nuclear proteins) to a
pre-chilled tube, and discard pellet (nuclear fragments)
5. aliquot nuclear proteins and store at −80 ◦C until use
• Quantify nuclear proteins:
1. add 28 µl 660 nm Protein Assay Solution to 2 µl sample or Complete Lysis Buffer as blank
2. vortex and incubate at least for 5 min at room temperature
3. quantify optical density on a spectrophotometer at 660 nm
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4. calculate nuclear protein concentration in accordance with BSA standard
• Quantify activated, DNA-binding RUNX2:
1. add 30 µl Complete Binding Buffer to each test well of the plate (add 2 µl (30 pmol) wild
type or mutated consensus oligonucleotide to specificity control wells)
2. add 20 µl nuclear extract (containing 2 − 20 µg nuclear protein) per test well (5 µg SAOS-2
extract (2 µl extract in 18 µl Complete Lysis Buffer) for positive control, 20 µl Complete
Lysis Buffer for negative control)
3. seal wells with adhesive foil and incubate shaking at 100 rpm for 1 h at room temperature
4. wash 3x with 200 µl 1X Washing Buffer per well and carefully aspirate wells in the last step
5. add 100 µl RUNX2 antibody per well (pre-diluted 1:1000 in 1X Antibody Binding Buffer)
6. seal wells and incubate for 1 h at room temperature
7. wash 3x with 200 µl 1X Washing Buffer per well and carefully aspirate wells in the last step
8. add 100 µl HRP-conjugated secondary antibody per well (pre-diluted 1:1000 in 1X Antibody
Binding Buffer)
9. seal wells and incubate for 1 h at room temperature
10. wash 4x with 200 µl 1X Washing Buffer per well and carefully aspirate wells in the last step
11. add 100 µl Developing Solution per well and incubate 2 − 10 min at room temperature in
the dark
12. add 100 µl Stop Solution per well and incubate maximally 5 min
13. quantify optical density in microplate reader at 450 nm (background at 655 nm)
3.2.4 Staining of Active Alkaline Phosphatase for Microscopy
Alkaline phosphatase (ALPL) catalyzes the hydrolysis of naphthol AS-MX phosphate in the presence of
the coupling reagent nuclear fast red [Hasselgren, 1978]. This coupling reagent is a diazonium salt which
traps the hydrolyzed phosphatase substrate [Talbot et al., 1993], initially via ionic interaction, but finally
by formation of a stable adduct of red color [Cox and Singer, 1999] (see figure 3.5 on page 35).
Staining of active alkaline phosphatase for visualization by phase-contrast microscopy was done in
12-well plates according to the following protocol previously established in this department:
1. wash cells 2x with PBS
2. fix cells for 10 min at room temperature in 4 % PFA pre-warmed to 37 ◦C
3. wash fixed cells 2x with PBS
4. add a solution of 0.03 % Naphthol AS-MX phosphate and 0.03 % Fast Red Violet in 20 mM AMPED
and incubate for 10 min at room temperature
5. wash stained cells 2x with PBS
• optional: wash 2x with ddH2O and coverslip cells in mounting medium
6. perform bright-field phase-contrast microscopy
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Figure 3.5: The principle of active alkaline phosphatase staining for microscopy. Staining of active alkaline
phosphatase relies on the phosphatase-driven hydrolysis of the substrate AS-MX phosphate which subsequently
forms a stable, insoluble adduct with the diazonium dye nuclear fast red. Illustration taken from [Sigma-Aldrich,
2008].
Figure 3.6: The principle of alkaline phosphatase stain-
ing for activity quantification. Alkaline phosphatase
catalyzes the hydrolysis of para-nitrophenyl phosphate
into para-nitrophenol, a water-soluble product of yel-
low color. Illustration taken and modified from [Sigma-
Aldrich, 2008].
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3.2.5 Quantification of Alkaline Phosphatase Activity
Alkaline phosphatase (ALPL) catalyzes the hydrolysis of an arylphosphate residue of its synthetic sub-
strate para-nitrophenyl phosphate (pNPP) into the colored product para-nitrophenol [Montalibet et al.,
2005] (see figure 3.6 on page 35). Thus, by quantification of the optical density of the colored product
generated in a given time, the ALPL activity can indirectly be determined. In an extending application of
this finding as e.g. in Western blotting, quantitative antigen detection is indirectly done by following the
pNPP conversion of an antibody-ALPL conjugate [Voller et al., 1976].
Quantification of alkaline phosphatase activity was done in 96-well plates according to the following
self-established protocol:
1. wash cells 2x with TBS
2. add 50 µl cell lysis buffer (1 % Tween 20 and 100 µM PMSF in ddH2O) and incubate for 10 min
at room temperature
3. add 200 µl ALPL substrate solution (10 mM pNPP, 100 mM AMPED and 5 mM MgCl2 in ddH2O)
and incubate for 60 min at 37 ◦C, 5 % CO2 in a humidified atmosphere
4. add 85 µl NaOH (2 M) to end ALPL activity
5. transfer 100 µl supernatant to an optical plate
6. quantify optical density in microplate reader at 405 nm
3.2.6 Quantification of Extracellular Matrix Calcium Content
In a largely unknown complexation mechanism, ortho-cresolphthalein complexon in solution binds the
divalent cations strontium, barium, magnesium and calcium and thereby develops a violet color whose
intensity is proportional to the concentration of the ions present. In order to quantify only the concen-
tration of calcium ions in solution, all other ions present have to be masked. For magnesium ions, this is
accomplished by adding the chelating agent 8-hydroxy chinoline [Sarkar and Chauhan, 1967]. Strontium
and barium ions in vitro are, if it all, only present in traces.
Initially, procedures for calcium quantification in serum samples were developed and optimized
[Moorehead and Biggs, 1974; Morin, 1974] and subsequently adapted for quantification of extracel-
lular matrix calcium [Proudfoot et al., 2000]. These methods involve acidic liberation of calcium ions
from the extracellular matrix and subsequent complexation under alkaline conditions.
Quantification of extracellular matrix calcium content was done in 96-well plates according to the
following self-established protocol:
1. wash cells 2x with PBS
2. fix cells for 10 min at room temperature in 4 % PFA pre-warmed to 37 ◦C
3. wash fixed cells 2x with ddH2O
4. add 100 µl cresolphthalein buffer (0.1 mg/ml ortho-cresolphthalein complexon, 1 mg/ml 8-hydro-
xy chinolin and 6 % of 37 % HCl in ddH2O) and incubate for 5 min at room temperature
5. add 100 µl AMP buffer (15 % AMP in ddH2O, pH=10.7) and incubate 15 min at room temperature
6. transfer 100 µl supernatant to an optical plate
7. quantify optical density in microplate reader at 580 nm
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3.2.7 Quantification of Secreted Osteoprotegerin
The concentration of ASC-secreted osteoprotegerin (OPG) in the cell culture supernatant was determined
by enzyme-linked immunosorbent assay (ELISA) in a kit-based system in 96-well plates and in accordance
with the manufacturer’s instructions as detailed below:
1. add 100 µl Capture Antibody (pre-diluted to 2 µg/ml in PBS) per well of an immunoplate, seal
plate with adhesive foil and incubate at room temperature over night
2. wash each well 3x with 200 µl Wash Buffer (carefully aspirate wells in the last step)
3. for blocking, add 300 µl Reagent Diluent per well and incubate for at least 1 h at room temperature
4. wash each well 3x with 200 µl Wash Buffer (carefully aspirate wells in the last step)
5. add 100 µl of samples (pre-diluted 1:20 in Reagent Diluent) and Standard Samples per well, seal
plate with adhesive foil and incubate at room temperature for 2 h
6. wash each well 3x with 200 µl Wash Buffer (carefully aspirate wells in the last step)
7. add 100 µl Detection Antibody (pre-diluted to 200 ng/ml in Reagent Diluent) per well, seal plate
with adhesive foil and incubate at room temperature for 2 h
8. wash each well 3x with 200 µl Wash Buffer (carefully aspirate wells in the last step)
9. add 100 µl Streptavidin-HRP per well, close plate using the lid and incubate for 20 min at room
temperature in the dark
10. wash each well 3x with 200 µl Wash Buffer (carefully aspirate wells in the last step)
11. add 100 µl Substrate Solution per well and incubate for 20 min at room temperature in the dark
12. add 50 µl Stop Solution per well and manually and gently agitate plate
13. quantify optical density in microplate reader at 450 nm (background at 540 or 570 nm)
14. calculate OPG concentration in accordance with OPG standard
3.2.8 Quantification of Cellular Lipid Content
Boron-dipyrromethene (Bodipy) dyes are lipophilic compounds that dissolve well in cellular neutral
lipids, most of which being triglycerides, that build the core of lipid droplets and that are surrounded
by a monolayer of phospholipids [Spandl et al., 2009]. The Bodipy dyes fluoresce upon excitation, the
unmodified form used here being excited at 480 nm and emitting a green fluorescence at 503 nm. Thus,
the intensity of the fluorescence emitted by the Bodipy stain is proportional to the total amount of lipid
stored within a cell.
Quantification of cellular lipid content was done in 96-well plates according to the following self-
established protocol:
1. wash cells 2x with PBS
2. fix cells for 30 min at room temperature in 100 µl 4 % PFA pre-warmed to 37 ◦C
3. wash cells 3x with PBS
4. add 100 µl Bodipy solution (1 µg/ml in 150 mM NaCl)
5. incubate for 10 min at room temperature in the dark
6. wash cells 2x with PBS and 3x with ddH2O
7. quantify fluorescence intensity in microplate reader at 515 nm (excitation at 480 nm)
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3.3 Real-Time RT-PCR
3.3.1 RNA Isolation
Isolation of total RNA from ASC cultured in 6-well plates was done using a kit-based system and in
accordance with the manufacturer’s instructions as detailed below:
• Cell lysis:
1. discard medium and incubate cells in 350 µl Lysis Buffer RL for 2 min at room temperature
2. lyse cells by manually shaking the plate and by pipetting lysis buffer over cell layer, and
incubate for further 3 min
3. load lysed cells onto QIAshredder column and centrifuge for 1 min and 4 ◦C at maximum
speed
• DNA removal:
1. load filtrate onto Spin Filter D in 2 ml Receiver Tube and centrifuge at 10,000 g and 4 ◦C for
2 min
• RNA retention:
1. discard Spin Filter D (with DNA bound to it) and add 350 µl of 70 % ethanol to the filtrate
2. mix ethanol and filtrate by pipetting up and down and transfer solution onto a Spin Filter R
in 2 ml Receiver Tube
3. centrifuge at 10,000 g und 4 ◦C für 2 min and transfer Filter to new Receiver Tube
• RNA washing:
1. add 500 µl Wash Buffer HS, centrifuge at 10,000 g and 4 ◦C for 1 min and transfer Filter to
new 2 ml Receiver Tube
2. add 700 µl Wash Buffer LS, centrifuge at 10,000 g and 4 ◦C for 1 min and transfer Filter to
new 2 ml Receiver Tube
3. centrifuge at 10,000 g and 4 ◦C for 3 min and transfer Filter to new 2 ml Receiver Tube
• RNA elution:
1. add 80 µl RNase-free water, incubate for 5 min at room temperature and centrifuge at 6,000
g for 1 min
2. aliquot eluted RNA and store at −80 ◦C until use
3.3.2 RNA Quantification
Quantification of the amount of isolated total RNA within the samples was done using a spectropho-
tometer measuring the optical density of the sample at different wavelengths ranging from ultraviolet to
visible light. In this setting, the optical density at 260 nm reflects the concentration of RNA in the sample,
whereas the optical density at other wavelengths can be used to determine potential contaminants within
the RNA sample: proteins exhibit an absorption maximum at 280 nm, contaminants containing peptide
bonds or aromatic compounds absorb maximally at 230 nm, and particulates in solution absorb maxi-
mally at 325 nm [Gallagher and Desjardins, 2008]. Thus, on a calibrated photometer, the concentration
of the RNA as well as that of contaminants can accurately be determined.
The RNA concentration was determined according to the instructions of the spectrophotometer man-
ufacturer as detailed below:
1. load 2 µl sample to the NanoDrop spectrophotometer (use RNase-free water as blank)
2. quantify the RNA concentration using the NanoDrop Software and the RNA40 program
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3.3.3 RNA Electrophoresis
In order to check the integrity of the isolated RNA, especially with regard to RNase-driven RNA degrada-
tion, a non-denaturing agarose gel electrophoresis was done for all samples.
Under heating, the polysaccharide agarose dissolves in an aqueous buffer and forms a gel after cool-
ing down to room temperature. This gel consists of agarose fibers building a meshwork of variable pore
size, the pore size depending on the agarose concentration used. The higher the agarose concentration of
the gel, the smaller the pores. By applying a voltage field, macromolecules are forced to migrate through
the gel and will be retarded in dependence of both their own charge to mass ratio and the pore size of
the gel. Thus, by casting a gel of high agarose concentration and small pore size, large macromolecules
will be largely hindered from migrating through the gel, whereas small ones will well be able to migrate
through it, having a migration rate inversely proportional to their size. Visualization of nucleic acids
as RNA separated in that manner is usually done by staining with intercalating dyes such as ethidium
bromide that are added to the agarose gel during the casting process.
Agarose gel electrophoresis was done according to the following protocol established during my
diploma thesis:
1. add 1 % agarose powder to 1x TAE buffer
2. boil suspension in microwave oven to dissolve agarose
3. add ethidium bromide solution at 0.1 µg/ml to agarose solution
4. pour agarose solution into agarose gel electrophoresis tray and wait for the gel to set at room
temperature
5. transfer the agarose gel electrophoresis tray to the electrophoresis chamber filled with fresh 1x
TAE buffer
6. load RNA samples pre-mixed with loading buffer to the gel pockets
7. run gel at 8 V/cm gel length for 1 h
8. document gel using the gel documentation system
The integrity of the total RNA isolated from the ASC was then evaluated visually by confirming the
presence of all RNA species usually present in a cell, i.e. by confirming the presence of RNAs of largely
different size as messenger RNA (mRNA), transfer RNA (tRNA), small nuclear RNA (snRNA) and other
non-coding RNAs, but most obviously by the prominent bands of the ribosomal RNA (rRNA) present in
the small and the large ribosomal subunit. In case of RNase-driven RNA degradation, weakening of the
rRNA bands can be observed first, followed by the continuous vanishing of all RNA species.
3.3.4 Reverse Transcription
After isolation of the entire RNA species present in ASC, the mRNA transcripts of genomic DNA were
transcribed into complementary DNA (cDNA) in an in vitro process of reverse transcription (RT) (see
figure 3.7 on page 40).
This reverse transcription was done in a kit-based system according to the manufacturer’s instructions
as detailed below:
• Removal of genomic DNA:
1. add 2 µl gDNA Wipeout Buffer (7x) to 12 µl total RNA (maximally 1 µg)
2. incubate at 42 ◦C for 2 min, then at 4 ◦C
• Reverse Transcription:
1. add 1 µl Quantiscript RT, 4 µl Quantiscript RT Buffer (5x) and 1 µl RT Primer Mix per
reaction
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Figure 3.7: The process of reverse transcription. Based on hybridization of oligo-dT primers to poly-A tails
and random primers to random sites of the mRNA, the reverse transcriptase catalyzes RNA-dependent DNA
polymerization and thus yields a population of double-stranded mRNA-cDNA hybrids. Upon presence of these
hybrids, the hybrid-dependent exoribonuclease activity of the reverse transcriptase degrades the mRNA strand
and leaves a population of single-stranded cDNAs. Illustration taken from [QIAGEN, 2005].
2. incubate at 42 ◦C for 30 min (reverse transcription), then at 95 ◦C for 3 min (reverse tran-
scriptase denaturation)
3. store cDNA at 4 ◦C for short term or at −20 ◦C for long term
3.3.5 Real-Time RT PCR
To quantify the number of mRNAs of a certain gene and thus the expression of this gene, real-time PCR
was done following reverse transcription of all mRNAs (real-time RT PCR). To avoid amplification of
genomic DNA sequences in real-time RT PCR, at least one primer of a primer pair was designed to bind
a sequence spanning from one exon to an adjacent one (see figure 3.8 on page 41).
These cDNA-specific primers were designed via the web interfaces of the Primer3 engine [Rozen and
Skaletsky, 2000] found at
http://frodo.wi.mit.edu/primer3/input.htm
and
http://www.ncbi.nlm.nih.gov/tools/primer-blast/.
Melting temperatures were set to maximally deviate one Kelvin from 60 ◦C, and the 3’-end of the primers
was defined to contain at least one guanine (G) or cytosine (C) residue to establish a stable G-C pairing
at this critical site.
The sequences of the primers used were as follows (sequences of exon-exon boundaries are indicated
in uppercase, fwd (forward) and rev (reverse) indicate the corresponding primer):
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Figure 3.8: Designing of cDNA-specific primers. By designing primers to span an exon-intron boundary,
amplification of genomic DNA is precluded. The 3’-end of the left primer in the illustration on the left is
complementary to an adjacent exon the 5’-end of this primer is complementary to. Therefore, it cannot
hybridize to the genomic sequence of the corresponding gene and amplification of genomic DNA will not
occur. However, the primer will be well able to hybridize to the cDNA made from the spliced mRNA, as is
illustrated on the right, resulting in the generation of a PCR product during thermal cycling. Illustration taken
and modified from [QIAGEN, 2005].
Primer Sequence (5’−3’) Amplicon size (bp)
GAPDH (fwd) ctctgctcctcctgttcgac 112
GAPDH (rev) acgaccaaaTCcgttgactc
TNFRSF1A (fwd) actgaggactcaGGcaccac 165
TNFRSF1A (rev) aagctcccCCtctttttcag
TNFRSF1B (fwd) cagtgcgttggacagaagg 116
TNFRSF1B (rev) caccaggggaagaaTCtgag
ZBTB16 (fwd) ggtcgagcttcctgataacg 237
ZBTB16 (rev) gccatgtcagtgCCagtatg
ALPL (fwd) cattgtgaccaccacgagag 173
ALPL (rev) ccatgatcaCGtcaatgtcc
The reaction mixture for PCR of cDNA was set up according to the following protocol:
Order Substance (concentration) Volume per reaction Final concentration
1 add Master Mix (2x) 10 µl 1x
2 add primers (12 µM each) 0.5 µl (= 6 pmol) each 300 nM
3 homogenize gently
4 aliquot to wells
5 add cDNA (max. 100 ng) 9 µl
Thermal cycling was then done according to the following temperature profile:
• 95 ◦C for 10 min (initial denaturation and FastStart Taq polymerase activation)
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• Thermal cycling (40x):
1. 95 ◦C for 15 s (template denaturation)
2. 60 ◦C for 1 min (primer annealing and extension)
• Melting curve analysis:
1. 95 ◦C for 15 s (template denaturation)
2. 60 ◦C for 1 min
3. heat samples at 1 K/s
4. 95 ◦C for 15 s
• room temperature (until analysis)
In the first cycle of this thermal cycling program, all single-stranded cDNAs targeted by a primer
are complemented, which doubles the number of temperature-denatured single-stranded cDNAs for the
next replication round and thus yields a linear increase of their number. Exponential amplification of the
cDNAs then begins with the second cycle.
Each of the PCR products generated during thermal cycling in this manner had to be tested for
specificity, since fluoresence-based detection of nucleic acids, as was done here using SYBR Green, will
stain both specific and unspecific PCR products, the latter occuring e.g. from amplification of primer
dimers. In real-time PCR, testing for PCR product specificity is done via analysis of the melting behavior
of the PCR products in a sample (see figure 3.9 on page 43).
3.3.6 Analysis of Real-Time PCR Data
In real-time PCR, the expression of a certain gene is determined indirectly as that cycle the fluorescence
signal of the amplification product of this gene’s transcript significantly exceeds the background noise.
For determination of this threshold cycle Ct , two parameters have to be defined: the threshold level and
the baseline cycles.
The baseline cycles are those cycles within which there is no significant change in the fluorescence
signal emitted by the fluorescent dye intercalated into the PCR product or emitted by the negative control
samples containing no template. Thus, the reporter fluorescence intensity R found within these cycles
defines the background fluorescence intensity. Based on the detector signal, the baseline cycles were
determined automatically by the software.
Since increasing the quantity of reporter dye in the master mix will, as long as stain saturation is not
reached, increase the quantity of fluorescence emission from the PCR product without an increase in the
amount of PCR product, the reporter fluorescence signal intensity R has to be put into relation to the
fluorescence intensity of a non-intercalating, so-called “passive” reference dye contained in the master
mix at a constant concentration. This yields the normalized reporter signal Rn which thus can be put as
Rn ≡
reporter dye fluorescence intensity
reference dye fluorescence intensity
.
Within the baseline cycles, Rn will not change. However, in the growth phase following these cycles,
Rn will increase with increasing number of PCR products. Thus, by subtracting the Rn obtained during
the baseline cycles or for the negative control samples from the Rn obtained for the template-containing
samples in the growth phase, one gets a reliable measure of the magnitude of the PCR product signal
generated under the given PCR conditions. This background fluorescence-corrected Rn can thus be put
as
Rn sample − Rn baseline ≡∆Rn.
With increasing number of PCR cycles and thus increasing number of PCR products, ∆Rn will in-
crease, until the depleting reagents of the master mix start to limit the PCR or the fluorescence emission.
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Figure 3.9: Testing of PCR product specificity in real-time PCR. In order to find unspecific PCR products
as e.g. primer dimers, melting curve analysis was done. By increasing the temperature θ of a PCR product
in solution and stained with an intercalating dye, the fluorescence intensity F.I . emitted by this PCR product
will continuously decrease as a consequence of increasing melting of the double-stranded PCR product. Since
the melting process shows a biphasic behavior, initially accelerating with increasing temperature, but then
proceeding increasingly slower with increasing temperature, the derivation of −F.I . by θ will peak at the
temperature of fastest melting. This temperature is characteristic for the length and composition of the PCR
product, the melting temperature increasing with length and G/C content of the PCR product. Since there are
two peaks in this diagram, two PCR products have been generated, the smaller of which being an unspecific
product of primer dimer amplification. Illustration taken and modified from [Applied Biosystems, 2006].
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Figure 3.10: Baseline cycles, threshold level and amplification plots in real-time PCR. The baseline cycles
define all cycles in which the normalized fluorescence signal intensity Rn does not correlate with the ongoing
cDNA amplification. Thus, these cycles define the background fluorescence intensity (a) (see all cycles below
cycle 15 in this illustration). When Rn raises above the background level, the exponential growth (b) of the PCR
product number in this logarhithmic depiction becomes apparent as a linear function of Rn in dependence
of the cycle number. When PCR substrates become limiting, the PCR product number, and thus Rn, will
grow no longer exponentially, but linearly (c), and finally will reach a plateau phase (d) in which no further
amplification occurs. Illustration taken and modified from [Applied Biosystems, 2006].
Within this context, the threshold defines a level of ∆Rn that is intermediate between the baseline level
Rn and the saturation level Rn and thus defines a reliable level of reporter fluorescence intensity. In the
experimental settings used here, ∆Rn was manually set to be 0.1. In this setting, the threshold level for
all reactions exactly corresponded to the middle of the exponential growth phase in the amplification
plot. Figure 3.10 on page 44 illustrates a typical amplication plot and baseline cycles and threshold level.
Having baseline cycles and threshold level defined, the expression level of a gene can be calculated
from the number of cycles that were needed to raise Rn to the threshold level. This defines the threshold
cycle Ct of that sample. The higher the Ct , the more replication rounds were needed to raise the transcript
signal above the background level and the lesser the number of transcripts present in that sample. Since
each PCR cycle will ideally double the amount of PCR product present, the
expression of gene x = 2−Ct gene x .
To determine the expression level of a certain gene, it has to be put into relation to a constant
representing the amount of RNA put into the PCR, for input of a larger amount of RNA will lower the
Ct of the investigated gene and thus misleadingly will result in calculation of a higher expression level
of that gene. Under the experimental conditions used here, such a gene with unregulated, so-called
housekeeping expression was glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Thus, the fraction
expression of gene x
expression of housekeeping gene
=
2−Ct gene x
2−Ct GAPDH
= 2−Ct gene x+Ct GAPDH
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delivers the absolute expression of the investigated gene independent from the amount of RNA used for
PCR.
With
∆Ct ≡ Ct gene x − Ct housekeeping gene,
it follows that
2−Ct gene x+Ct GAPDH = 2−(Ct gene x−Ct GAPDH) = 2−∆Ct .
Therefore, the absolute expression of a specific gene can shortly be put as
absolute expression of gene x = 2−∆Ct .
Statistical evaluation of the expression data was then done on basis of differences in the ∆Ct values
and cannot be done on basis of differences in 2−∆Ct , since 2−∆Ct transfers the de facto measured data
from a linear scale (Ct values) to an exponential scale (2
−∆Ct values). Therefore, significance testing
of real-time PCR data has to invoke Ct -based data and is recommended to be done by non-parametric
significance tests as the Mann-Whitney U test [Yuan et al., 2006], for real-time data, as most biological
data, are unlikely to follow a normal distribution (see page 51 for further details).
3.4 Conventional and Confocal Fluorescence Microscopy
Fluorescence microscopy was used to asses expression and localization of signal transduction proteins
in ASC as well as to analyze ASC viability. Due to the inherent advantages of confocal fluorescence
microscopy over conventional, non-confocal fluorescence microscopy, immunofluorescence analyses were
done on a confocal microscope, whereas live-dead staining could sufficiently well, but much faster be
done on a non-confocal microscope. Figure 3.11 on page 46 illustrates the basis of conventional and
confocal microscopy and underlines the differences between them.
3.4.1 Immunofluorescence Staining
Immunofluorescence staining for confocal microscopy was done in chamber slides according to the fol-
lowing self-established protocol based on recommendations given by the antibody-producing company
Cell Signaling Technology [Cell Signaling Technology, 2011]:
1. wash cells in PBS
2. fix cells for 15 min at room temperature in 500 µl 4 % PFA pre-warmed to 37 ◦C
3. wash fixed cells 3x with PBS and incubate for 1 h at room temperature in blocking buffer (5 %
goat serum and 0.3 % Triton X-100 in PBS)
4. discard blocking buffer and add primary antibody in antibody dilution buffer (1 % IgG-free BSA
and 0.3 % Triton X-100 in PBS)
5. incubate at 4 ◦C over night
6. wash cells 3x with PBS and add secondary antibody in antibody dilution buffer
7. incubate for 1 h at room temperature in the dark
8. wash cells with PBS and 2x with aqua ad iniectabilia
9. embed cells in mounting medium for fluorescence microscopy
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Figure 3.11: The principle of conventional, non-confocal and confocal fluorescence microscopy. (A) In
conventional, non-confocal fluorescence microscopy, the light emited by a high pressure mercury vapor lamp
is first barrier filtered for the desired excitation wavelength and then reflected to the specimen by a dichroic
mirror. The light emitted by the specimen, which is of longer wavelength as the excitation light, is not reflected
by the mirror and passes through a second barrier filter to the ocular or a camera. (B) In confocal microscopy,
the monochromatic excitation light of a LASER passes through a pinhole and thus illuminates the specimen
in a focussed fashion (a). Light emitted by the specimen in this focus plane is focussed by the objective
to pass through a second pinhole and to the detector (b), whereas light emitted from specimen portions
out of excitation focus will not focus to the detector pinhole and thus will not reach the detector (c). (C)
In large three-dimensional specimens as this Drosophila embryo stained for actin, non-confocal microscopy
suffers from diffuse images due to the detection of light above and below the focus plane (a). In confocal
microscopy, this light does not pass the detector pinhole and thus will not contribute to the image (b). By
varying the excitation focus plane, optical sections of the entire specimen can be done and subsequently be
computationally post-processed into three-dimensional images. Illustrations taken and modified from [Alberts
et al., 2002].
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3.4.2 The Live-Dead Assay
Visualization of live and dead ASC was done in conventional, non-confocal microscopy by fluorescence
staining with calcein AM and propidium iodide. The acetoxymethyl- (AM)-functionalized form of calcein,
calcein AM, is non-fluorescent and uncharged, which allows it to permeate the cell membrane. Inside
living cells, active nonspecific esterases hydrolyze the acetoxymethyl group from the calcein backbone
and thus allow calcium binding by calcein, which results in emission of green fluorescence light. Calcein
shows a low degree of cytotoxicity, which requires microscopy to be done fast in order to avoid false
positive results for dead cells. Propidium iodide is an intercalating nucleic acid stain which, due to its
polarity, cannot permeate the cell membrane and thus stains only cells with defect membranes commonly
considered to be damaged or dead.
The Live-Dead Assay was done in chamber slides according to the following protocol established in
our group:
1. add propidium iodide at 500 nM and calcein AM at 1 µM to cell culture medium to prepare
staining medium
2. exchange the medium of cells in culture with this staining medium and incubate for 10 min at 37
◦C, 5 % CO2 in a humidified atmosphere
3. replace the staining medium by standard cell culture medium and quickly microscope cells:
• calcein: excitation at 496 nm, emission at 516 nm
• propidium iodide: excitation at 535 nm, emission at 617 nm
3.5 Flow Cytometry
By flow cytometry, the expression of TNF receptors and the distribution of ASC within the distinct cell
cycle phases was quantified. In contrast to fluorescence microscopy, flow cytometry facilitates the fast
and precise quantification of fluorescence properties of a cell, but gives no visual result. Therefore, it is
well-suited for quantification of cellular properties in statistical analyses.
The principle of the flow cytometry technique and its difference to fluorescence-activated cell sorting
(FACS) is illustrated in figure 3.12 on page 48.
3.5.1 Quantification of Cell Surface Antigens
Staining of surface proteins for flow cytometry is based on immunofluorescence, but avoids cell fixation
and undesired modification of antigens due to the fixation process. To preclude internalization of surfacial
antigens and to diminish a decline in cellular viability, cells have to be kept on ice over the entire staining
procedure, and centrifuging must not exceed an acceleration of 400 g. To determine the level of unspecific
binding of the antibodies used for staining of a specific antigen, control stainings with antibodies derived
from the same host species and being of identical isotype as the antibody directed against the specific
epitope, but being directed against an antigen not expressed in the target species, were done. These
antibodies are referred to as “isotype controls” and allow not only for the determination of unspecific
staining of an antibody due to non-antigen-binding-domain-mediated protein-protein interactions, but
also for the determination of the extent of autofluorescence emitted by the cells to be stained. In case
there is no unspecific staining, the fluorescence intensity emitted by isotope control-stained cells will be
the same as that of unstained cells.
Quantification of cell surface antigens was done according to the following self-established protocol:
• Harvest ASC:
1. wash cells 2x with PBS
2. add 0.25 % Trypsin and incubate for 5 min at 37 ◦C and 5 % CO2 in a humidified atmosphere
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Figure 3.12: The principle of flow cytometry
and fluorescence-activated cell sorting (FACS).
In Flow Cytometry, fluorescence properties of
cells are quantified on the single-cell level. A sus-
pension of cells is stained for a specific marker,
incorporated into a stream of sheath fluid and
exposed to laser irradiation. Those cells that
express the specific marker fluoresce upon irra-
diation. The fluorescence emission and its in-
tensity are detected for each cell by a detector.
In fluorescence-activated cell sorting (FACS),
the cell-bearing stream of sheath fluid is bro-
ken into droplets by an ultrasonication mech-
anism, each droplet containing maximally one
cell. Those droplets that contain a cell express-
ing the marker under investigation are polar-
ized to have a distinct charge, whereas those
that do not are polarized exactly oppositely.
Empty droplets remain uncharged. The oppo-
sitely charged droplets are deflected into op-
posed directions in an electric field and thus are
collected in different tubes. Illustration taken
and modified from [Alberts et al., 2002].
3. resuspend detached cells in ice-cold PBS (5 % FCS)
4. wash cells 2x with ice-cold PBS (1 % BSA) and resuspend them therein
• Stain cell surface antigens:
1. aliquot cells to FACS tubes on ice at 100,000 cells and 100 µl PBS (1 % BSA) per tube
2. add primary, directly labeled antibody
3. incubate on ice for 60 min in the dark
4. wash cells 2x in ice-cold PBS (1 % BSA) and resuspend them in 200 µl ice-cold PBS
5. store cells on ice until flow cytometry (avoid long-term storage)
For analysis of the level of expression of a specific antigen, its median fluorescence intensity, as
measured by the fluorescence signal generated by the dye-conjugated specific antibody, was normalized
to the median fluorescence intensity of unstained cells. These normalized fluorescence intensities of
specific antigens were than compared either to identically normalized isotype stainings in order to judge
the significance of antigen expression or compared to other treatment groups to determine significant
differences in antigen expression between them. For further details on significance testing see page 51.
3.5.2 Cell Cycle Analysis
By quantifying the fluorescence intensity of a cell nucleus following fluorescent nucleic acid staining,
the amount of DNA present in that cell can be determined using flow cytometry. This allows for exact
quantification of the distribution of a population of cells within the distinct cell cycle phases (see figure
3.13 on page 49).
Due to the linear relationship between DNA amount and fluorescence intensity emitted, two G1 cells
which simultaneously pass the detector will erroneously be detected as one G2 cell. To avoid such erro-
neous enlargement of the G2 population, the width of the fluorescence peak generated by a cell passing
the detector has to be analyzed: A single cell (singlet) passing the detector will have a gaussian profile
of fluorescence intensity emission, first increasing when entering the detector, then peaking when being
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Figure 3.13: The principle of cell cycle analy-
sis by flow cytometry. Upon staining of nuclear
DNA with an intercalating fluorescent dye, the
intensity of the fluorescent dye can be used as
a signal which is directly proportional to the
amount of DNA in that cell. Those cells that
have a diploid set of chromosomes, i.e. cells in
the first gap phase (G1) of the cell cycle, will flu-
oresce half as intense as cells having replicated
their entire genome once and being in G2 or
mitosis (M) phase. The nuclear fluorescence in-
tensity of cells in the process of DNA synthesis
(S phase) will lie intermediate between G1 and
G2 phase cells. Here, the number of cells in G1
is greater than the number of cells in G2 and M
phase, which means that cell passage through
G1 takes longer than passage through G2 and
M. Illustration taken from [Alberts et al., 2002].
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completely inside, and finally decreasing again when leaving the detector. When two cells (a doublet)
pass the detector, the fluorescence intensity generated by the first cell will decrease already when the
fluorescence intensity of the second cell still increases. Thus, the width of the fluorescence peak becomes
greater, and this greater width can be used as a measure to exclude doublets and even higher orders of
cell aggregates from cell cycle analysis.
Nuclear DNA staining for cell cycle analysis by flow cytometry was done according to the manufac-
turer’s instructions as detailed below:
• Harvest ASC:
1. wash cells 2x with PBS
2. add 0.25 % Trypsin and incubate for 5 min at 37 ◦C and 5 % CO2 in a humidified atmosphere
3. resuspend detached cells in ice-cold PBS (5 % FCS)
4. wash cells 2x with ice-cold PBS and resuspend them in ice-cold PBS
• Stain nuclear DNA:
1. add cell suspension drop-wise to 3 ml ice-cold 70 % ethanol in a FACS tube under vortexing
2. incubate cells for 45 min on ice
3. wash cells 2x in PBS, centrifuging at 2,000 g
4. resuspend cells in RNase-containing propidium iodide staining solution at 106 cells per 500
µl solution
5. incubate for 30 min in the dark at 37 ◦C
6. transfer tubes on ice and perform flow cytometry
The result of this analysis is a graph representing the number of cells as a function of the nuclear
fluorescence intensity, i.e. a graph that depicts how many cells exhibit a distinct nuclear fluorescence
intensity and thus how many cells contain a distinct amount of nuclear DNA (see figure 3.13 on page
49 for an example). In order to determine the percentage of cells within a distinct cell cycle phase on
basis of such a graphic representation, an algorithm has to be used that fits the experimental data to a
concrete mathematical model defining begin, course and end of each cell cycle phase. This algorithm can
subsequently be used to calculate the number or percentage of cells within a distinct cell cycle phase. I
used the Watson algorithm which fits the experimental data to meet the simple assumptions that data are
normally distributed and that a G1 peak is present [Watson et al., 1987]. In contrast to all other assays
used in this work, normal distribution of the experimental data obtained can be assumed, since the
number of observations in flow cytometry is extremely high and usually exceeds the number of 10,000
by far, whereas most other biological assays are done only in triplicate.
3.6 Data Analysis and Statistics
3.6.1 Data Normalization
To facilitate statistical data analysis, all metrical data obtained in the in vitro assays were subjected to
normalization. To this end, all data obtained for a certain parameter, as e.g. alkaline phosphatase activity,
and for a certain individual, i.e. the adipose tissue donor, were collected, and the minimum (xmin) and
maximum (xmax) value for all treatment conditions and time points analyzed in this individual was
determined. The position of a distinct value x obtained for this parameter and individual with respect to
the extremes xmin and xmax was then represented as
xnorm ≡
x − xmin
xmax − xmin
.
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This operation scales all values obtained for a certain individual and parameter to a range from zero (the
lowest value measured, x = xmin) to one (the highest value measured, x = xmax). This yields a set of
normalized data for each individual and parameter analyzed.
In order to allow for the representation of one parameter in relation to another, as as e.g. alkaline
phosphatase activity in relation to the cell number, the metrical data obtained for the first parameter and
individual were divided by the metrical data obtained for the second parameter of the same individual.
Then, data normalization was done as described before.
In case both parameters to be related to each other were determined in different individuals, the
median value of the metrical data obtained for the first parameter, as e.g. alkaline phosphatase activity,
at a distinct experimental condition in a variety of individuals was determined and then divided by the
median value of the metrical data obtained for the second parameter, as e.g. the cell number, at the
same experimental condition in a variety of individuals. Then, data normalization was done as described
before. In contrast to the procedure described in the last paragraph, this yields only one set of normalized
data for each parameter analyzed, and intra-individual differences cannot be depicted.
3.6.2 Data Illustration
Data are mostly presented as box plots. The solid box of such a plot represents 50 % of the measured
values that assemble around a central value called median and that is indicated by a horizontal line. The
box ranges from the 25th to the 75th percentile, i.e. that 25 % of the measured values lay below the lower
border of the box and 25 % of them lay above the upper border of the box. Error bars starting below and
above the box indicate the 5th and 95th percentile and are called whiskers.
3.6.3 Statistics
Since the data obtained for the parameters analyzed were in virtually all cases not normally distributed,
i.e. they did not deviate to the same extent above and below a central mean, testing for significance in
the difference between two datasets had to be done by non-parametric significance tests. These tests, in
contrast to parametric significance tests as e.g. the Student’s T , do not assume a specific, usually normal
distribution of the dataset. The non-parametric significance test applied here is the Mann-Whitney U test.
The level of significance was set to a p-value of lower or equal 0.05 (p ≤ 0.05), i.e. the probability that
the significance test failed and erroneously indicated a significant difference between two datasets that
de facto arose from pure chance is five percent.
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Results
4.1 Expression of TNF Receptors by ASC
TNF binds two distinct surfacial receptors officially designated TNFRSF1A and TNFRSF1B. By
real-time RT PCR and flow cytometry, I confirmed that mesenchymal stem cells derived from
the adipose tissue express these receptors.
On both the RNA and protein level, TNFRSF1A was much stronger expressed than TN-
FRSF1B (compare figures 4.1 and 4.2 on the pages 53 and 53, respectively). With increasing
duration of ASC culture, expression of both receptor genes showed a tendency of being up-
regulated, which however was significant only for TNFRSF1A (see figure 4.1). TNF stimulation
showed a tendency of increasing the expression of both receptor genes, which was significant
for expression of TNFRSF1B, but not for TNFRSF1A (see figure 4.1).
On the protein level, this tendency was not confirmed (see figure 4.2). Furthermore, TN-
FRSF1A showed a tendency of being reduced by TNF treatment of ASC, though not significantly.
Despite the weak expression level of TNFRSF1B, TNF receptor protein expression was strong
enough to significantly escape the background fluorescence level defined by the isotype control.
4.2 Impact of TNF on NFκB Signaling Pathway Activation
in ASC
Upon binding its surfacial receptors, TNF can induce three distinct signaling axes: the NFκB
pathway, the MAPK pathway and the apoptosis pathway.
A potential activating effect of TNF on the NFκB pathway was analyzed by staining the p65
subunit of the NFκB transcription factor. p65, also designated as RELA, heterodimerizes with
NFκB1 to form the most abundant transcription factor variant of the NFκB family [Pruitt et al.,
2009]. In case TNF activates the NFκB pathway, translocalization of NFκB – and thus also of its
subunit p65 – from the cytoplasm to the nucleus will occur.
And indeed, even after only one hour of stimulation, transduction of the TNF signal from
the extracellular space to the nucleus was observed (see figure 4.3 on page 54). NFκB activation
was also present at later time points and at least until the end of observation after one week
(data not shown). In contrast to TNF, neither osteogenically stimulated nor unstimulated ASC
showed NFκB activation, whereas under co-treatment of ASC with both TNF and osteogenic
stimulants, NFκB activation was also observed. Hence, TNF acted as a strong activator of the
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Figure 4.1: Expression of TNF receptor genes by ASC. Absolute expression levels of TNF receptor genes
1 and 2, designated as TNFRSF1A and TNFRSF1B, were determined by real-time RT PCR, and data were
normalized to the expression of the housekeeping gene GAPDH. The level of significance was set to a p-value
of less or equal 0.05 and determined applying the non-parametric Mann-Whitney U test. US: unstimulated
ASC. TNF: TNF-stimulated ASC.
Figure 4.2: Expression of TNF receptor proteins by ASC. In (A), the protein expression level of TNFRSF1A
and TNFRSF1B after one week of stimulation was analyzed by flow cytometry and is displayed for one individ-
ual as a histogram overlay of stained (unfilled histogram) and unstained (filled histogram) ASC. Subfigure (B)
displays a flow cytometric expression analysis of multiple individual stem cell donors. Data quantification was
done by normalizing the fluorescence intensity (F.I.) of the specific receptor staining to the F.I. of unstained
ASC. Significance of the absolute expression levels of the receptor proteins was determined by comparing
the normalized F.I. of the specific receptor staining to the F.I. of isotype control stainings normalized to
unstained ASC. The level of significance was set to a p-value of less or equal 0.05 and determined applying
the non-parametric Mann-Whitney U test. US: unstimulated ASC. TNF: TNF-stimulated ASC.
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Figure 4.3: Impact of TNF on activation of the NFκB pathway in ASC. By confocal microscopy, the
translocalization of NFκB after one hour of stimulation with TNF was visualized in ASC by staining with a
primary antibody directed against the p65 subunit of this heterodimeric transcription factor. Nuclei were co-
stained using a primary antibody directed against the nuclear envelope protein dimer lamin A/C. All primary
antibodies were visualized by fluorescently labeled secondary antibodies directed against the host species of
the primary antibody. All images were captured at identical magnification, the scale bar corresponding to 29
µm. US: unstimulated ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
NFκB pathway in ASC.
4.3 Impact of TNF on MAPK Signaling Pathway Activation
in ASC
As was done for the NFκB pathway, a potential activating effect of TNF on the MAP kinase
pathway was analyzed by observation of nuclear translocalization of activated transcription
factors and kinases. As is summarized in figure 1.1 on page 6, the MAPK pathway comprizes
three distinct signaling axes that transduce extracellular signals via the transcription factor AP1
and the MAP kinases ERK and p38.
4.3.1 Analysis of p38 Activation
p38 is a member of the MAP kinase family and is designated as MAPK14. Upon activation
through phosphorylation by upstream kinases, p38 translocalizes to the nucleus to regulate the
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Figure 4.4: Impact of TNF on activation of the MAPK pathway kinase p38 in ASC. By confocal microscopy,
active p38 was detected by staining for the phosphorylated and thus activated form of this MAP kinase,
designated as P-p38. Nuclei were co-stained using a primary antibody directed against the nuclear envelope
protein dimer lamin A/C. All primary antibodies were visualized by fluorescently labeled secondary antibodies
directed against the host species of the primary antibody. All images were captured at identical magnification,
the scale bar corresponding to 29 µm. US: unstimulated ASC. OS: osteogenically stimulated ASC. TNF:
TNF-stimulated ASC.
activity of a variety of transcription factors by phosphorylation [Bradham and McClay, 2006].
Thus, by staining the phosphorylated form of p38, translocalization and thus activation of this
transcription factor was analyzed.
Active p38 was found under any stimulatory condition after six hours of stimulation (see
figure 4.4 on page 55), but also at earlier and later time points for up to one week (data not
shown). Thus, the specific stimuli applied did not have any regulatory impact on p38 activation.
4.3.2 Analysis of AP1 Activation
Activator protein 1 (AP1) is a dimeric transcription factor present either as a homodimer con-
sisting of two identical JUN family member subunits or as a heterodimer consisting of one JUN
family member and one FOS or ATF family member [Karamouzis et al., 2007]. Activation of
AP1 occurs through phosphorylation of the JUN transactivation domain by JUN N-terminal ki-
nases (JNKs), which themselves are activated by upstream JNK kinases. Upon activation, JNKs
translocalize to the nucleus to activate JUN by phosphorylation. Thus, by staining of the phos-
phorylated form of cJUN, translocalization and activation of the AP1 transcription factor was
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Figure 4.5: Impact of TNF on activation of the MAPK pathway transcription factor AP1 in ASC. By
confocal microscopy, active AP1 was detected by staining for the phosphorylated and thus activated transac-
tivation domain of its subunit cJUN, designated as P-cJUN. Nuclei were co-stained using a primary antibody
directed against the nuclear envelope protein dimer lamin A/C. All primary antibodies were visualized by flu-
orescently labeled secondary antibodies directed against the host species of the primary antibody. All images
were captured at identical magnification, the scale bar corresponding to 29 µm. US: unstimulated ASC. OS:
osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
analyzed.
Active AP1 was found under any stimulatory condition after one hour of stimulation (see
figure 4.5 on page 56), but also at later time points for up to one week (data not shown). Thus,
the specific stimuli applied did not have any regulatory impact on AP1 activation.
4.3.3 Analysis of ERK Activation
Extracellular signal-regulated kinases (ERKs), which are also called mitogen-activated protein
kinases (MAPKs), regulate nuclear transcription factors by phosphorylation. ERKs themselves
are activated by phosphorylation through upstream kinases [Pruitt et al., 2009]. Thus, by stain-
ing the phosphorylated form of a domain homolog for both ERK1 and ERK2, translocalization
and activation of these kinases was analyzed.
Active ERK1 and ERK2 was found under no stimulatory condition after one hour of stimula-
tion (see figure 4.6 on page 57), but also not at later time points for up to one week (data not
shown). Thus, the specific stimuli applied did not have any regulatory impact on the activation
of ERK1 and ERK2.
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Figure 4.6: Impact of TNF on activation of the MAPK pathway kinases ERK1 and ERK2 in ASC. By
confocal microscopy, active ERK1 and ERK2 was detected by staining for the phosphorylated and thus
activated form of a domain homolog in both kinases, designated as P-ERK1/2. Nuclei were co-stained using
a primary antibody directed against the nuclear envelope protein dimer lamin A/C. All primary antibodies
were visualized by fluorescently labeled secondary antibodies directed against the host species of the primary
antibody. All images were captured at identical magnification, the scale bar corresponding to 29 µm. US:
unstimulated ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
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Figure 4.7: Effect of TNF on cytoskeletal organization and viability of ASC. Organization of the f-actin
cytoskeleton after three days of stimulation was visualized by confocal microscopy (A), whereas viability of
ASC after 14 days of stimulation was visualized by non-confocal fluorescence microscopy (B). In (A), actin
staining was done with phalloidin conjugated to a fluorescent dye, whereas nuclei staining was with SYTOX
Blue. The scale bar corresponds to 90 µm. In (B), live cell staining was with calcein acetoxymethyl esther,
and dead cell staining was with propidium iodide. The scale bar corresponds to 180 µm. US: unstimulated
ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
4.4 Impact of TNF on ASC Cytoskeletal Organization and
Viability
In addition to the NFκB and MAPK pathway, TNF can potentially exhibit an activating effect
on the apoptosis pathway in ASC was analyzed. Since changes in the cytoskeletal organization
are early hallmarks of apoptosis, I analyzed both the organization of filamentous actin (f-actin)
in ASC after three days of stimulation and ASC viability as a late parameter after 14 days of
stimulation.
Both actin organization and ASC viability were unchanged, irrespective of the applied stim-
ulus (see figure 4.7 on page 58). Hence, TNF as well as osteogenic treatment of ASC did not
induce apoptosis in these cells. Contrastingly, both types of stimulation increased ASC prolifera-
tion rates, since the number of cells per image, as judged by the number of nuclei, in both cases
was clearly higher than in the corresponding unstimulated controls.
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Figure 4.8: Effect of TNF on proliferation and cell cycle of ASC. In (A), the ASC number was determined
indirectly by quantifying the optical density (O.D.) of the DNA-staining agent crystal violet. In (B), the
percentage of ASC in the different cell cycle phases was assessed by nuclear staining with propidium iodide
and subsequent cell cycle analysis on a flow cytometer. The level of significance was set to a p-value of less
or equal 0.05 and determined applying the non-parametric Mann-Whitney U test. US: unstimulated ASC. OS:
osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
4.5 Impact of TNF on ASC Proliferation, Cell Cycle and
Metabolic Activity
4.5.1 Analysis of Proliferation and Cell Cycle
The proliferation-inducing effect of TNF-treatment on ASC proliferation indicated by the greater
number of cells seen in figure 4.7 on page 58 could subsequently be confirmed by quantification
of cell numbers for up to four weeks in a large number of individuals.
While cell numbers of unstimulated ASC increased comparatively slowly and rather linearly,
treatment with TNF or osteogenic substances yielded exponential trends (see figure 4.8A on
page 59). From two weeks on, the number of TNF-treated ASC was significantly higher than
that of the unstimulated ASC at the same point of time. Osteogenic stimulation also led to
an increase in proliferation rate that was significant beginning from three weeks after start of
stimulation, while it was significant beginning from two weeks when ASC were co-stimulated
with TNF and osteogenic compounds.
Cell cycle analysis by flow cytometry revealed a differing impact of TNF and osteogenic
treatment of ASC on the distribution of cells within the three cell cycle phases G0/G1 (gap phase
of cellular quiescence and gap phase before DNA replication, respectively), S (DNA synthesis)
and G2/M (gap and mitosis phase after DNA replication, respectively).
Under TNF-treatment, the proliferative increase seen for cell numbers in subfigure 4.8A
was accompanied by a significant reduction of the portion of cells being into the S phase of
the cell cycle (see figure 4.8B). Simultaneously, the portion of cells being into the G0/G1 and
G2/M phase increased significantly. For osteogenic stimulation, exactly the opposite was true:
Significantly more cells were detected in the S phase, at the expense of cells being into the
G0/G1 and G2/M phase. When ASC were co-treated with both TNF and osteogenic substances,
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Figure 4.9: Effect of TNF on metabolic activity of ASC. In (A), the metabolic activity of ASC was determined
indirectly by quantifying the optical density (O.D.) of the NADH-mediated conversion of the tetrazolium salt
MTS into a formazan salt. To determine the metabolic activity per cell as illustrated in (B), the metabolic
activity of the MTS assay in subfigure (A) was put into relation to the cell number determined indirectly by
quantifying the O.D. of the DNA staining agent crystal violet at the corresponding experimental condition. The
level of significance was set to a p-value of less or equal 0.05 and determined applying the non-parametric
Mann-Whitney U test. US: unstimulated ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated
ASC.
the opposed actions of the single substances on ASC cell cycle added to give rise to a cell cycle
distribution that lay exactly intermediate. In comparison to osteogenic treatment alone, the
TNF and osteogenically co-treated ASC showed a significant increase in the portion of G0/G1
and G2/M phase cells, whereas the portion of cells being into the S phase was significantly
reduced.
Interestingly, the duration of cell culture also affected the cell cycle distribution of ASC, but
in a different manner as both TNF and osteogenic stimuli. With increasing time of ASC culture,
the portion of cells in G0/G1 increased, while the portion of cells being into the S and G2/M
phase decreased. Contrastingly, the specific stimuli always altered the portion of S phase cells in
one direction and the portion of gap phase cells in the other. These concerted changes therefore,
as a reflection of the specific reaction of ASC to a specific stimulus, can well be distinguished
from the temporal changes in ASC cell cycle distribution.
4.5.2 Analysis of Metabolic Activity
To shed more light on the processes going on on the proliferation and cell cycle level, global
analysis of ASC metabolic activity was done. Under all treatment conditions, the metabolic
activity increased strongly with time over the three weeks of observation (see figure 4.9A on
page 60). After two weeks of stimulation, all kinds of treatment resulted in a significant increase
of metabolic activity in comparison to the unstimulated cells. Additionally, the metabolic activity
of ASC that were osteogenically stimulated or co-treated with TNF and osteogenic stimuli was
significantly increased compared to those ASC that were treated with TNF alone.
To get not only an idea about the changes of metabolic activity of the entire ASC culture, but
also of the change in metabolic activity per cell, I normalized the metabolic activity data shown
in subfigure 4.9A to the corresponding cell numbers shown in subfigure 4.8A. In the unstimu-
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lated ASC, the metabolic activity per cell showed a sigmoidal shape: it increased during the first
week of culture, declined to the starting value around the second week of culture and subse-
quently increased very strongly until the end of observation after three weeks of culture (see
figure 4.9B). For the TNF-treated ASC, the metabolic activity per cell showed a weak tendency
of increasing also during the first week of culture, but subsequently declined continuously until
the end of observation.
Interestingly, osteogenic stimulation also led to a sigmoidal shape of metabolic activity per
cell, but exactly inversely to that observed for the unstimulated ASC: After an initial decline at
day seven of culture, the metabolic activity per cell strongly increased to peak at day 14 and
subsequently declined to end in the range of the value observed at day zero. Co-treatment with
TNF and osteogenic substances induced a stronger initial reduction of metabolic activity than
osteogenic treatment alone, and the metabolic activity was reduced a second time at the end
of observation after three weeks of ASC culture. Hence, TNF supplementation to osteogenic
medium reduced the peaking of metabolic activity observed for soleley osteogenically treated
ASC at day 14, but ended with the typical decrease that was found for both single treatments.
Thus, both TNF and osteogenic substances increased proliferation rates of ASC, which how-
ever resulted from a differing regulation of the cell cycle. Additionally, the temporal course of
metabolic activity per cell differed greatly from that of osteogenically stimulated ASC. There-
fore, these analyses imply that the increase in proliferation rate observed for both TNF and
osteogenic treatment is accomplished through differing cellular processes.
4.6 Impact of TNF on Osteogenic Differentiation of ASC
To gather a comprehensive insight into a putative role of TNF in regulation of osteogenic dif-
ferentiation of ASC, the differentiation process was analyzed in a variety of functional and
non-functional assays addressing numerous osteogenic marker genes and proteins ranging from
transcription factors involved in early osteogenesis-inducing steps over enzymes facilitating ex-
tracellular matrix mineralization to finally the determination of the extracellular matrix calcium
content.
4.6.1 Analysis of Osteogenic Transcription Factors
Representing a very early marker of the osteogenic differentiation pathway, the expression of
ZBTB16, a zinc finger transcription factor regulating transcription of the osteogenesis key player
gene RUNX2, was analyzed by real-time RT PCR.
In unstimulated ASC, ZBTB16 expression showed a tendency to peak around day seven of
cell culture and to decline subsequently, an effect that however was characterized by a large
variance (see figure 4.10A on page 62). Under TNF-treatment, the expression level of ZBTB16
was also strongly variable between individuals and showed a tendency of hitting the bottom
around day 14 of culture. However, the expression level did never differ significantly from the
level found for the unstimulated cells.
Contrastingly, ZBTB16 expression in osteogenically stimulated ASC increased significantly
and by a factor of approximately 10,000 over the unstimulated control cells. In addition, it
was significantly higher than observed for the TNF-treated ASC and exhibited a much narrower
distribution of intra-individual variances in expression level. In ASC co-treated with TNF and
osteogenic stimuli, the ZBTB16 expression profile closely resembled that found for osteogenic
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Figure 4.10: Effect of TNF on expression of the osteogenic transcription factor ZBTB16 and on RUNX2
DNA-binding activity. In (A), the expression level of the zinc finger and BTB domain containing 16 gene
(ZBTB16) was analyzed by real-time RT PCR and put into relation to the expression of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In (B), nuclear target DNA sequence-bound RUNX2
was determined colorimetrically in an enzyme-linked immunosorbent assay (ELISA) and put into relation to
the optical density (O.D.) of total nuclear protein. The level of significance was set to a p-value of less or
equal 0.05 and determined applying the non-parametric Mann-Whitney U test. US: unstimulated ASC. OS:
osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
stimulation alone. Again, a very narrow variance in expression level was observed between the
individuals analyzed.
Since TNF did not increase ZBTB16 expression significantly, while osteogenic stimulation of
ASC did, and since both kinds of ASC stimulation resulted in a significantly different ZBTB16
expression profile, the result of the expression analysis of this osteogenesis-related transcription
factor denies an inductive effect of TNF on osteogenic differentiation of ASC. Additionally, TNF
treatment of ASC under osteogenic stimulation did neither increase nor decrease expression of
this transcription factor and thus apparently did not influence osteogenic differentiation.
Activation of the ZBTB16 downstream target RUNX2 was analyzed in a functional assay.
Upon osteogenic stimulation, runt-related transcription factor 2 (RUNX2, also known as core-
binding factor subunit alpha-1, CBF-alpha-1) is activated by phosphorylation and translocalizes
to the nucleus. There, it activates transcription of genes involved in osteogenic differentiation.
If TNF treatment would induce osteogenic differentiation of ASC, activated RUNX2 would be
found bound to the consensus binding sequence in the promoter region of its target genes. In
the assay used, the amount of activated RUNX2 bound to an oligonucleotide representing this
consensus binding sequence was measured.
In the unstimulated ASC, activated DNA-bound RUNX2 was found at a medium extent which
remained unchanged by the time of ASC culture (see figure 4.10B on page 62). TNF treatment of
ASC induced a small, though significant increase in initial RUNX2 activity after two days of treat-
ment, which, however, strongly declined after nine days of ASC exposure to TNF. Contrastingly,
osteogenic stimulation, starting from the medium RUNX2 activities that were found also for the
unstimulated and TNF-treated ASC after two days, strongly and significantly increased RUNX2
activity after nine days of stimulation. Co-treatment of ASC with both TNF and osteogenic stim-
uli yielded this strong increase in RUNX2 activity already after two days of treatment and ended
at the low activity found for TNF treatment alone. Thus, TNF treatment of ASC under osteogenic
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stimulation did not preclude the strong peaking of RUNX2 DNA-binding activity, but accelerated
its onset, whereas TNF treatment alone was not able to induce the peaking of RUNX2 activity
found under osteogenic conditions.
Therefore, a potential inductive or repressive effect of TNF treatment on osteogenic differ-
entiation of ASC is denied by both the result of the gene expression analysis (ZBTB16) and by
the result of the functional, gene-regulatory analysis (RUNX2).
4.6.2 Analysis of Alkaline Phosphatase Activity
The process of extracellular matrix calcification involves activation of the bone-expressed vari-
ant of the enzyme alkaline phosphatase, which is designated ALPL. An overview staining of
this osteogenic marker for bright-field phase contrast microscopy after 21 days of ASC culture
revealed that alkaline phosphatase activity in the TNF-treated ASC raised over the level of the
untreated cells, which interestingly showed some islets of alkaline phosphatase-positive cells
(see figure 4.11A on page 64). However, alkaline phosphatase activity in both cases was clearly
lower than observed for the osteogenically stimulated cells. The intensity of the staining was
the highest in the co-stimulated cells, indicating an additive effect of both stimulants. Thus, os-
teogenic stimulation of ASC strongly increased the activity of alkaline phosphatase, and TNF
treatment also showed a tendency of driving cells into osteogenic differentiation, though to a
lesser extent.
In order to facilitate a statistically representative analysis of a quantitative measure as alka-
line phosphatase activity, assessment of this parameter in fully quantifiable assays and employ-
ing a large number of individuals was done.
Real-time RT PCR-based analysis of the expression of the ALPL gene revealed a tendency of
a time-dependent increase in the expression of this gene for TNF-treated ASC, which however
was true also for the unstimulated control cells (see figure 4.11B on page 64). Contrastingly, the
osteogenically stimulated ASC showed a much stronger increase in ALPL expression as compared
to the unstimulated, but also TNF-treated ASC, which was significant at almost any time point
of analysis. Co-treatment with TNF and osteogenic stimuli resulted in an expression pattern
similar to that obtained for osteogenic stimulation alone.
In order to confirm that the results obtained for the gene expression level hold true also for
the protein level, I analyzed the activity of alkaline phosphatase in a substrate conversion assay.
The experimental outcome was very similar to what was seen on the RNA level: TNF-treated
ASC showed a tendency of a time-dependent increase in alkaline phosphatase activity, which
however was also true for the control cells and which was not significant at any point of time
(see figure 4.11C on page 64). Only the osteogenically or co-stimulated ASC exhibited a reliable
and significant increase in the activity of this enzyme for all time points analyzed when being
compared to the untreated ASC, but mostly also when being compared to the TNF-treated ASC.
To exclude the possibility that the increased alkaline phosphatase activity observed following
osteogenic stimulation of ASC was the result of the increased cell number under this condition,
the median activity determined for each experimental condition was put into relation to the
median cell number at that condition. These analyses delivered exactly the same result as be-
fore: Beginning from one week after start of osteogenic stimulation, ASC strongly increased
alkaline phosphatase activity per cell (see figure 4.11D on page 64). This was not observed for
TNF-treated or unstimulated ASC. Co-treatment of ASC with both TNF and osteogenic stimuli
resulted in a similar increase of alkaline phosphatase activity per cell as osteogenic stimulation
alone, beginning to be significant one week after start of stimulation.
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Figure 4.11: Effect of TNF on alkaline phosphatase activity of ASC. Subfigure (A) displays a bright-field
phase contrast microscopic image acquired after stimulation of ASC for 21 days and after staining for active
alkaline phosphatase with Fast Red Violet and Naphthol AS-MX phosphate. The scale bar corresponds to
200 µm. In (B), the expression level of the alkaline phosphatase gene ALPL was analyzed by real-time
RT PCR and put into relation to the expression level of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). In (C), the activity of alkaline phosphatase was determined indirectly by quantifying
the optical density (O.D.) of the converted phosphatase substrate para-nitrophenyl phosphate (pNPP). In
(D), the alkaline phosphatase activity, as displayed in subfigure (C), was put into relation to the cell number
determined indirectly by quantifying the O.D. of the DNA-staining agent crystal violet at the corresponding
experimental condition. The level of significance was set to a p-value of less or equal 0.05 and determined
applying the non-parametric Mann-Whitney U test. US: unstimulated ASC. OS: osteogenically stimulated
ASC. TNF: TNF-stimulated ASC.
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Figure 4.12: Effect of TNF on extracellular matrix calcium content of ASC. In (A), the calcium content of
the extracellular matrix was determined indirectly by quantifying the optical density (O.D.) of the calcium-
chelating agent ortho-kresolphthalein. In (B), the calcium content, as displayed in (A), was put into relation to
the cell number determined indirectly by quantifying the O.D. of the DNA-staining agent crystal violet at the
corresponding experimental condition. The level of significance was set to a p-value of less or equal 0.05 and
determined applying the non-parametric Mann-Whitney U test. US: unstimulated ASC. OS: osteogenically
stimulated ASC. TNF: TNF-stimulated ASC.
Thus, all statistically evaluable metrical analyses of alkaline phosphatase activity match in
their basic outcome, namely the finding that there is no indication for an osteogenic effect of
TNF on ASC in vitro, but also not for an inhibitory effect of TNF under osteogenic conditions.
4.6.3 Analysis of Extracellular Matrix Calcium Content
Calcification of the extracellular matrix of ASC, as a reliable functional and late hallmark of os-
teogenic differentiation, was absent in unstimulated and TNF-treated ASC (see figure 4.12A on
page 65). Contrastingly, the osteogenically stimulated ASC, beginning with day 21 of stimula-
tion, showed a significantly increased matrix calcium content as compared to the unstimulated
ASC and beginning with day 14 also in comparison to the TNF-treated ASC. When ASC were
co-treated with TNF and osteogenic stimuli, a significant difference was observed for both com-
parison groups.
Again, I additionally analyzed the extracellular calcium content as a function of the cell
number, and the results that were obtained are very similar to what was found for alkaline
phosphatase activity before. The unstimulated and TNF-treated ASC both showed a slightly de-
creasing extracellular calcium content per cell with time (see figure 4.12B), an effect that is
likely to have occured from increasing cell numbers at constant background levels of extracel-
lular matrix calcium. Again, the osteogenically stimulated ASC began to strongly increase their
extracellular calcium content beginning from day 21, and they did so equally strong as those
ASC that were co-treated with TNF and osteogenic stimuli.
Therefore, the analysis of extracellular matrix calcification also argues against an inductive
impact of TNF on osteogenic differentiation of ASC as well as against an impact of TNF on os-
teogenic differentiation when osteogenic stimulants were present. All marker genes or proteins
of osteogenic differentiation analyzed, either acting at a very early (ZBTB16 expression), early
(RUNX2 DNA-binding activity), middle (alkaline phosphatase activity) or late stage of differ-
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Figure 4.13: Effect of the TNF concentration on osteogenic differentiation of ASC. In (A), the activity of
alkaline phosphatase was determined indirectly by quantifying the optical density (O.D.) of the converted
phosphatase substrate para-nitrophenyl phosphate (pNPP). In (B), the calcium content of the extracellular
matrix was determined indirectly by quantifying the O.D. of the calcium-chelating agent ortho-kresolphthalein.
The level of significance was set to a p-value of less or equal 0.05 and determined applying the non-parametric
Mann-Whitney U test. US: unstimulated ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated ASC.
I.U.: international unit.
entiation (extracellular matrix calcification), contradict a potential effect of TNF on osteogenic
differentiation of ASC in vitro. In addition, they do also not give any indication for an inhibitory
or promotive impact of TNF on osteogenic differentiation of ASC when osteogenic stimulants
were present simultaneously.
4.7 Impact of the TNF Concentration on Osteogenic Differ-
entiation of ASC
To reveal a potential dose-dependent effect of TNF on osteogenic differentiation of ASC, TNF
concentrations ranging from 30 to 3,000 international units (I.U.) TNF per milliliter cell cul-
ture medium were used. It turned out that, irrespective of the TNF concentration applied,
pro-inflammatory stimulation of ASC did neither induce any significant increase in alkaline
phosphatase activity nor calcification of the extracellular matrix (see subfigures 4.13A and B,
respectively, on page 66). Solely osteogenic stimulation raised alkaline phosphatase activity and
matrix calcium content significantly over the level of the unstimulated controls. Supportingly,
both markers of osteogenic differentiation were significantly lower in TNF-treated than in os-
teogenically stimulated ASC, and there were no significant differences between the different
TNF concentrations.
Thus, the inability of TNF to induce osteogenic differentiation of ASC was not due to a dose-
dependent effect, but rather reveals an intrinsic inability of this pro-inflammatory cytokine to
induce an osteogenic differentiation program in ASC in vitro at whatever concentration ana-
lyzed. Since the amount of TNF secreted by ASC themselves was in the range of few picograms
per ml medium (data not shown) and thus at the lower detection limit of current enzyme-linked
immunosorbent assay-based approaches, a potential autocrine effect of TNF on ASC can be ex-
cluded. Noteworthy, ASC viability was not reduced even by the highest TNF concentration used,
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Figure 4.14: Effect of the cell seeding density
on osteogenic differentiation of ASC. ASC were
seeded at 3,000 and 20,000 cells per square cen-
timeter, respectively. After 28 days of stimulation,
osteogenic differentiation was analyzed. The cal-
cium content of the extracellular matrix was de-
termined indirectly by quantifying the optical den-
sity (O.D.) of the calcium-chelating agent ortho-
kresolphthalein. The level of significance was set
to a p-value of less or equal 0.05 and determined
applying the non-parametric Mann-Whitney U test.
US: unstimulated ASC. OS: osteogenically stimu-
lated ASC. TNF: TNF-stimulated ASC.
as can be deduced from the active alkaline phosphatase found even under these conditions and
after 28 days.
4.8 Impact of the Seeding Density on Osteogenic Differen-
tiation of ASC
In addition to the concentration of TNF, the seeding density of ASC could potentially affect
their osteogenic differentiation capacity. Therefore, I compared osteogenic differentiation of
ASC seeded at a low density of 3,000 cells per square centimeter to a nearly confluent culture
seeded at 20,000 cells per square centimeter, which was the default density in all experiments.
It turned out that there was no significant difference in the extent of osteogenic differenti-
ation between those ASC that were seeded at low or standard density. The activity of alkaline
phosphatase (data not shown) and the extracellular matrix calcium content did not show any
significant differences after 28 days of stimulation (see figure 4.14 on page 67). Additionally, the
number of ASC was virtually identical after 28 days, irrespective of the initial seeding density
(data not shown).
Hence, osteogenic differentiation of ASC in vitro was not affected by the degree of con-
fluence at the beginning of stimulation. Even at low seeding densities, ASC differentiated os-
teogenically and to the same extent as observed at nearly confluent seeding density, and TNF
had no impact on this differentiation pathway at either seeding density.
4.9 Impact of TNF Pre-Treatment on Osteogenic Differen-
tiation of ASC
Since neither the concentration of TNF nor the seeding density of ASC indicated an impact of
TNF on osteogenic differentiation of ASC when TNF was present for the entire duration of cell
culture, I analyzed the ability of ASC to differentiate osteogenically after having treated them
only for three days with TNF. Subsequently, cells were stimulated osteogenically as before. As
ASC are derived from the adipose tissue and are able to differentiate into adipocytes, adipogenic
differentiation of ASC was analyzed in addition.
Neither osteogenic nor adipogenic differentiation of ASC was affected when cells were pre-
treated with TNF, since alkaline phosphatase activity and cellular lipid content did not differ
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Figure 4.15: Effect of TNF pre-treatment on osteogenic and adipogenic differentiation of ASC. ASC were
treated for three days with TNF and subsequently exposed to osteogenic and adipogenic stimulants for 14
days. In (A), the ASC number was determined indirectly by quantifying the optical density (O.D.) of the
DNA-staining agent crystal violet. In (B), the activity of alkaline phosphatase was determined indirectly by
quantifying the O.D. of the converted phosphatase substrate para-nitrophenyl phosphate (pNPP). In (C), the
cellular lipid content was determined indirectly by quantifying the fluorescence intensity (F.I.) of the lipophilic
dye boron-dipyrromethene (also called BODIPY), which subsequently was put into relation to the number
of cells at the corresponding experimental condition, as determined indirectly by quantifying the O.D. of the
DNA-staining agent crystal violet. The level of significance was set to a p-value of less or equal 0.05 and
determined applying the non-parametric Mann-Whitney U test. US: unstimulated ASC. OS: osteogenically
stimulated ASC. TNF: TNF-stimulated ASC. AS: adipogenically stimulated ASC.
significantly between the TNF pre-treated and the non-treated ASC (see subfigures 4.15B and
C on page 68). Alkaline phosphatase activity raised significantly only for the osteogenically
stimulated ASC, whereas cellular lipid content increased significantly only for the adipogenically
stimulated ASC. In addition, ASC number increased significantly only for the osteogenically
stimulated cells, whereas the adipogenically stimulated ASC showed a significant reduction
of cell number in comparison to the unstimulated, slowly proliferating ASC, an observation
that resulted from the stagnation of proliferation with beginning of adipogenic stimulation (see
subfigure 4.15A). Again, there were no considerable and significant differences between the
TNF pre-treated and the non-treated ASC.
Hence, neither osteogenic nor adipogenic differentiation of ASC was found to be affected by
short-term pre-treatment of cells with TNF, which was true also for the continuous exposure of
these cells to the cytokine. Therefore, the duration of TNF exposure had no impact on osteogenic
differentiation of ASC in vitro.
4.10 Impact of Ascorbic Acid and β-Glycerophosphate on
Osteogenic Differentiation of TNF-Treated ASC
Osteogenic stimulation of ASC was done with ascorbic acid, β-glycerophosphate and dexam-
ethasone. Since TNF and the synthetic glucocorticoid dexamethasone are involved in regulation
of partially overlapping pathways [Adcock, 2001], I tested whether supplementation of TNF-
containing medium with ascorbic acid and β-glycerophosphate induces osteogenic differentia-
tion of ASC.
It turned out that also in conjunction with ascorbic acid and β-glycerophosphate, TNF was
not able to induce osteogenic differentiation of ASC. The extracellular calcium content of ASC
cultures that were treated with TNF, ascorbic acid and β-glycerophosphate was at no time point
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Figure 4.16: Effect of ascorbic acid and β-
glycerophosphate on osteogenic differenti-
ation of TNF-treated ASC. The calcium
content of the extracellular matrix was de-
termined indirectly by quantifying the opti-
cal density (O.D.) of the calcium-chelating
agent ortho-kresolphthalein. The level of sig-
nificance was set to a p-value of less or
equal 0.05 and determined applying the non-
parametric Mann-Whitney U test. US: un-
stimulated ASC. OS: osteogenically stim-
ulated ASC. TNF: TNF-stimulated ASC.
b-Glycero-P+AA: β-Glycerophosphate and
Ascorbic Acid.
of analysis significantly higher than that of the unstimulated ASC, which contrastingly was true
for the osteogenically stimulated ASC (see figure 4.16 on page 69). Supportingly, the extracel-
lular matrix calcium content in ASC treated with TNF, ascorbic acid and β-glycerophosphate
was significantly lower than in the osteogenically stimulated ASC, and there was no significant
difference between ASC treated with either unsupplemented medium, medium supplemented
with ascorbic acid and β-glycerophosphate, medium supplemented with TNF or medium sup-
plemented with TNF and ascorbic acid and β-glycerophosphate.
This analysis therefore does not only extend the previous findings that TNF has no impact
on osteogenic differentiation of ASC at either concentration, ASC seeding density or TNF ex-
posure time analyzed, but underlines that the osteopromotive compounds ascorbic acid and
β-glycerophosphate are not sufficient to induce osteogenic differentiation in ASC in vitro, either
in presence or absence of TNF. Therefore, TNF cannot be considered to be at least a weak stimu-
lus for osteogenic differentiation of ASC. Moreover, the synthetic glucocorticoid dexamethasone
is strictly required for this differentiation pathway to succeed in these cells.
4.11 Impact of TNF on Osteoprotegerin Secretion by ASC
Since TNF treatment of ASC did not influence osteogenic differentiation of these cells in vitro,
I analyzed whether it has an impact on osteogenic differentiation of other cells via paracrine
mechanisms. To this end, secretion of osteoprotegerin (OPG), a factor acting as a decoy receptor
for the major osteoclast differentiation-inducing factor RANKL, being involved in balancing the
extent of osteoclast-mediated bone resorptive activity to the osteoblast-mediated bone-forming
activity in vivo, was quantified in an enzyme-linked immunosorbent assay (ELISA).
Under all treatment conditions, OPG secretion increased time-dependently, an effect that
was significant for both osteogenic treatment groups (see figure 4.17 on page 70). Following
TNF treatment, OPG secretion by ASC was strongly, though not significantly, increased. Con-
trastingly, osteogenic stimulation yielded a significant reduction in OPG secretion as compared
to the TNF-treated ASC. In the ASC treated with both TNF and osteogenic stimulants, OPG se-
cretion was significantly higher than observed for osteogenic stimulation alone, indicating that
the OPG secretion-increasing effect of TNF outweighed the OPG secretion-reducing effect of
osteogenic stimulation.
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Figure 4.17: Effect of TNF on osteoprotegerin
(OPG) secretion by ASC. The OPG concentration
in ASC supernatants was determined indirectly in
an enzyme-linked immunosorbent assay (ELISA).
The level of significance was set to a p-value of
less or equal 0.05 and determined applying the
non-parametric Mann-Whitney U test. US: unstim-
ulated ASC. OS: osteogenically stimulated ASC.
TNF: TNF-stimulated ASC.
Thus, TNF was found to increase OPG secretion by ASC in vitro, while osteogenic stimula-
tion reduced secretion of this decoy receptor for the osteoclast differentiation-promoting factor
RANKL. Taking only these actions on ASC into account, these findings in vivo would translate
into a reduction of osteoclast maturation rates by TNF and an increase of osteoclastogenesis for
osteogenic conditions, illustrating that TNF exerted directly opposed effects on ASC as compared
to osteogenic stimulation.
4.12 Summary of Results
Summarizing the main results presented above, I found that TNF did not induce osteogenic
differentiation of ASC, since the results obtained in the analyses of osteogenic markers are the
same for TNF-treated and unstimulated ASC and at the same time different for TNF-treated and
osteogenically stimulated ASC (see table 4.1 on page 71). Most of these osteogenic markers
remained unchanged when TNF was added to osteogenic stimulants, with exception of the
RUNX2 DNA-binding activity, which increased earlier, but was reduced later as compared to the
osteogenically stimulated ASC. Hence, TNF did neither induce osteogenic differentiation of ASC
nor have a considerable promotive or reductive impact on this differentiation pathway in ASC
in vitro.
In contrast to the osteogenic markers, the parameters cell cycle progression, metabolic activ-
ity, NFκB pathway activity and secretion of the osteoclast differentiation-inhibiting factor osteo-
protegerin (OPG) by ASC changed by TNF treatment in comparison to unstimulated conditions,
but also in comparison to osteogenically stimulated ASC and to ASC treated with both TNF and
osteogenic stimulants. These parameters can help elucidating mechanistic differences in the cel-
lular reactions following TNF-mediated pro-inflammatory treatment of ASC and treatment with
stimulants inducing osteogenic differentiation of these cells.
Contrastingly, ASC proliferation rate is not an informative marker, since it was changed in
the same direction by all experimental conditions.
TNF receptor expression, ASC f-actin organization and viability as well as nuclear translo-
calization of the activated transcription factor AP1 and the MAP kinases ERK1/2 and p38 were
not affected by any stimulatory condition and thus are not regulated by them. However, the
constitutive activation of AP1 and p38 can help to explain observations that were made for all
ASC treatment groups.
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Table 4.1: Summary on the impact of TNF on osteogenic differentiation of ASC. Results are grouped in accordance to the context they belong to. = indicates
equal findings for the corresponding parameter, ∆ indicates differing findings. US: unstimulated ASC. OS: osteogenically stimulated ASC. TNF: TNF-stimulated
ASC.
effect on ... US OS TNF OS+TNF TNF vs. US TNF vs. OS OS vs. OS+TNF
TNF receptor 1 and 2 expression temporally increased not determined temporally increased not determined = not applicable not applicable
actin organization and viability no effect no effect no effect no effect = = =
NFκB pathway inactive inactive activated activated ∆ ∆ ∆
MAPK pathway: AP1 active active active active = = =
MAPK pathway: ERK1/2 inactive inactive inactive inactive = = =
MAPK pathway: p38 active active active active = = =
proliferation rate default strong strong strong ∆ = =
cell cycle default increased portion of S phase
cells, but decreased portion of
neighboring G phases cells
reduced portion of S phase
cells, but increased portion of
neighboring G phases cells
intermediate between pheno-
type in TNF and OS
∆ ∆ ∆
temporal course of metabolic
activity
initially increased, intermedi-
ately decreased, lately strongly
increased
early decreased, intermedi-
ately strongly increased, lately
decreased
continuously decreased early and lately decreased ∆ ∆ ∆
ZBTB16 expression largely constant strongly increased largely constant strongly increased = ∆ =
RUNX2 DNA-binding activity largely constant initially and temporally
increased
temporally decreased initially increased, but tempo-
rally decreased
∆ ∆ ∆
alkaline phosphatase expression
and activity
temporally increased very strongly temporally
increased
temporally increased very strongly temporally
increased
= ∆ =
extracellular matrix calcium
content
largely constant strongly temporally increased largely constant strongly temporally increased = ∆ =
OPG secretion temporally increased temporally increased, but
overall reduced
very strongly overall and
temporally increased
strongly overall and tempo-
rally increased
∆ ∆ ∆
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Discussion
5.1 ASC Express both TNF Receptors
TNF can bind two distinct receptors, TNFRSF1A and TNFRSF1B [Aggarwal et al., 1985]. I found
both TNF receptors to be expressed on ASC, TNFRSF1A being expressed much stronger than
TNFRSF1B (see figures 4.1 and 4.2 on pages 53 and 53, respectively). This finding fits well to
expression data for cells derived from related tissues and developmental stages which can be
retrieved in public databases. According to the latest annotation of expressed sequence tags in
the UniGene Database of the National Center for Biotechnology Information (NCBI), TNFRSF1A,
the gene encoding TNF receptor 1, is expressed in almost any tissue and throughout all devel-
opmental stages, whereas transcripts of TNFRSF1B, encoding TNF receptor 2, are found only
at fetal and adult stage and are much more restricted to distinct tissues, including adipose and
connective tissue, but not bone marrow e.g. (see figures 5.1A and B on page 73). The overall
level of TNFRSF1B transcripts is annotated to be much lower than that of TNFRSF1A.
Protein expression data for both receptors were also retrieved in silico using the Human
Protein Atlas. The protein data largely confirmed the data obtained for the transcripts, with ex-
ception of TNF receptor 2 which is referenced to be present also in cells of the bone marrow (see
figure 5.2 on page 74). Hence, both receptors are expressed in most cell types and tissues, and
although expression data for TNF receptors were so far not published for ASC, the expression
pattern found goes well together with what is known about related cells and tissues.
I found an influence of TNF on the expression of the TNF receptors, precisely a significant
upregulation of the expression of the receptor 2 gene and an insignificant downregulation of
the receptor 1 protein. This is in accordance with previous findings revealing TNFRSF1A being
either not regulated or partially downregulated after TNF treatment, whereas TNFRSF1B was
upregulated [Bradley, 2008]. Both findings fit well to the promoter structure of the correspond-
ing receptor-encoding genes: the TNFRSF1A promoter resembles those of housekeeping genes,
explaining its constitutive expression, whereas the TNFRSF1B promoter has a non-housekeeping
structure and provides binding sites for e.g. the signal transducers nuclear factor of kappa light
polypeptide gene enhancer in B-cells (NFκB) and the jun proto-oncogene (JUN, also known as
cJUN or activator protein 1, AP1) [Bradley, 2008], which is a member of the mitogen-activated
protein kinase (MAPK) pathway family. Both NFκB and JUN are activated by TNF, which im-
plies a positive feedback loop for the TNFRSF1B regulation: the more TNF is present, the more
receptor will be expressed, as was observed for ASC on the RNA level.
The upregulation of TNFRSF1B expression may have been stronger if pro-TNF would have
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Figure 5.1: Expression of TNF receptor genes in various tissues and developmental stages. (A) Abundancy
of Expressed Sequence Tags (ESTs) of the TNF receptor 1 gene TNFRSF1A and (B) of the TNF receptor 2
gene TNFRSF1B. Expression data were retrieved from the NCBI UniGene Database [Wheeler et al., 2005].
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Figure 5.2: Expression of TNF receptor proteins in various tissues. (A) Expression of TNF receptor 1 (TN-
FRSF1A) and (B) TNF receptor 2 (TNFRSF1B), respectively, as judged by the intensity of the corresponding
immunostaining. Expression data were retrieved from the Human Protein Atlas [Berglund et al., 2008].
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been used. Pro-TNF is the membrane-bound precursor of TNF (also designated “mTNF”) which
is cleaved into soluble TNF by ADAM 17, a member of the metalloproteinase family. In contrast
to TNFRSF1A, TNFRSF1B has only low affinity to the soluble form of TNF, but high affinity to
the membrane-bound form [Grell et al., 1995]. Therefore, the membrane-bound TNF type may
have yielded a higher upregulation of the gene encoding TNFRSF1B.
The low expression level of TNFRSF1B in comparison to TNFRSF1A does not necessarily
diminish its biological action, since TNFRSF1B can pass its ligand to the highly expressed TN-
FRSF1A and thereby potentiate TNFRSF1A-mediated signaling [Haridas et al., 1998]. To inacti-
vate the highly expressed TNFRSF1A, it is shedded from the cell surface by metalloproteinase-
mediated cleavage to yield a soluble, but inactive form [Bradley, 2008].
Thus, as both TNF receptors were found to be expressed by ASC, the effect of TNF binding
to them was investigated. The best characterized effect of TNF receptor activation known so
far is activation of the NFκB and MAPK signal transduction pathways as well as induction of
apoptosis (see figure 1.1 on page 6).
5.1.1 TNF Induced the NFκB Pathway in ASC
The NFκB pathway is involved in regulation of almost any cellular process, as e.g. inflammation,
immunity, proliferation, differentiation and apoptosis [Oeckinghaus and Ghosh, 2009]. I found
that TNF activated the NFκB pathway in ASC (see figure 4.3 on page 54), and this activation
lasted at least until day seven of stimulation. In the NFκB pathway, ligand-binding to the re-
ceptor is transduced into gene expression via a hierarchical system of kinases that activate the
transcription factor NFκB (see figure 5.3 on page 76).
The non-finding of NFκB activation in unstimulated ASC underlines the correctness of the
non-finding of TNF secretion by ASC in an ELISA-based approach (data not shown): If the lower
limit for TNF detection would have been too low and TNF would not have been detected for that
reason, although it was secreted by ASC, an activating effect of TNF on NFκB translocalization
in unstimulated, but also in osteogenically stimulated ASC must have been observed – which
obviously was not the case.
5.1.2 TNF did not Induce the MAPK Pathway in ASC
The MAPK pathway is involved in regulation of various cellular processes such as proliferation,
differentiation and apoptosis [Raman et al., 2007]. It consists of three signaling axes that can
be activated independently of each other (see figure 5.4 on page 77).
While the ERK signaling axis was inactive at all experimental conditions, the p38 and AP1
axis were not.
p38 was Constitutively Active in ASC
The MAP kinase p38 is involved in regulation of cell proliferation and cancer, differentiation and
response to stress [Krens et al., 2006; Bradham and McClay, 2006]. I found it to be constitutively
activated in ASC, at least until day seven of cell culture (see text and figure 4.4 on page 55).
In order to find a potential function of this constitutively activated kinase on ASC, one has to
take into account all cellular reactions that were driven into the same direction for either culture
condition applied. One such parameter was the basal level of osteogenic differentiation that
was seen even in the unstimulated ASC cultures. Supportingly, p38 activity was reported to be
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Figure 5.3: Schematic representation of TNF-induced activation of the NFκB pathway. Binding of a TNF
homotrimer to its homotrimeric receptors induces a rearrangement of the clustered cytoplasmic receptor
domains. This rearrangement activates the receptor-bound adapter proteins TNF-associated death-domain
protein (TRADD) and TNF-receptor-associated factor 2 (TRAF2) as well as the kinase receptor-interacting
protein kinase (RIP). By subsequent activation of inhibitor of kappa B (IκB) kinase kinase kinase (IKKK) and
IκB kinase kinase (IKK), IκB is phosphorylated, which drives its ubiquitinylation and proteasomal degradation.
Dissociation of IκB from NFκB makes the nuclear localization signal of NFκB accessible. This drives the
transport of NFκB into the nucleus, where it regulates expression of its target genes possessing κB binding
sites. Contrastingly to IκB, phosphorylation activates NFκB by increasing its DNA-binding and transcriptional
activity [Naumann and Scheidereit, 1994]. The transcription factor NFκB is a heterodimer consisting of an
NFκB1 (p50) or NFκB2 subunit on the one hand and a REL, RELA (p65) or RELB subunit on the other, the
p50-p65 heterodimer being the most abundant form of NFκB. Illustration taken from [Alberts et al., 2002].
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Figure 5.4: Schematic representation of the
MAPK pathway. Via a hierarchical system of
mitogen-activated protein kinases (MAPK), the
MAP kinase pathway transduces extracellular
signals into intracellular changes of gene ex-
pression. These signals are transduced to the
nucleus via three routes, one involving the ki-
nase extracellular signal-regulated kinase (ERK)
which activates proliferation, differentiation and
survival, whereas the others involve the kinases
JUN N-terminal kinase (JNK) and p38 and gen-
erally lead to inflammation and cell death. JNK
activates a transcription factor called activator
protein 1 (AP1) whose activity was analyzed in-
stead of that of JNK. Illustration taken from
[Cooper and National Center for Biotechnology
Information (U.S.), 2000].
indispensable for skeletal development in mammals. p38 knockout mice exhibited significantly
reduced bone mass, defective osteoblast differentiation, clavicular hypoplasia and incomplete
fontanelle closure, the latter features reminding of the human disease phenotype observed in
cleidocranial dysplasia caused by RUNX2 mutations [Greenblatt et al., 2010]. Mechanistically,
these mice failed in phosphorylating Runx2 to facilitate its association with transcriptional co-
activator CREB binding protein to induce transcription of Runx2 target genes.
TNF was found to induce phosphorylation and thus activation of the α-isoform of p38 which
is specific to osteoclasts and osteoclast precursors and drives their maturation into osteoclasts
[Boehm et al., 2009]. By osteoclast-specific deletion of p38α in mice, TNF-induced arthritic bone
loss was precluded locally as well as systemically, which raises the hope that specific pharmaco-
logical inactivation of p38α in human osteoarthritic patients could augment disease progression.
Hence, an important role of the p38 pathway in osteoclastogenesis is much more closely
characterized than its role in osteoblastogenesis. The role of its constitutive activation in ASC
during culture thus remains elusive.
AP1 was Constitutively Active in ASC
AP1 is involved in the regulation of cell growth and proliferation, differentiation and apoptosis
[Krens et al., 2006]. The transcription factor is active as a dimer, the most abundant form being
composed of one JUN and one FOS subunit. Activation of the JUN subunit occurs through
phosphorylation of its N-terminal transactivation domain by JUN N-terminal kinases (JNKs).
Since I observed nuclear translocalization of the phosphorylated and activated AP1 subunit
cJUN in all ASC cultures irrespective of the stimulus added to the cell culture medium and at
least until day seven of culture (see figure 4.5 on page 56), the considerations made before for
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the p38 activation also suggest a role for AP1 in the basal level of osteogenic differentiation
found for all ASC cultures.
Indeed, AP1 was reported to be a promoter of osteogenic differentiation and to be induced
by bone anabolic agents as e.g. vitamin D3 [Wagner, 2002; Wagner and Nebreda, 2009]. Jun-
Fos is the most abundant AP1 heterodimer found in the early stages of osteoblastogenesis and
is successively replaced by JunD-Fra2 at the mineralization stage. Supportingly, JNK activation
was reported to be essentially required for later stages of osteogenic differentiation, since it
was found to be required for osteocalcin and bone siaoloprotein gene expression, but not for
the expression of the alkaline phosphatase, osteopontin or Runx2 genes in mouse MC3T3-E1
pre-osteoblasts [Matsuguchi et al., 2009].
Mice overexpressing Fra2, the AP1 subunit present at late stages of osteogenic differenti-
ation, were reported to develop an osteosclerotic bone phenotye [Wagner, 2002], and Fra2
knockout resulted in incomplete osteoblastic differentiation [Bozec et al., 2010]. Moreover, the
osteocalcin and collagen 1α2 genes in vitro were revealed as direct targets of Fra2-AP1.
Since JNKs are activated themselves in response to extracellular stimuli as e.g. growth fac-
tors [Raman et al., 2007], the observed constitutive AP1 activation – and also the p38 activation
– may have been due to growth factors present in the fetal calf serum added to the medium.
Serum-supplemented medium without any adipogenic factors was shown to induce adipogenic
differentiation of human bone marrow-derived MSC via the ERK pathway [Wu et al., 2010].
Thus, the serum-supplemented medium may also have been the stimulus for AP1 and p38 ac-
tivation and the basal level of osteogenic differentiation observed for ASC under all treatment
conditions.
5.1.3 TNF did not Induce Apoptosis in ASC
The effect of TNF receptor activation on apoptosis of ASC was analyzed via surveillance of
changes in the actin cytoskeleton and nuclear lamin structure as well as via surveillance of
changes in the subsuming parameter cellular viability.
Analysis of Cytoskeletal Organization
An early hallmark of ongoing apoptotic processes can be seen in fundamental structural changes
in cytoskeletal organization. These remodeling processes are very obvious in confluent cul-
tures of human endothelial cells, TNF inducing re-organization of the prominent circumfer-
entially distributed filamentous actin fibers into elongated, cell-spanning stress fibers [Peters
et al., 2008; Millan et al., 2010]. Human synovial fibroblasts, also developing from mesodermal
mesenchyme, but having a more ASC-like phenotype, lack ostentatious circumferential actin,
but clearly increase their stress fiber number and thickness in response to TNF [Vasilopoulos
et al., 2007]. Contrastingly, TNF-treated smooth muscle cells completely depolymerize their
actin stress fibers to increase their motility, a prerequisite in the pathogenesis of atherosclerosis
[Jovinge et al., 1997].
TNF-treated ASC did not show any change of their actin structure, neither in direction of the
stress fiber type nor in direction of depolymerization (see figure 4.7A on page 58). Therefore,
the analysis of ASC cytoskeletal organization does not give any early indication for ongoing
apoptotic processes.
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Figure 5.5: Changes in nuclear lamin organiza-
tion during mitosis. Nuclear DNA is enveloped
by a nuclear membrane whose inner surface is
connected to a network of nuclear lamin fila-
ments, whereas the outer membrane confines
the nucleus from the cytoplasm. Inner and outer
membrane define a lumenal space continuous
to the endoplasmic reticulum and interrupted
by nuclear pore complexes. During mitosis and
apoptosis, the membrane fragments into vesi-
cles that remain associated with B-type lamins,
whereas A-type lamins dissociate from it and
are released to the cytoplasm as free dimers
with B-type lamins. During apoptosis, DNA is
subsequently cleaved by nucleases, which is not
the case for mitosis. Illustration taken from
[Cooper and National Center for Biotechnology
Information (U.S.), 2000].
Analysis of Nuclear Envelope Integrity
In addition to the cytoskeletal organization, apoptotic processes will affect the integrity of the
nuclear envelope and thus the organization of lamins which constitute one of the major envelope
components (see figure 5.5 on page 79).
Lamins serve as mandatory structural anchors for transcription factors within the nuclear
membrane, which was confirmed for the retinoblastoma protein whose transcriptional repres-
sive function depends on lamin A/C binding, and for OCT1 which co-localizes with lamin B
to suppress expression of an aging-dependent collagenase gene in fibroblast precursors [Imai
et al., 1997]. During apoptosis, caspase-mediated cleavage of lamins acts as a signal activat-
ing nucleases for subsequent DNA cleavage [Cohen et al., 2001]. Thus, desintegration of the
lamin filaments is a well-suited indicator of ongoing apoptosis before cell viability is seriously
impaired.
Since I did not find any indications for breakdown of lamin filaments after up to one week of
TNF treatment (see e.g. figure 4.4 on page 55 for a microscopic image captured after six hours
of stimulation), a putative apoptosis-inducing effect of TNF, but also of osteogenic stimulation,
on ASC can be neglected.
Analysis of Cell Viability
Supporting the results obtained from actin and lamin staining, a check of the cellular viability as
a terminal indicator of apoptotic processes revealed that even after two weeks of TNF treatment,
hardly any cell in culture was dead (see figure 4.7B on page 58). Even after four weeks of
stimulation with TNF concentrations increased by a factor of up to 100, ASC viability was not
impaired, as can be judged indirectly by the still detectable activity of alkaline phosphatase (see
figure 4.13A on page 66), an enzyme whose activity decreases to 10 % within three days under
physiologic conditions within a cell and when no activated alkaline phosphatase is replenished
[Fukunaka et al., 2011].
Since ZBTB16 acts as a pro-apoptotic factor [Barna et al., 2000], its high expression during
osteogenic differentiation (see figure 4.10A on page 62) is putatively cytotoxic. The fact that
I did not observe any obvious decrease in ASC viability during osteogenic differentiation thus
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may be attributed to ZBTB16’s additional role as a repressor of apoptosis: it represses the ex-
pression of the central apoptotic pathway member BID, which consequently precludes cleavage
of BID to truncated BID (tBID) and thus finally precludes the release of cytochrome c from the
mitochondria [Parrado et al., 2004].
The NFκB Pathway in Apoptosis
A potential mechanistic explanation for the observation that ASC did not undergo apoptosis
following treatment with the potentially pro-apoptotic cytokine TNF, which was shown to induce
apoptosis in endothelial cells [Sato et al., 1986] or mature human osteoblasts [Tsuboi et al.,
1999], but not in most other primary cells [Clark et al., 2005], may be given through the NFκB-
driven expression of genes encoding proteins belonging to the family of cellular inhibitors of
apoptosis (c-IAPs). These c-IAPs prevent assembly of the TNFRSF1A-associated death signaling
complex and additionally upregulate pro-survival NFκB signaling pathways [Varfolomeev and
Vucic, 2008].
Part of the pro-apoptotic action of TNF may also be compensated by expression of TNF
decoy receptors by ASC, as is done e.g. by osteoblasts [Bu et al., 2003]. These receptors lack the
intracellular death domain needed for activation of apoptosis signaling and thus indirectly shift
the balance between survival and apoptosis towards survival.
While TNFRSF1A has an intracellular TNF receptor-associated death domain (TRADD) en-
abling it to directly activate a distinct caspase without moderation of TRAFs, TNFRSF1B needs
TRAF2 with other co-factors to accomplish this. Therefore, a role of TNFRSF1B in apoptosis was
initially underestimated. Later it turned out that TNFRSF1B is well able to activate not only the
NFκB and MAPK pathways, but also to induce apoptosis [Haridas et al., 1998]. Thus, it is the
delicate balance in the extent of caspase activation on the one hand and NFκB activation on the
other that determines death or survival of a cell [Aggarwal, 2003].
Although both TNF receptors can in principal activate all the signaling pathways described
above, they do so with differing efficiency, making the net effect of TNF receptor activation
depending on the expression ratio of both receptors and the abundance of the ligands binding
them, as each ligand activates only distinct pathways. Therefore, the main effect that TNF exerts
on ASC apparently is activation of the pro-survival NFκB, but not the apoptosis pathway.
The MAPK Pathway in Apoptosis
The activation of JUN, which was found for all ASC cultures irrespective of their stimulation,
indicates an active JNK. Since JNK activates transcription factors of the family of signal trans-
ducers and activators of transcription (STAT) which increase expression of BCL2, a gene en-
coding a protein of the B-cell lymphoma (BCL) family, the MAPK pathway is directly involved
in regulation of apoptosis. By binding the outer mitochondrial membrane, BCL2 prevents the
swelling process observed in mitochondria at early stages of apoptosis [Janeway et al., 2001].
Thus, cytochrome c leakage and the activation of caspases are precluded and apoptosis will not
occur.
However, active JNKs also activate other BCL members as e.g. BCL2-associated X protein
(BAX) and BH3 interacting domain death agonist (BID), the latter being active only as cleaved
(truncated) form tBID [Wagner and Nebreda, 2009]. Both promote the release of cytochrome c
from the mitochondria and therefore are pro-apoptotic factors.
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Hence, JNK activate both pro- and anti-apoptotic BCL family members, and the activity of
a distinct JNK family member and the simultaneous activity of other cross-talking pathways
determines the net effect on apoptosis. Since I did not observe any apoptotic events in ASC in
response to either stimulus, the activation of JUNmay thus have resulted in increased expression
of anti-apoptotic BCL members.
5.2 ASC Proliferation Rate and Cell Cycle
5.2.1 TNF Increased ASC Proliferation Rate and Accelerated S Phase
Transition
TNF-treated ASC showed increased proliferation rates, and this increase in proliferation rate
was accompanied by a decreased portion of cells being into the synthesis (S) phase of the cell
cycle (see figure 4.8 on page 59). Simultaneously, an increased portion of cells was into the
neighboring gap phases G0/G1 and G2/M.
An increased proliferation rate means that passage through the entire cell cycle needs shorter
time. Under such highly proliferative conditions, a smaller fraction of cells in a distinct cell
cycle phase thus means that this phase is passed faster than another phase consisting of a
larger fraction of cells. For the TNF-treated ASC showing a reduced S phase fraction and a
concomitantly increased fraction of cells within the G phases, these considerations mean that
the increase in proliferation rate observed is accomplished by faster passage of ASC through
the S phase. To promote faster passage of ASC through the S phase, either the entry into the
S phase or the exit from it has to be accelerated. Since S to G2 transition is not subject to cell
cycle regulation, but G1 to S transition is, G1 to S transition needs to be accelerated in order to
facilitate the faster passage through the S phase and the increased proliferation rate observed
for TNF-treated ASC. And indeed, such an impact of TNF on G1 to S transition was reported in
a number of studies.
G1 to S transition is a cell cycle checkpoint under control of the cyclin E-CDK2 complex.
In different mouse and human embryonic and adult cells, G1 to S transition was reported to
be regulated by NFκB-mediated activation of the cyclin D-CDK4 complex, which itself is an
upstream regulator of cyclin E-CDK2 [Hinz et al., 1999]. Cyclin D1 associates with CDK4 or
CDK6 to promote G1 to S transition by phosphorylating and thus activating the retinoblastoma
protein [Dahlman et al., 2009]. In mouse embryonic fibroblasts, p65 was found to associate
with the cyclin D1 complex to stabilize and decrease its degradation. Shutdown of the p65
signal and thus reduction of the abundancy of the cyclin D1 complex hampers G1 to S transition
and in that manner is thought to facilitate cell cycle exit and differentiation, which in case of
these mouse embryonic fibroblasts was skeletal differentiation. Thus, this mechanism of NFκB-
mediated stabilization of the cyclin D1 complex may also be true for the increase in proliferation
rate observed for TNF-treated ASC.
In supportance of the role of NFκB as a promoter of proliferation, this pathway was found
to increase proliferation in a human T-cell line by transcriptional upregulation of one of the
major proto-oncogenes, MYC [Duyao et al., 1990]. In tumor cells from patients suffering from
Hodgkin’s lymphomas and breast cancer, NFκB was found to be constitutively active, and anti-
cancer treatment in these patients is done by NFκB inhibition through anti-inflammatory agents
as e.g. corticosteroids [Bours et al., 2000].
Thus, TNF-mediated upregulation of NFκB was multiply reported to be associated with the
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observation of increased proliferation throughout the literature. Since TNF treatment of ASC,
either in the presence or absence of osteogenic stimuli, induced p65 translocalization into the
nucleus, and since TNF-treated ASC differed significantly regarding the progression through
the cell cycle compared to the osteogenically stimulated ASC, this effect might have been a
consequence of the p65 activation.
5.2.2 Osteogenic Stimulation Increased ASC Proliferation Rate, but De-
celerated S Phase Transition
Osteogenic stimulation of ASC, as TNF treatment, resulted in a strongly increased proliferation
rate. However, the simultaneously observed distribution within the different cell cycle phases in
these ASC was exactly the opposite of what was found for the TNF-treated ones: The portion of
ASC in the S phase was significantly increased, whereas the portion of ASC in the surrounding
gap phases was reduced (see figure 4.8 on page 59).
As mentioned above, an increased portion of cells within a specific cycle phase indicates
that passage of this phase occurs more slowly as compared to the others. Slower passage of
ASC through the S phase can be the consequence of either a limited entry or exit rate into it.
Since S to G2 transition is not subject to cell cycle regulation, G1 to S transition needs to be
decelerated in order to facilitate the slower passage through the S phase that was observed for
osteogenically stimulated ASC.
5.2.3 The Role of ZBTB16 in Proliferation and Cell Cycle Regulation
The findings stated before may be well explained by the strongly increased expression of the zinc
finger and BTB domain containing 16 gene (ZBTB16), formerly called promyelocytic leukemia
zinc finger (PLZF), during osteogenic stimulation of ASC (see figure 4.10A on page 62). This
gene encodes a transcription factor involved in the regulation of cell cycle progression and os-
teogenic differentiation. ZBTB16 decelerates cell cycle progression at the G1 to S checkpoint
[Costoya et al., 2008]. Following the considerations made before for TNF-treated ASC, this
would have a directly opposed effect on ASC cell cycle progression as was found for TNF treat-
ment and thus would result in an increased portion of cells within the S phase.
Substantiating this role of ZBTB16 on cell cycle regulation, the transcription factor was
found to be negatively regulated through phosphorylation by cyclin E-CDK2, the main kinase
involved in G1 to S transition, by triggering its ubiquitinylation and subsequent proteasomal
degradation [Costoya et al., 2008]. Hence, the changes in ASC cell cycle during osteogenic
differentiation may be due to the upregulated expression of ZBTB16. A further mechanistic
explanation of the action of ZBTB16 on the cell cycle comes from the finding that this tran-
scription factor represses the prominent proto-oncogene MYC on the transcriptional level [Mc-
Connell et al., 2003] as well as on the post-translational level by downregulation of the MAPK
pathway. This subsequently reduces MYC activation by phosphorylation through ERK [Shi and
Vogt, 2009]. Both the direct action of ZBTB16 on cell cycle progression and the indirect, MYC-
mediated action of this transcription factor give an explanation for why ZBTB16 loss-of-function
mutations were first described in distinct cancer types as acute promyelocytic leukemia.
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5.2.4 The Role of RUNX2 in Proliferation and Cell Cycle Regulation
DNA-binding activity of runt-related transcription factor 2 (RUNX2) was strongly increased dur-
ing osteogenic stimulation of ASC, but reduced following TNF treatment and following TNF
treatment under osteogenic conditions (see figure 4.10B on page 62).
As the osteogenic marker ZBTB16, RUNX2 was found to have not only a role in osteogenic
differentiation, but also in regulation of cell cycle progression. RNAi-based RUNX2 knock down
in hMSC resulted in an increase in proliferation rate and cyclin A and B protein levels [Ghali
et al., 2010]. Moreover, RUNX2 was shown to promote cell cycle exit at G1 via induction of
P27KIP1 in terminally differentiating osteoblasts, whereas G1 exit and osteoblastic differentia-
tion were not observed in cancer cells of the osteosarcoma type [Thomas et al., 2004]. G1 exit
will necessarily result in reduced G1 to S transition. Altogether, these findings assign RUNX2 an
anti-proliferative role in cell cycle progression and underline that exit from the cell cycle and
entrance into a non-proliferative, quiescent state occur simultaneously and can be considered
to be a prerequisite for osteogenic differentiation to be accomplished.
The balance between proliferating and differentiating cells in the course of osteogenic differ-
entiation and cell cycle exit at the terminal differentiation stage is regulated via the phosphory-
lation degree of RUNX2 and the activity of telomerase. RUNX2, when hyperphosphorylated by
cyclin B-CDK1, activates primarily mitotic genes, whereas RUNX2 dephosphorylation by phos-
phatases PP1 and PP2A shifts its activity towards driving expression of osteoblastic genes [Ra-
jgopal et al., 2007]. Telomerase activity in bone marrow-derived stromal cells was found to
induce, alongside with some osteogenic genes, expression of cyclins D and E and thereby fa-
cilitated G1 to S transition to yield the increase in proliferation rate typical for early stages of
osteogenic differentiation [Gronthos et al., 2003].
Thus, both ZBTB16 and RUNX2, whose expression and activity was increased during os-
teogenic differentiation of ASC, were numerously reported to be negative regulators of G1 to S
transition to promote stem cell exit from the proliferative state and entry into the differentiating
state.
5.2.5 The Role of p38 and AP1 in Proliferation and Cell Cycle Regulation
The constitutive activation of the MAP kinase p38 and the transcription factor AP1 observed
in all ASC treatment groups irrespective of their distinct stimulation was discussed above to
possibly have promoted the basal level of osteogenic differentiation found in all ASC treatment
groups (see page 75 for further details). In addition, both MAP kinase signal transduction path-
way members were reported to play a role in regulation of proliferation.
Activation of TACE, the enzyme catalyzing the processing of the membrane-bound TNF
precursor into soluble, mature TNF, by inflammatory stimuli through p38 activation was re-
ported to result in the release of TGF family ligands that subsequently lead to activation of
pro-proliferative EGF receptor signaling in CHO-derived cells in vitro [Xu and Derynck, 2010].
Additionally, constitutive activation of AP1 was reported to be found in all tumor cells from pa-
tients with classical Hodgkin’s lymphomas and Anaplastic Large Cell Lymphomas (ALCL), AP1
in these cells stimulating proliferation by upregulating expression of cyclin D2 [Mathas et al.,
2002].
Thus, the constitutive activation of p38 and AP1 may also have supported proliferation of
ASC as was observed to at least a basal level for all cells in culture.
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5.2.6 Concluding Remarks on the Regulation of Proliferation and Cell
Cycle Progression
Hence, osteogenic differentiation is regulated via the opposed activity of cyclins D and E on the
one hand and ZBTB16 and RUNX2 on the other. Initially, cyclin D-CDK4 and cyclin E-CDK2 pro-
mote the fast G1 to S transition needed for increased proliferation at early stages of osteogenic
differentiation. Then, the more active products of the ZBTB16 and RUNX2 genes are present
with ongoing osteogenic differentiation, the more they exert their inhibitory effect on G1 to S
transition to slow down proliferation and to allow for cell cycle exit and terminal osteoblastic
differentiation. Remaining bound to DNA even during mitosis, RUNX2 is involved in keeping
expression of lineage-specific genes upright after differentiation has taken place and thus acts
as a cell fate-determining transcription factor [Young et al., 2007], which gives an explanation
for the gene’s constitutive expression and its complex regulation through multiple degrees of
phosphorylation. In supportance with the inhibition of cell cycle progression during osteogenic
differentiation, ascorbic acid, a common compound in osteogenic differentiation mixtures, in
HeLa cells was found to transiently block G1 to S and G2 to M transition [Thomas et al., 2005].
The findings for ZBTB16 expression and RUNX2 DNA-binding activity bring proliferation and
differentiation into a common context and underline that proliferation continuously diminishes
when differentiation proceeds. If G1 to S transition is increasingly hampered in the progress of
osteogenic differentiation of ASC, but cells still showed high proliferation rates even after four
weeks of osteogenic stimulation, how can these opposed observations then be explained?
As was stated in the results section, TNF treatment of ASC, in contrast to osteogenic stim-
ulation, did not result in osteogenic differentiation of these cells and additionally decreased
the S phase portion of ASC, but had identical impact on cellular proliferation by strongly in-
creasing it. In generalizing this finding of a small S phase portion of cells, as observed for
TNF treatment of ASC, as an indicator of proliferation, but not of differentiation, one can as-
sume that the osteogenically differentiating cells, showing a significantly larger S phase portion,
but also high proliferation rates, consist of at least two sub-populations: A fast proliferating
sub-population characterized by a small S phase portion and a slowly proliferating, but dif-
ferentiating sub-population exhibiting a large S phase portion. As cell cycle analysis necessarily
gives the summary of both sub-populations and shows a significantly increased overall S portion
of cells, these considerations imply that in osteogenic differentiation of ASC, the fast prolifer-
ating sub-population is comparatively small, but proliferates fast enough to sustain the larger
sub-population of differentiating cells. If that would be true, TNF treatment would reduce the in-
crease in S phase cells in osteogenically stimulated ASC – and that is exactly what was observed
when ASC were co-treated with TNF and osteogenic stimulants.
Following this assumption, osteogenic differentiation, although characterized by the simul-
taneous occurrence of differentiation and proliferation, is not accomplished by a single popu-
lation of precursor cells that both proliferate and differentiate, but rather by two distinct sub-
populations that are assigned to either the one function or the other. In supportance of this hy-
pothesis that a cell cannot differentiate and proliferate at the same time, NFκB-driven activation
of cyclin D1 expression was reported to clearly increase proliferation, but to inhibit myogenesis
[Guttridge et al., 1999]. Consequently, NFκB activity and subsequent cyclin D1 expression was
gradually shut down in the developing myoblast.
A probable way how such a co-culture of two different cell types, one proliferating and
one differentiating, can develop from a culture of indistinguishable precursors is the mode of
asymmetric cell division that was found for hematopoietic stem cells [Giebel and Bruns, 2008]
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and for neural stem cells [Farkas and Huttner, 2008]. In such asymmetric divisions, one cell
will differentiate, whereas the other exactly reduplicates to self-renew and keep the pool of
stem cells upright. A well accepted explanation for how such asymmetric cell divisions can take
place is that differentiation factors are inherited inequally during mitosis, which drives the fates
of the progeny into different directions. In addition, postmitotic decisions due to interactions
between the two daughter cells are discussed.
These asymmetric cell divisions would explain why islets of alkaline phosphatase-positive
cells are present in osteogenically stimulated cultures, whereas other islets consist of alkaline
phosphatase-negative cells. However, publications demonstrating asymmetric cell divisions in
differentiation of mesenchymal stem cells are so far not available, though this mode of cell
division is likely, since these cells share the same niche with hematopoietic stem cells in vivo
and, at least for ASC, were reported to be able to differentiate along the entire hematopoietic
lineage [Corre et al., 2006].
5.3 The Impact of TNF and Osteogenic Stimulation on ASC
Metabolic Activity
Comparatively little is known regarding changes in the metabolic activity of stem cells during
differentiation. When being calculated down to the single cell level, osteogenic stimulation of
ASC initially led to a reduction of metabolic activity after one week of culture, followed by
a strong peak after two weeks and a final decline to the starting levels after three weeks of
culture (see figure 4.9B on page 60). Contrastingly, TNF treatment of ASC led to a continu-
ously decreasing metabolic activity over the three weeks of experimentation. When cells were
co-treated with both stimulants, the metabolic activity-reducing effect of TNF outweighed the
activity-increasing effect of osteogenic stimulants and thus showed no peaking at day 14, but
subsequently a hardly unchanged and decreasing activity profile to the end of observation after
21 days.
Cellular metabolic activity was analyzed by following the reduction of a tetrazolium com-
pound into a formazan dye [Berridge and Tan, 1993]. Reduction of the tetrazolium compound
MTS is driven by direct electron transfer from NAD(P)H to MTS via the electron coupling
reagent PES. Like tests of the ATP/ADP ratio indicate the energy status of cells, the MTS as-
say indicates how many electrons can be transferred from NAD(P)H to MTS in a given time and
therefore is a measure of the overall cellular metabolic activity (see figure 5.6 on page 86).
Since a high NAD(P)H/NAD(P)+ ratio results from NAD(P)H generation in catabolic reac-
tions as e.g. glycolysis, high tetrazolium conversion rates reflect a high catabolic activity, more
specifically a high respiratory activity in case of MTS [Berridge et al., 2005]. When comparing
osteogenically stimulated with unstimulated ASC, the observed increase of MTS conversion per
cell may thus reflect the switching-on of glycolysis and oxidative phosphorylation. This assump-
tion is substantiated by the outcome of a recent analysis of the metabolism of ASC that was
done in our group and that revealed an increased activity of the glycolytic enzyme glucose-6-
phosphate dehydrogenase and the citric acid cycle enzyme NADP+-specific isocitrate dehydro-
genase under osteogenic stimulation of ASC (Juliane Meyer, unpublished results).
These observations of an increasingly oxidative metabolism fit well to what is nowadays
considered as a common hallmark of reduced “stemness” and increased degree of differentia-
tion [Rehman, 2010]. Interestingly, this metabolic adaptation finds its fingerprint also at the
organellar level, since mitochondria number increases during differentiation of precursors. Con-
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Figure 5.6: Cellular metabolism and the reduction equivalents and energy-rich compounds produced therein.
(A) The reduction equivalent NAD+ is reduced to NADH + H+ by catabolic pathways, mainly the citric acid
cycle. In the electron transport chain, NADH + H+ is oxidized to NAD+, yielding the energy-rich compound
ATP. Illustration taken from [Wikipedia, 2011]. (B) Thus, NAD+ regeneration and ATP production are func-
tionally coupled processes, a high ATP/ADP ratio corresponding to a high NADH/NAD+ ratio. Illustration
taken from [Alberts et al., 2002].
sequently, the hypoxic conditions of the stem cell niches in vivo in contrast to the mostly well
oxygen-supplied compartments of mature differentiated cells are thought to be responsible for
keeping stem cells in an undifferentiated state.
The importance of the redox state of cellular metabolism on differentiation of precursor cells
is not only represented by the fact that extracellular differentiation factors affect the intracellular
redox state, but more strikingly by the finding that the direct change of the redox state by pro-
and antioxidant drugs induces the same outcome on differentiation as these factors, as was
reported for rat neuronal progenitor cells [Noble et al., 2003]. Pharmacological antagonists
of the redox effects induced by extrinsic signaling molecules also antagonized their effects on
self-renewal and differentiation. The more oxidized differentiating cells were found to show a
stronger response to inducers of differentiation or cell death, but to respond less to inducers
of proliferation or survival, whereas the opposite was true for less differentiated neuronal cells
[Noble et al., 2005].
These generalized changes of cellular redox state appear to also be true for ASC. In bone
marrow-derived and umbilical cord-derived MSC, the increased number of mitochondria and
the switch of metabolic activity towards a stronger respiratory, oxidative phenotype was ac-
companied e.g. by an increased oxygen consumption after 14 days of osteogenic stimulation
[Pietilae et al., 2011] and by a shift in the redox potential in direction of oxidation [Imhoff and
Hansen, 2011].
Consistently with the increasingly oxidative metabolic phenotype of differentiating cells, the
amount of ATP per cell was shown to increase with differentiation degree from embryonic over
induced pluripotent stem (iPS) cells to differentiated cells, and lactate concentration inversely
decreased [Varum et al., 2011]. The increase in ATP generation is associated with an increase in
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generation of radical oxygen species (ROS), which was reported to be a stimulus for differentia-
tion: ROS activate the MAPK pathway which is involved in many differentiation programs, and
they reduce the stability of transcription factors associated with keeping cells in an undifferen-
tiated state, as e.g. OCT4 having higher transcriptional activity when bound to the antioxidant
thioredoxin (TRX) [Ogasawara and Zhang, 2009].
A recent study revealed a global relationship between the oxidative level of diverse cellular
metabolites and cellular differentiation. During differentiation of mouse and human embryonic
stem cells, the portion of unsaturated metabolites continuously decreased due to oxidation re-
actions [Yanes et al., 2010]. During these oxidation reactions, the intracellular concentration of
the reducing agent ascorbic acid peaked, whereas the concentration of the reduced form of glu-
tathion dipped simultaneously, both indicating the switching-on of cellular reactions directed
against the oxidative stress occuring. After differentiation took place, concentrations of both
redox agents returned to the values found before differentiation. Hence, increasing the differ-
entiation degree of cells increases their oxidative level, and reduced, unsaturated compounds
are simultaneously used up. Supportingly, the oxidized metabolites generated during differen-
tiation reactions in that study were reported to be able to induce neurogenic and cardiogenic
differentiation of the embryonic stem cells used.
Therefore, one can state that cellular differentiation in general is functionally coupled to
an oxidative metabolic phenotype, in special to a peaking in ascorbic acid concentration. By
supplying progenitor cells with ascorbic acid, the ascorbic acid concentration is artificially raised
as it is during differentiation which may therefore act as a signal forcing cells into differentiation,
and all additional factors and the physical environment present then influence which path of
differentiation is taken.
The complete lack of the prominent peaking of metabolic activity found for osteogenic stim-
ulation, but not for TNF treatment, indicates significant differences in the regulation of the cellu-
lar redox system by these differing stimuli and thus may be responsible for the lack of osteogenic
differentiation of TNF-treated ASC. In the ASC co-treated with both TNF and osteogenic stim-
ulants, the peaking of metabolic activity after 14 days was considerably less pronounced, but
obviously strong enough to support osteogenic differentiation as found in that ASC treatment
group.
5.4 Osteogenic Differentiation of ASC in vitro
5.4.1 Basal Level Osteogenic Differentiation Occurred in Unstimulated
ASC Cultures
Before I go into detail on the impact of TNF as a putative inducer of osteogenic differentiation of
ASC, it is noteworthy to underline that not only in the osteogenically stimulated ASC, but also
in those ASC cultures kept in cell culture medium without osteogenic stimulants, osteogenic
differentiation was observed to a certain, though in comparison to osteogenically stimulated
ASC much lesser extent.
There is a variety of factors that may have caused such spontaneous osteogenic differentia-
tion of ASC. In general, differentiation of stem cells is regulated by the concerted action of three
environmental parameters: by both soluble factors and by membrane-bound factors during di-
rect cellular interaction with other cells, and by interaction with the extracellular environment,
i.e. its physical and chemical properties.
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Impact of Soluble Factors
Besides basal nutrients for cellular metabolism as glucose and sodium pyruvate, inorganic salt
ions, diverse amino acids and vitamins, Dulbecco’s Modified Eagle Medium (DMEM) used for
ASC culture contains two soluble factors that play a role in the process of osteogenic differenti-
ation: the red-colored pH indicator phenol red and fetal calf serum.
Fetal calf serum was reported to positively regulate osteogenic differentiation of stem cells.
It was reported to spontaneously induce chondrogenic differentiation of bone marrow-derived
MSC while simultaneously reducing expression of mesenchymal stem cell markers in a dose-
dependent fashion [Yokoyama et al., 2008]. With exception of the skull which is formed by
direct differentiation of mesenchymal stem cells into bone in a process called intramembranous
ossification, all developmental processes of bone formation in vivo involve the intermediate
formation of cartilage which subsequently is replaced by bone, a process called endochondral
ossification. Therefore, by inducing chondrogenic differentiation of MSC in vitro, fetal calf serum
itself may initiate ossification of these cells via the endochondral differentiation pathway.
Supportingly, the extent of proliferation and osteogenic, adipogenic and chondrogenic dif-
ferentiation of bone marrow- and adipose tissue-derived stem cells, as induced by standard
stimuli, was reported to decrease with decreasing fetal calf serum concentration [Lund et al.,
2009]. Since the MAPK pathway is involved in regulation of various differentiation pathways,
the constitutive activation of the MAP kinase p38 and the transcription factor AP1 that was
found in ASC under unstimulated conditions (see page 75) may be mediated by fetal calf serum
and thus gives a potential mechanistic explanation for the basal level of osteogenic differention
found under all conditions in vitro.
In addition to the osteogenesis-promoting action of fetal calf serum, phenol red was shown
to have a supportive effect on osteogenic differentiation induced by different bone anabolic
stimuli in rat bone marrow stromal cells, but also being reported not to be able to induce
osteogenic differentiation on its own, and the permissive effect of phenol red on osteogenic
differentiation is thought to be due to additional lipophilic impurities present in the phenol red
charge [Still et al., 2003]. The lipophilic nature of phenol red suggests that it acts via nuclear
receptors as e.g. the estrogen receptor, and supportingly, SAOS cells cultured in phenol red-free
medium irreversibly lost their estrogen receptor [Nasir and Speirs, 1997].
The estrogen receptor was shown to be involved in bone formation in vivo through activation
of nitric oxide signaling. No bone formation occured in nitric oxide synthase knockout mice, and
nitroglycerin, which auto-decomposes into nitric oxide, enhanced osteoblastic differentiation of
human bone marrow-derived MSC [Huang et al., 2008]. Therefore, nitroglycerin is a promis-
ing candidate in osteoporosis treatment in estrogen-deficient, post-menopausal women, since
its lacks the adverse side effects of estrogen-replacement therapy as increased breast and en-
dometrial cancer rates and is recognized as safe from its long use in treatment of cardiovascular
disease.
Impact of Environmental Properties
In addition to soluble factors present in the cell culture medium, physical and chemical char-
acteristics of the growth substrate, which here was standard tissue culture polystyrene (TCPS),
also affect stem cell differentiation. Besides the bare chemical properties of a surface, i.e. its cov-
erage with distinct functional groups or even whole factors as fibronectin, the surface charge,
elasticity and nanotopography of the growth substrate strongly impact the proliferation, migra-
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tion and differentiation behavior of stem cells seeded onto them.
TCPS, as compared to the cell adhesion substrates from extracellular matrices present in the
body, is a hard material having an elasticity similar to that of bone. Thus, it is prone to induce
osteogenic differentiation of MSC instead of other differentiation pathways as e.g. adipogene-
sis or myogenesis, the corresponding extracellular matrices exhibiting much higher elasticities.
Strikingly, the low elasticity of the rigid fibrotic tissue generated during wound healing by scar
formation within a soft tissue environment having a much higher elasticity was observed to fa-
cilitate adhesion of stem cells onto it and thus is thought to act as a homing signal for stem cells
in a process of directed migration and adhesion called durotaxis [Discher et al., 2009]. How-
ever, this less elastic, more bone-like environment preferentially makes the MSC differentiate
into osteoblasts to drive ectopic calcification of fibrotic scar tissue.
Hence, the soluble factors phenol red and fetal calf serum contained in the cell culture
medium as well as the cell culture substrate tissue culture polysterene with its bone matrix-like
elasticity were reported to induce osteogenic differentiation of mesenchymal stem cells in vitro.
The mechanism the cell senses the mechanic properties of its environment largely depends,
as far as is known, on growth substrate-forced changes of cell shape. During differentiation
of MSC, cell shape changes in dependency on the differentiation pathway taken: differentia-
tion into osteoblasts results in a flat, well-spread phenotype that allows the osteoblast to maxi-
mize mineral deposition into its environment, whereas adipogenic differentiation results in the
roundly-shaped adipocyte phenotype with only limited adherence to the surface, but maximized
capacity for lipid storage. Vice versa forcing bone marrow-derived MSC into these differing cell
shapes was reported to result in differentiation of the undifferentiated cells into the mature
cells of the corresponding phenotype [McBeath et al., 2004]. The phenotype-shaping force in
this study was applied by varying the cell seeding density, a low plating density allowing the cells
to spread into a flattened phenotype, whereas a high seeding density allowed only a roundly
shaped phenotype. The signal of the actual cell shape adopted was found to be transduced into
changed actin cytoskeleton structure and tension via the RHOA-RHOA kinase (ROCK) signaling
pathway: Activation of ROCK lead to an increase in cytoskeletal stress fibers and tension and
finally to osteogenic differentiation, even if adipogenic differentiation factors were present or
the cell phenotype was rounded, whereas the opposite was true for constitutive inactivation of
ROCK. Thus, the ROCK-mediated regulation of actin stress fiber generation and the resulting
change in cellular mechanical tension and phenotype provides an important system regulating
osteogenic and adipogenic differentiation in a way that was even found to be superordinated
to common soluble differentiation factors. Consistently, Rhoa activation and increased actin ten-
sion in murine MSC were shown to preclude adipogenic and chondrogenic differentiation, but
not osteogenic differentiation [Arnsdorf et al., 2009].
The cell shape is also a critical factor for differentiation into other cell types, as was re-
ported for the differentiation of bone marrow-derived MSC into smooth muscle cells and chon-
drocytes: TGFβ3-treated MSC allowed to spread and flatten differentiated into smooth muscle
cells, whereas those kept on micropatterned surfaces preventing spreading differentiated into
chondrocytes [Gao et al., 2010]. For these differentiation pathways, the activity of the RHOA-
ROCK system remained hardly changed, whereas the activity of AKT1 for MSC on the SMC
differentiation pathway was strongly increased and resulted in upregulation of N-cadherin.
Varying the cell seeding density in three-dimensional culture in vitro also was reported to
affect differentiation and proliferation of cells, as was analyzed for cell types as e.g. the osteosar-
coma cell line MG-63. These cells proliferated more strongly when seeded at lower density in
three dimensional culture, whereas expression of osteogenic markers decreased to either side
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around an optimum [Bitar et al., 2008]. For human MSC in three-dimensional micro-mass cul-
ture, expression of chondrogenic markers was the stronger the higher the seeding density was
[Hui et al., 2008], an observation that is thought to be the consequence of forcing cells into a
condensation step-like aggregate as found during embryonic chondrogenesis.
Therefore, mechanical cues in the environment of stem cells have a considerable impact
on their differentiation behaviour and play a long-time underestimated, though at least equally
important role as the soluble differentiation factors commonly applied in approaches character-
izing differentiation of the plethora of different stem cell types. These mechanical properties of
the environment, in contrast to soluble factors, are steadily present and thus are a potent driver
of stem cell differentiation as well as of keeping differentiated cells in a differentiated state in
vitro and in vivo.
Impact of the Stem Cell Type
In addition to these environmental parameters affecting stem cell differentiation, these cells
differ intrinsically which makes each of the differing stem cell types preferentitially follow a dis-
tinct route of differentiation. Osteogenically stimulated human bone marrow-derived MSC e.g.
showed a much faster increase in alkaline phosphatase activity and earlier onset of extracellular
matrix calcification than ASC, but also exhibited a constitutive activation of osteogenic genes
alkaline phosphatase, collagen type I, osteocalcin and osteonectin [Frank et al., 2002]. These
indications of a higher osteogenic and chondrogenic potential of bone marrow-derived MSC in
comparison to ASC were independently confirmed [Im et al., 2005; Glass et al., 2011]. Con-
cludingly, bone marrow-derived MSC, in comparison to ASC, are likely to exhibit a higher basal
degree of osteogenic differentiation in an environment mechanically promoting osteogenic dif-
ferentiation. This stronger degree of osteogenic differentiation is apparently coupled to a higher
background degree of differentiation, which may keep the ratio between signal (induced differ-
entiation) and noise (background differentiation) at a constant level for the diverse stem cell
types existing.
5.4.2 The Impact of TNF on Osteogenic Differentiation of ASC
TNF had no Impact on ZBTB16 Expression in ASC
ZBTB16 is involved in osteogenic differentiation by increasing RUNX2 transcript level and pro-
tein activity and thereby was shown to indirectly induce osteoblastic differentiation of human
bone marrow-derived MSC via activation of RUNX2 and thus RUNX2-targeted genes [Ikeda
et al., 2005]. Interestingly, ZBTB16 expression in human endometrial stromal cells and myome-
trial smooth muscle cells exposed to the synthetic glucocorticoid dexamethasone was found to
be increased [Fahnenstich et al., 2003], but was not increased in BMP2-driven osteogenic dif-
ferentiation of human bone marrow-derived MSC [Ikeda et al., 2005]. Since both BMP2 and
dexamethasone activate RUNX2, dexamethasone-induced ZBTB16 expression activates RUNX2
in a BMP2-independent manner.
Expression of the ZBTB16 gene in ASC remained unaffected by TNF treatment, but increased
strongly following osteogenic stimulation (see figure 4.10A on page 62). Addition of TNF to the
osteogenic stimulants did also not alter the expression profile of ZBTB16. Thus, the ZBTB16
expression profile gives no indications for a TNF-induced or TNF-inhibited osteogenic differenti-
ation program in ASC in vitro.
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TNF had no Initial Impact on RUNX2 DNA-Binding Activity in ASC
The DNA-binding activity of RUNX2 was found to be significantly and time-dependently in-
creased following osteogenic stimulation of ASC, but was initially unaffected and later on
decreased by TNF treatment as compared to the unstimulated cells showing hardly changed
RUNX2 activity over culture time (see figure 4.10B on page 62). Interestingly, the contrasting
RUNX2 activity profiles obtained for TNF treatment and osteogenic stimulation in the co-treated
ASC gave rise to a RUNX2 activity profile consisting of the characteristic features of both single
treatments: the RUNX2 activity peaking characteristic for osteogenic stimulation, but observed
earlier in the co-treated ASC, and the significant late-stage decrease in RUNX2 activity char-
acteristic for TNF-treated ASC. Since ASC co-treated with both TNF and osteogenic stimulants
showed an unchanged extent of osteogenic differentiation as compared to the osteogenically
stimulated ASC, this earlier peaking of RUNX2 activity, although necessarily followed by an ear-
lier shutdown of RUNX2 activity, did not hamper the osteogenic differentiation program to be
induced in ASC. Therefore, the peaking of RUNX2 activity, irrespective of its time point, obvi-
ously is the key requirement for osteogenic differentiation to be induced.
Remarkably, the variance of RUNX2 activity in unstimulated ASC was higher after two days
of culture than after nine days. This elevated initial variance may indicate that ASC differentia-
tion fate under this condition is less defined than one week later.
Thus, the RUNX2 DNA-binding activity gives also no indications for a TNF-induced or TNF-
inhibited osteogenic differentiation program in ASC in vitro.
TNF had no Impact on ALPL Activity and Mineralization of ASC
TNF treatment did not increase neither expression nor activity of alkaline phosphatase (ALPL)
in ASC, whereas osteogenic stimulation clearly did (see figure 4.11 on page 64). Since not only
ALPL activity was not induced in TNF-treated ASC, but also mineralization of the extracellular
matrix did not occur (see figure 4.12 on page 65), an inductive effect of TNF on osteogenic
differentiation of ASC can clearly be denied. In addition, there were no indications for an impact
of TNF on osteogenic differentation of ASC, neither reductive nor promotive, when osteogenic
stimulation was done simultaneously.
TNF had no Dose-Dependent Effect on Osteogenic Differentiation of ASC
A potential dose-dependent effect of TNF on osteogenic differentiation of ASC was analyzed
by treatment of ASC with TNF concentrations ranging from 30 to 3,000 international units per
milliliter medium. However, an inductive effect of TNF on osteogenic differentiation was still
not observed even at the highest concentration (see figure 4.13 on page 66).
In healthy individuals, the serum TNF concentration is extremely low and mostly falls below
the detection limit of current methods. In patients with chronic spinal cord injury, the serum
TNF concentration raised to approximately 30 pg/ml, whereas no TNF was detectable in serum
of healthy individuals [Hayes et al., 2002]. In patients suffering from coronary artery disease, a
disease associated with elevated serum TNF levels, the TNF concentration was increased to 1.59
pg/ml, whereas healthy controls again fell below the detection limit [Safranow et al., 2009].
Patients suffering from hemorrhagic fever with renal syndrome showed a mean serum TNF
concentration of 10 pg/ml [Saksida et al., 2011]. Interestingly, exposure to tobacco smoke was
found to positively correlate in a dose-dependent manner with serum TNF levels, TNF serum
91
CHAPTER 5. DISCUSSION
levels in the non-smokers group being found as low as 5 pg/ml, whereas it was up to 50 pg/ml
in the smokers group [Petrescu et al., 2010]. Thus, the highest concentrations of TNF found in
inflammatory processes in vivo are in the range of 50 pg/ml.
In comparison to these biologically active TNF serum levels, even the lowest TNF concentra-
tion used for ASC treatment was considerably high: 30 international units of TNF per milliliter
medium correspond to a TNF concentration of 0.3 ng/ml or 300 pg/ml, and 3,000 international
units per milliliter medium accordingly correspond to 30,000 pg/ml. Therefore, the absence of
an osteogenic effect of TNF on ASC can obviously not be due to a too low dosage.
Inversely to increasing the concentration of TNF applied to ASC, the cell seeding density was
reduced to increase the TNF dose per cell. This approach however did not alter the experimental
outcome: Largely reducing the cell seeding density from 20,000 cells per cm2 to 3,000 cells per
cm2 did also not result in osteogenic differentiation of TNF-treated ASC, whereas osteogenic
differentiation in the osteogenically stimulated ASC still occurred (see figure 4.14 on page 67).
In addition, this finding underlines that a reduction in the initial seeding density had also no
beneficial effect on the extent of osteogenic marker expression, a finding that was reported ear-
lier for bone marrow-derived MSC whose matrix calcium deposition was significantly reduced
when being seeded at 3,000 cells per cm2 versus 5,000 cells per cm2 [Jaiswal et al., 1997].
Thus, a limited dose of TNF as a cause for the absence of osteogenic differentiation of ASC
can be excluded. Since even addition of the osteogenesis-supporting factors ascorbic acid and
β-glycerophosphate, which besides dexamethasone were present in the osteogenic stimulation
mixture, did also not result in osteogenic differentiation of ASC (see figure 4.16 on page 69),
and since ASC pre-treatment with TNF before osteogenic and adipogenic differentiation were
induced also did not affect these differentiation pathways (see figure 4.15 on page 68), the
cytokine TNF can clearly be stated to be neither able to induce nor to inhibit osteogenic differ-
entiation of ASC in vitro.
TNF Increased OPG Secretion by ASC
Osteoprotegerin is a decoy receptor and thus inactivator of the osteoclast differentiation-promo-
ting factor receptor activator of nuclear factor kappa-B ligand RANKL [Simonet et al., 1997].
Opg knockout mice were reported to have high bone turnover rates and severe osteoporosis
due to high osteoclast activity [Wright et al., 2009]. In contrast to their phenotype of systemic
bone loss, they developed ectopic calcification in the vascular system [Bucay et al., 1998]. cFos
knockout mice were reported to develop osteopetrosis, since this AP1 subunit is an essential
mediator of RANKL-induced osteoclastogenesis [Wagner, 2002].
OPG secretion by ASC, either in the presence or absence of osteogenic stimulants, was sig-
nificantly increased following TNF treatment (see figure 4.17 on page 70), which matches to
the observations made for murine bone marrow-derived MSC [Zhu et al., 2009], but also for
human endothelial and smooth muscle cells [Cohen et al., 2007]. The TNF-induced increase in
secretion of this anti-osteoclastogenic factor in ASC suggests that ASC may counteract inflamma-
tory bone loss in vivo. However, since the outcome of inflammatory bone diseases nevertheless
is a gradual decrease in bone mineral density, the osteoclastogenic effect of TNF in vivo must
exceed the anti-osteoclastogenic effect exerted by the increased OPG secretion by these stromal
cells by far.
Under osteogenic stimulation however, OPG secretion by ASC was reduced, what in vivo
would result in increased osteoclastogenesis and thus higher bone turnover rates. In the context
of the higher osteoblast precursor differentiation rate and osteoblast activity in an osteogenic
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environment, this adaptation appears to be reasonable.
TNF and Osteogenic Differentiation in the Literature
In order to classify the absence of an impact of TNF on osteogenic differentiation of ASC in
vitro, the current literature on the impact of TNF on osteogenic differentiation of mesenchymal
stem cells in general will have to be reviewed. In accordance with the outcome of these studies,
these reports can be subdivided into a group of reports of an inhibitory impact of TNF on os-
teogenic differentiation and a group of reports of no inhibitory impact of TNF on osteogenic dif-
ferentiation in vitro or in vivo. A putative inductive effect of TNF without additional osteogenic
stimulants was so far not analyzed.
Studies Reporting an Inhibitory Effect of TNF on Osteogenic Differentiation in vivo
Transgenic mice overexpressing TNF suffer from osteoarthritis, a chronic inflammatory disease
associated with joint inflammation and bone loss [Zhao et al., 2011]. Bone marrow-derived
MSC isolated from these mice showed significantly reduced alkaline phosphatase activity and
expression of other osteoblast marker genes. The molecular origin was found in overexpression
of Wwp1, an ubiquitin ligase which ubiquitinylates the MAPK transcription factor AP1 and thus
drives its proteasomal degradation. Wwp1 knockdown could rescue the disease phenotype.
In patients suffering from multiple myelomas, an inflammatory disease that is accompanied
by elevated serum TNF levels and severe bone loss, the expression of the WWTR1 gene and
protein was found to be significantly reduced [Li et al., 2007]. As stated earlier, WWTR1 is a
transcriptional co-activator of the osteogenic key transcription factor RUNX2, and neutralization
of TNF partially restored the osteogenic potential of bone marrow cells isolated from these
patients.
In a study using a murine model of osteoarthritis, administration of osteoprotegerin and
antibodies against TNF supportingly significantly decreased bone loss [Saidenberg-Kermanac’h
et al., 2004]. In the treatment of human rheumatoid arthritis, the monoclonal TNF antibodies
infliximab and etanercept are used [Taylor, 2001]. Clinical use of the monoclonal RANKL anti-
body denusomab further underlines the importance of the TNF-regulated RANKL/RANK/OPG
system in bone homeostasis [Wright et al., 2009], TNF promoting bone resorption by increasing
osteoclast maturation from their hematopoietic precursors both directly, but also indirectly by
increasing secretion of the osteoclast precursor differentiation-promoting factor RANKL by os-
teoblasts and other bone stromal cells [Nanes, 2003]. Thus, the overall balance between bone
formation and bone resorption is shifted towards a resorptive phenotype of bone metabolism in
vivo.
RANK activation via RANKL induces not only osteoclastogenesis, but also enhances T cell
maturation, which links regulation of the immune system to regulation of bone metabolism [Kim
et al., 1999]. Additionally, activated T cells at sites of inflammation express RANKL to activate
dendritic cells, but in that manner also induce differentiation of osteoclast precursors to mature
osteoclasts [Wong et al., 1999]. This gives direct evidence of how inflammatory conditions
promote bone resorption in vivo.
Supporting the osteolytic role of TNF in vivo, mice deficient for the TNF receptor 1 gene were
reported to exhibit increased expression of bone markers and increased amounts of cartilage and
bone formed in the process of endochondral ossification [Lukic et al., 2005], and mice deficient
for TNF and TNF receptor 1 exhibited increased bone mass [Cho et al., 2010]. TNF-induced
inhibition of osteoblast differentiation was shown to be mediated by TNF receptor 1 in mice
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[Gilbert et al., 2005]. In this model, TNF inhibited the expression of bone-matrix proteins, IGF1
and the parathyroid hormone receptor by mature osteoblasts, but stimulated the expression of
osteoclastogenic signals and inhibited differention of new osteoblasts from precursors.
Studies Reporting an Inhibitory Effect of TNF on Osteogenic Differentiation in
vitro TNF treatment of murine bone marrow-derived MSC was reported to reduce expres-
sion of osteogenic markers as alkaline phosphatase, α1 type 1 collagen, Runx2 and osterix,
and cells subsequently failed to differentiate into osteoblasts [Lacey et al., 2009]. TNF was re-
ported to inhibit osteogenic differentiation of osteoblast precursors rat fetal calvarial cells and
mouse MC3T3 cells, but not to affect their viability [Gilbert et al., 2000]. TNF treatment of
rat bone marrow-derived MSC stimulated osteogenically with dexamethasone and then seeded
onto biodegradable electrospun poly-3-caprolactone scaffolds per se supporting osteogenic dif-
ferentiation resulted in a dose-dependent decrease of alkaline phosphatase activity [Mountziaris
et al., 2010].
In murine MC3T3-E1 osteoblast precursor cells, TNF was found to inhibit BMP2-induced al-
kaline phosphatase activation and subsequent osteogenic differentiation [Nakase et al., 1997].
The inhibitory effect of TNF on TGFβ signal transduction in C2C12 mouse pluripotent mesenchy-
mal precursor cells was found to result from a decreased phosphorylation and thus activation
of BMP signal transducing Smads 1, 5 and 8 as well as from an increased expression of the
inhibitory Smad6, which all in all resulted in decreased expression of the Runx2 and osteocalcin
genes [Mukai et al., 2007]. In diverse mouse cell culture systems, Smad6 was reported to bind
to and activate the ubiquitin ligase Smurf1, which in turn ubiquitinylates Runx2 to drive protea-
somal degradation of this osteogenic key transcription factor [Shen et al., 2006]. In addition,
Smad6 was reported to recruit histone deacetylases to activated, promoter-bound glucocorticoid
receptors to silence expression of their target genes [Ichijo et al., 2005]. This general mechanism
may also apply for other Smad6-regulated transcription factors to mediate the inhibitory effect
of TNF on osteogenic differentiation. Interestingly, the inhibitory action of TNF on TGFβ signal-
ing was reported to depend on activation of the MAPK pathway member MAPK8, since blockade
of MAPK8 action by a specific inibitor precluded the TNF-mediated decrease in Smad1,5,8 phos-
phorylation and increased expression of the gene encoding the inhibitory Smad6 [Mukai et al.,
2007]. This indicates that the inhibitory effect of TNF on osteogenic differentiation is exerted
indirectly by activation of the MAPK pathway which in turn represses the TGFβ signaling path-
way.
Another mechanistic explanation for a direct inhibitory effect of TNF on osteogenic differ-
entiation involves activation of the NFκB pathway and comes from the finding that the p65
subunit of the TNF-activated NFκB dimer binds to the vitamin D receptor. This inhibits recruit-
ment of steroid co-activator 1 to this receptor and in rat osteosarcoma cells was shown to in
turn preclude induction of transcription from the osteocalcin promoter [Lu et al., 2004].
TNF was also found to inhibit osteogenic differentiation driven by the WNT pathway. Dick-
kopf homolog 1, an antagonist of nuclear accumulation of WNT pathway key signal trans-
ducer beta catenin, was found to be induced under inflammatory conditions as in diseases
as osteoarthritis that are characterized by increased chondrocyte apoptosis rates [Weng et al.,
2009]. Neutralization of Dickkopf homolog 1 did not only ameliorate loss of chondrocytes in os-
teoarthritis, but also loss of bone in a mouse model [Heiland et al., 2010] that develops arthritis
due to overexpression of a human TNF transgene [Keffer et al., 1991].
These findings underline the importance of the WNT signaling pathway for osteogenesis in
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vivo and in vitro and illustrate how TNF-mediated induction of the WNT antagonist Dickkopf
homolog 1 results in the directly opposed pathogenesis of bone resorption. Further evidence for
a Janus-faced relationship between inflammation and osteogenesis in the Wnt context comes
from the recent finding that the RUNX2 agonist Wnt3a is able to post-transcriptionally inhibit
TNF-mediated induction of Il6 secretion by mouse osteoblast-like MC3T3-E1 cells [Natsume
et al., 2011].
Further evidence for an inhibitory action of TNF on osteogenic differentiation comes from
functional studies on tumor necrosis factor alpha-induced protein 6 (TNFAIP6, formerly called
TNF-stimulated gene 6, TSG6). TNFAIP6 encodes a factor which is hardly expressed in unstim-
ulated cells, but which is strongly upregulated by pro-inflammatory cytokines as TNF and IL1
as well as in inflammatory diseases as e.g. rheumatoid arthritis [Milner and Day, 2003]. TN-
FAIP6 is involved in extracellular matrix remodeling by catalyzing the transfer of heavy chains
from chondroitin sulfate onto newly synthesized hyaluronan, a process that is crucial in carti-
laginous extracellular matrix biosynthesis [Sanggaard et al., 2008], but also in oocytogenesis
[Varki et al., 2009]. Tnfaip6 knockout in mice results in erroneous ovulation and female infer-
tility. Thus, TNFAIP6 is an important factor both in developmental as well as in inflammatory
matrix remodeling.
In osteogenic differentiation of human bone marrow-derived MSC, TNFAIP6 expression is
significantly downregulated, and overexpression of TNFAIP6 was found to inhibit osteogenic dif-
ferentiation induced by osteogenic chemicals as well as by BMP2 [Inoue et al., 2006]. TNFAIP6
was found to directly bind to and repress BMP2-binding to its receptor [Tsukahara et al., 2006],
which gives evidence for a direct inhibitory action of TNF on osteogenic differentiation. Since
TNFAIP6 also binds to and increases the activity of the serin protease inhibitor inter-alpha-
trypsin inhibitor, it indirectly reduces the activity of proteases involved in matrix remodeling
during osteogenic differentiation. Thus, the TNF-driven upregulation of TNFAIP6 expression im-
pairs osteogenic differentiation on multiple levels.
In mature dells, TNF was not only reported to activate osteoclast-precursor mobilisation
and differentiation, but also to directly inhibit the bone matrix-secreting activity of mature os-
teoblasts [Nanes, 2003; Tat et al., 2004; Datta et al., 2008].
A mechanistic explanation comes from the finding that expression and transactivation ac-
tivity of the vitamin D receptor are repressed through protein-protein interactions with TNF-
activated NFκB signaling pathway members. In addition, TNF treatment of rat bone marrow-
derived MSC was reported to increase secretion of matrix metalloproteinases 2 and 9 in vitro,
which suggests an unusual catabolic role for osteoblasts in bone remodeling in vivo [Ben David
et al., 2008]. TNF induced sclerostin (SOST) expression via the ERK1/2 MAPK pathway in
human adult primary osteoblasts [Vincent et al., 2009], sclerostin being an antagonist of BMP-
induced osteogenesis, and loss-of-function mutations of sclerostin cause a disease phenotype of
progressive bone overgrowth.
Hence, TNF is numerously reported to act as an inhibitor of osteogenic differentiation both
in vitro and in vivo. Contrastingly, TNF treatment of ASC did not reduce the extent of their
osteogenic differentiation. Nevertheless, there is a number of studies that support this finding
both in vitro and in vivo.
Studies Reporting No Inhibitory Effect of TNF on Osteogenic Differentiation in vitro
Bone marrow-derived MSC were reported to show increased expression of the BMP2, RUNX2,
ALPL and osterix gene and to also show stronger extracellular matrix mineralization following
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TNF stimulation under osteogenic conditions induced by ascorbic acid and β-glycerophosphate
[Hess et al., 2009]. The increased expression of osteogenic markers was assigned to the TNF-
mediated activation of the NFκB pathway, and a constitutively active version of the NFκB-
inducing kinase IKK2 increased expression of the above-mentioned osteogenic markers. How-
ever, blocking of the NFκB pathway by expression of an IKK substrate that cannot be phospho-
rylated by this kinase and therefore dominantly suppresses NFκB activity did not interfere with
osteogenic differentiation, which questions the biological relevance of the NFκB pathway for
osteogenic differentiation of bone marrow-derived MSC. Additionally, the predominant portion
of osteogenic markers in this study was investigated only at the gene expression, but not at
the protein level, and the extracellular matrix calcium content was not put into relation to the
simultaneously increased cell number under TNF treatment. Nevertheless, these results show
that TNF is not able to abrogate the osteogenic stimulus in bone marrow-derived MSC in vitro,
a finding that was confirmed also for ASC [Crop et al., 2010; Cho et al., 2010].
Studies Reporting No Inhibitory Effect of TNF on Osteogenic Differentiation in vivo
Treating muscle-derived stromal cells (MDSC) with TNF before implanting them into a bone
fracture in mice significantly increased osteogenic differentiation and fracture healing [Glass
et al., 2011]. The same was true when TNF was directly applied to the fracture site. Since TNF-
treated MDSC showed significantly increased migratory activity and since supernatants from
tibial bone fragments induced osteogenic differentiation of these cells in vitro, the combinatorial
effect of the differentiation-inducing environment and the migration-inducing pro-inflammatory
stimulus are thought to concert the improved fracture healing observed in vivo. This hypothesis
was substantiated by the outcome of an earlier study reporting impaired bone formation in both
the process of endochondral and intramembranous ossification in a mouse model knocked out
for both TNF receptors and thus being insensitive to TNF [Gerstenfeld et al., 2001].
Moreover, TNFAIP6, the factor whose expression just was discussed to be upregulated by
inflammatory cytokines as TNF, but needs to be downregulated for osteogenic differentiation to
succeed, may, due to its inhibitory action on proteases, also have a protective function against
inflammatory osteolysis in vivo. Supportingly, TNFAIP6 was found to inhibit RANKL-induced
osteoclast activation [Mahoney et al., 2008]. Besides its general anti-inflammatory action as
inhibitor of neutrophil migration and reducer of plasmin activity, TNFAIP6 expression by the in-
flammatory stimulated cells therefore provides an autocrine feedback inhibition loop to limit in-
flammatory bone erosion [Mahoney et al., 2011]. Thus, TNFAIP6 participates both in regulation
of osteoblastogenesis and osteoclastogenesis, and TNF can exert both anti- and pro-osteogenic
effects through it.
In diseases associated with low-grade vascular inflammation, as e.g. diabetes, the upregu-
lated TNF levels in mice were found to induce BMP2-mediated osteogenic differentiation to
finally lead to ectopic arterial calcification [Shao et al., 2005, 2006]. Mechanistically, Bmp2 was
found to induce the transcription factor Msx2, and a multipotential mouse embryonic meso-
dermal cell line transduced to constitutively express Msx2 was found to upregulate expression
of Wnt agonists Wnt3a and Wnt7a and to downregulate Wnt antagonist Dkk1. This resulted
in nuclear translocation of Wnt key transcription factor beta catenin to activate alkaline phos-
phatase in a Runx2-dependent manner and thus to lead to matrix mineralization. Interestingly,
even conditioned medium from these constitutively Msx2 expressing cells induced osteogenic
differentiation of untransduced cells via the same mechanism of Wnt activation in vitro, which
suggests a paracrine mechanism of vascular calcification in vivo.
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This finding that elevated serum TNF levels indirectly induce Wnt signaling in arterial was
reproduced in aortic myofibroblasts in vitro and resulted in increased arterial calcification in vivo
[Al-Aly et al., 2007]. This mechanism of TNF-mediated vascular calcification was found to apply
also for chronic kidney disease in vivo [Al-Aly, 2008] and thus may reflect a common mech-
anism of inflammation-mediated ectopic mineralisation in vivo. Thus, inflammatory cytokines
regulate osteogenic differentiation of vascular cells, which occurs both in direction of osteoblasts
and osteoclasts and generates an active bone metabolism resembling that of trabecular bone tis-
sues [Abedin et al., 2004]. Hence, inflammation and ectopic, cardiovascular calcification are
numerously reported to be associated.
Additionally, cardiovascular calcification, atherosclerosis and chronic renal disease are as-
sociated with osteoporosis, and recent work in mice has demonstrated that arterial and aor-
tic calcification inversely correlate with osteoporotic bone remodeling, i.e. that with ongoing
inflammation-mediated osteolysis of hard cortical and trabecular bone tissue, new bone is ec-
topically generated in vascular soft tissues [Hjortnaes et al., 2010]. Thus, the disease state of
systemic inflammation leads to both the common effect of monocyte/macrophage activation,
but inflammatory activation of these cells subsequently leads to opposed effects, i.e. to osteoly-
sis in the long bone and to osteogenic differentiation in arteries and valves. Supportingly, mice
exhibiting high bone turnover rates due to knockout of the osteoprotegerin gene were reported
to suffer from ectopic calcification [Bucay et al., 1998].
Besides TNF, the calcium and phosphate ions liberated in the osteolytic reactions in the
long bone directly contribute to ectopic calcification and subsequently to increased local cy-
tokine levels, since basic calcium phosphate was reported to be internalized into vacuoles by
monocytes/macrophages, which elicits an inflammatory stimulus resulting in the secretion of
pro-inflammatory cytokines as TNF [Nadra et al., 2005]. This colorfully illustrates the vicious
cycle of inflammatory bone remodeling.
Interestingly, TNF in mature osteoblasts and MG-63 cells was found to increase alkaline
phosphatase activity even in an RUNX2-independent mechanism involving inhibition of the adi-
pogenic transcription factor PPARγ, and inhibition of prostaglandin synthesis abolished calcifica-
tion [Lencel et al., 2011]. In human mesenchymal stem cells, TNF inhibited RUNX2, osteocalcin
and collagen expression, but increased alkaline phosphatase activity and mineralization and
thus induced an incomplete program of osteogenic differentiation [Ding et al., 2009]. These
findings allow two important conclusions. On the one hand, they link the onset of ectopic cal-
cification to the suppression of adipogenic differentiation, a hypothesis that is substantiated by
the fact that patients treated with serum lipid-lowering statins show reduced cardiovascular
calcification rates [Hjortnaes et al., 2010]. On the other hand, these findings emphasize that
ectopic calcification does not necessarily require osteogenic differentiation of stem cells, since it
can also take place if a pre-existing collagen network is calcified by mature osteoblast-like cells.
Moreover, the mechanical properties of this extracellular environment can act as an inducer
of ectopic calcification, since vascular tunica lesion-healing in Peyronie’s disease is not only ac-
companied by the deposition of abnormal amounts of fibrotic tissue, but also by osteogenic
differentiation of mesenchymal stem cells residing in the pericytal region and thus in contact to
this fibrotic tissue [Vernet et al., 2005].
Hence, systemic inflammation, via a variety of pathways, leads to the apparent, though
explainable paradox of simultaneous osteolysis in long bone and calcification at ectopic sites
and therefore can be summarized to cause “softening” of hard tissue and “hardening” of soft
tissue.
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Concluding Remarks on the Impact of TNF on Osteogenic Differentiation in vitro
and in vivo Although a pro-inflammatory stimulus as TNF on its own was not able to induce
osteogenic differentiation of multipotent progenitor cells as ASC in vitro, it increased their pro-
liferation rate and thus their number. If the inflamed tissue simultaneously provides stimuli that
promote osteogenic differentiation, there will be a significantly higher number of progenitor
cells that can undergo osteogenic differentiation. This mechanism will then indirectly lead to
the establishment of ectopic calcification observed in the cardiovascular system under chronic
inflammatory conditions in vivo.
5.5 Summary and Conclusions
Summarizingly, both TNF receptors were found to be expressed on ASC, though at strikingly dif-
ferent intensity. As was reported for most cell types, TNFRSF1A was found to be much stronger
expressed than TNFRSF1B, the latter being formerly thought to be confined to immune cells,
but in recent times being published to be expressed on an increasing number of other cell types.
Upon binding of TNF to its receptors, these receptors can activate three distinct signal trans-
duction pathways: The apoptosis pathway, the MAP kinase pathway and the NFκB pathway. TNF
induced the NFκB, but not the apoptosis pathway, whereas the MAP kinase p38 and the MAPK
transcription factor AP1 were found to be constitutively active in ASC. Osteogenic stimulation
had no impact on these signaling pathways.
Thus, although other cell types as endothelial cells, synovial fibroblasts or smooth muscle
cells are highly susceptible to TNF-induced apoptosis, ASC were not. This may have been the
consequence of the activated NFκB pathway and the activated MAP kinase transcription factor
AP1, the former being generalized to have pro-survival properties and the latter being known to
activate expression of anti-apoptotic genes of the B cell lymphoma family.
TNF significantly increased ASC proliferation rates and accelerated their passage through the
S phase of the cell cycle. This effect may have been the consequence of a promoted transition
through the G1 to S checkpoint of the cell cycle. This transition was reported to be regulated
by activation of the NFκB pathway which itself increases activity of distinct cyclins and the
prominent proto-oncogene MYC.
Osteogenically stimulated ASC also showed increased proliferation rates, but decelerated
passage through the S phase. Slower S phase passage may have been the consequence of the
increased expression of ZBTB16, a transcription factor reported to suppress activity of cyclins
involved in G1 to S transition and found to decrease expression of MYC. In addition, osteogenic
stimulation of ASC increased DNA-binding activity of RUNX2, the osteogenic key transcription
factor that was reported to promote cell cycle exit from G1 to G0 in order to facilitate differentia-
tion. Although increased expression and DNA-binding activity of these osteogenic transcription
factors easily explain the induction of an osteogenic differentiation program in ASC, the high
proliferation rates observed simultaneously are not. For hematopoietic and neural stem cells,
differentiation is known to occur in a process of asymmetric cell division, one daughter cell dif-
ferentiating and the other self-renewing to keep the pool of stem cells upright. Since ASC were
reported to be able to undergo the full hematopoietic differentiation program and since bone
marrow-derived MSC even share the same niche with HSC, this mode of differentiation appears
to be possible, though not explicitely demonstrated for ASC in special and MSC in general.
Osteogenic stimulation of ASC was found to result in an intermediate increase in metabolic
activity that was absent in the TNF-treated cells, and a simultaneous study revealed an increas-
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ingly glycolysis- and citric acid cycle-driven metabolism during osteogenic differentiation of ASC.
Therefore, this differentiation pathway coincides with an increasingly oxidative metabolism,
which nowadays is considered to be a general hallmark of ongoing differentiation processes
and interestingly was also shown to inversely induce differentiation of stem cells.
Treatment of ASC with TNF did not induce osteogenic differentiation of these stem cells in
vitro. This is in contrast to the well-known differentiation-promoting effect of TNF on osteoclas-
tic precursor cells from the hematopoietic lineage. Since TNF did neither increase nor reduce
the osteogenic differentiation capacity of ASC in an osteogenic environment in vitro, the effect
of osteolysis of the long bone observed in chronic inflammatory diseases presumably is mainly
due to the pro-osteoclastogenic effect of this cytokine in vivo.
Seemingly paradoxically, the same inflammatory stimuli that induce osteolysis of the long
bone induce calcification at ectopic sites, primarily the vasculature, via a variety of different
pathways. Therefore, chronic inflammatory diseases can be summarized to cause “softening” of
hard tissue and simultaneous “hardening” of soft tissue.
Generalizing the main finding of this study, i.e. the finding that TNF did not impair ASC os-
teogenic differentiation capability, but increased ASC proliferation rate, inflammatory processes
in vivo appear to act as a driving force for stem cell self-renewal without affecting their differ-
entiation potential, and factors other than the mediators of inflammation govern subsequent
differentiation of this enlarged stem cell pool into the desired tissue. Thus, inflammatory acti-
vation of infected or damaged tissue increases its regenerative potential as a starting point, but
requires further signals for regeneration to complete.
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